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I. INTRODUCTION
In the nearly forty years since adoption of the Federal Water Pollu-
tion Control Act Amendments in 1972' and Safe Drinking Water Act in
1974,' the United States has seen dramatic improvement in the quality of
both surface and drinking water. Despite these improvements, serious
problems and questions remain.
Chemicals occur in the environment through a wide variety of natural
processes and human actions. The various federal, state and tribal pro-
grams implementing the Clean Water Act, the Safe Drinking Water Act,
and other environmental laws, regulate only a small portion of these
chemicals. Although the number of regulated chemicals is very small
when compared to the universe of chemicals in the environment, an im-
plicit assumption underlying this regulatory approach is that "these selec-
tive lists of chemicals are responsible for the most significant share of risk
with respect to environmental or economic impairment or to human
health."'
In recent years, new information has arisen to challenge this assump-
tion. Chemicals from a wide variety of pharmaceutical and personal care
products ("PPCPs"), their byproducts and endocrine disrupting com-
pounds ("EDCs") have received growing attention from the water treat-
ment and wastewater treatment community because of the ability of
1. Federal Water Pollution Control Act Amendments of 1972, Pub. L. No. 92-500,
86 Stat. 816 (codified as amended at 33 U.S.C. § 1251 et seq. (2006)) (with subsequent
amendments, now known as the "Clean Water Act").
2. Safe Drinking Water Act of 1974, Pub. L. No. 93-523, 88 Stat. 1661.
3. Christian G. Daughton, Non-Regulated Contaminants Emerging Research, Exist-
ing and Future Pollutants in Water Supplies: Old Pollutants, New Concerns - New Pol-
lutants, Unknown Issues (Oct. 16, 2003) (paper presented at the National Academies,
Institute of Medicine: Roundtable on Environmental Health Science, Research, and
Medicine (EHSRT)) (on file with author).
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PPCPs to persist, or only partially degrade, in water and during wastewa-
ter treatment.
Several federal agencies, including the EnvironmentAl Protection
Agency ("EPA"), the Food and Drug Administration ("FDA"), the U.S.
Department of Agriculture ("USDA"), the U.S. Geological Survey
("USGS"), and the Centers for Disease Control and Prevention ("CDC"),
have the potential to be involved in various aspects of the management of
PPCPs. In addition to these federal agencies, numerous units of state,
tribal, and local governments are (or could be) involved in implementing
federal, state, and tribal environmental programs that are relevant to the
management of PPCPs. Industry stakeholders also play significant roles,
both directly and indirectly, in PPCP management.
PPCPs are an extremely diverse group of chemicals used in human
health care, cosmetic care, veterinary medicine, and agriculture. In 2004,
it was estimated that "there may be as many as six million PPCP sub-
stances commercially available worldwide . . . ." PPCPs are also ubiqui-
tous pollutants, entering the environment worldwide due to widely dis-
persed usage by individuals and in both industry and agriculture.' Recent
reports in popular media regarding pharmaceuticals in drinking water
have contributeal to increasing public awareness of and concern about
this issue.'
4. For the purposes of this report, the term "PPCPs" includes a diverse group of
chemicals that include pharmaceuticals, such as: prescription and over-the-counter hu-
man drugs, veterinary drugs; diagnostic agents; and personal care products, including:
fragrances, lotions, cosmetics, and nutritional supplements. PPCPs also comprise the
various byproducts of these substances as well as related endocrine disrupting com-
pounds (EDCs). Concern regarding the presence of such compounds in water supplies
was expressed by Masters:
[Thesel are compounds that interfere with natural production, release, trans-
port, metabolism, binding, action, or elimination of hormones in the body.
We know that the normal functions of all organ systems are regulated by endo-
crine factors.. Small disturbances in endocrine function, especially during cer-
tain stages of the life cycle, can lead to profound and lasting effects. There is
evidence that specific populations of invertebrate, fish, avian, reptilian, and
mammalian species have been, or currently are being, adversely affected by ex-
posure to environmental contaminants that effect the endocrine systems. . . .
The major groups of animals potentially at risk include fish, birds, reptiles, ma-
rine mammals, and invertebrates
Robert W. Masters, Pharmaceuticals and Endocrine Disruptors in Rivers and On Tap,
120 WATER RESOURCES UPDATE, Sept. 2001, at 1; see also K. Xia et al., Occurrence,
Distribution, and Fate of 4-Nonylphenol in Kansas Domestic Wastewater Treatment
Plants, 120 WATER RESOURCES UPDATE, Sept. 2001, at 41.
5. J.B. Ellis, Pharmaceutical and Personal Care Products (PPCPs) in Urban Recei-
ing Waters, 144 ENvTL. POLLUTION 184, 185 (2006).
6. CHRISTIAN C. DAUGHTON, PHARMACEUTICALS IN THE ENVIRONMENT: SOURCES,
FATE, EFFECTS AND RISKS 463 (Klaus Kimmerer ed., 2d ed. 2004).
7. For example, in 2008, the Associated Press released a series of investigative re-
ports entitled AN AP INVESTIGATION: PHARMACEUTICALS FOUND IN DRINKING WATER.
These reports, were distributed by both print and electronic media worldwide. See, e.g.,
Jeff Donn, Drug Traces Turn Up in Source Waters for Nation's Biggest City, U.S.
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In 2006, the Center for Water Law & Policy at Texas Tech University
(the "Center") was awarded funding by the Environmental Protection
Agency to conduct a study related to micropollutants (including PPCPs)
in the natural environment. This study was divided into three specific
projects.
Project 1 focused on the development of a PPCP database containing
documents, reports, publications, and other material related to PPCPs.
While information in the database was designed for use in Project 3 (dis-
cussed below), the information was also intended to be made available to
those interested in understanding water law and policy issues, including
researchers, decision-makers in the public and private sectors, stake-
holders, interest groups, and the general public. The creation of the Mi-
cropollutants Clearinghouse ("Clearinghouse") achieved this latter objec-
tive.
Project 2 focused on primary research to improve the understanding
of the presence and fate of mixtures of micropollutants in the environ-
ment. This research, which was based on field studies conducted on dis-
charges from a wastewater treatment facility in West Texas, forms the
basis for the case study noted below.
Project 3 focused on an analysis of alternative strategies for address-
ing the presence and effects of PPCPs in fresh water resources. It identi-
fied and evaluated statutory and regulatory approaches that are (or could
be) utilized to prevent PPCPs from entering the aquatic environment in
concentrations that would exceed concentrations determined appropriate
for protection of human health and the environment.' Potential alterna-
tive strategies were also identified and evaluated. Project 3 addressed
three basic questions: 1) can existing statutory and regulatory authorities
be utilized to collect information about and/or effectively manage PPCPs
entering the environment?; 2) are there other alternative strategies that
should be considered?; 3) what are the relative strengths and weaknesses
of the existing authorities and alternative strategies? The results of Pro-
ject 3, as well as answers to these three questions, are contained herein.
A. METHODOLOGY
Preparation of this report relied on both the outputs of Projects 1 and
2 and on the collective expertise of the authors. As noted above, the
output of Project 1 (the Micropollutants Clearinghouse) contained an
extended collection of materials relating to PPCPs in fresh water re-
WATER NEWS, March 2008; Martha Mendoza, On Eve of Hearings, White House
Documents Show Feds Failing to Take Action on Drugs in Water, THE ASSOCIATED
PRESS (D.C.), Apr. 13.
8. The alternatives analysis contained in Project 3 was not designed to determine
whether human health and environmental hazards presented by PPCPs and their by-
products warrant specific regulatory activities. Instead, Project 3 was intended to evalu-
ate alternative strategies that could be utilized should scientific research determine that
PPCPs or their byproducts are hazardous to human health or the environment.
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sources. The following section summarizes the current scientific re-
search. Both this summary and Section IV regarding alternative strategies
were prepared after the authors had reviewed a large number of articles
and reports contained in the Clearinghouse.
To ensure comprehensiveness, and as a quality control measure, the
authors also undertook an independent review of the literature. This
review utilized a variety of online data retrieval systems. The results of
this independent review were then compared to the contents of the Clear-
inghouse. Any items not already in the Clearinghouse were added follow-
ing this review.'
Project 2 provided the information contained in the case study dis-
cussed below. This research, which focused on the presence of PPCPs in
soil and groundwater in West Texas, was initiated by researchers at Texas
Tech University, specifically Dr. Todd A. Anderson, Dr. Deborah L.
Carr, Dr. Adcharee Karnjanapiboonwong, Dr. Jonathan D. Maul, Dr.
Audra N. Morse, and Dr. John C. Zak." Meetings were held with one or
more of these researchers during the course of this project. Copies of
research presentations and drafts of final reports were provided to the
authors. The cooperation and assistance of Dr. Anderson, Dr. Carr, Dr.
Karnjanapiboonwong, Dr. Maul, Dr. Morse, and Dr. Zak are both ac-
knowledged and very much appreciated.
The legal review contained in Section IV and the analysis of the
strengths and weaknesses of a variety of statutory and regulatory alterna-
tives contained in Section VI are based primarily on the expertise of the
authors, both of whom have taught environmental, natural resources, and
water law for many years. Legal research supplemented this expertise
regarding recent initiatives unique to the issue of PPCPs in fresh water
resources."
B. ORGANIZATION OF THE REPORT
The following section provides a brief summary of current scientific
research regarding sources of PPCPs in fresh water resources. Processes
or mechanisms by which PPCPs get into such resources are described.
Both short- and long-term impacts on human and environmental health
resulting from the presence of PPCPs in fresh water resources are re-
viewed.
9. The comprehensiveness of the research upon which the Clearinghouse was based
is revealed by the fact that relatively few new references were added following the au-
thors' independent review of the literature.
10. Dr. Anderson, Dr. Carr, Dr. Karnjanapiboonwong, and Dr. Maul are with the
Institute of Environmental and Human Health, Department of Environmental Toxicol-
ogy. Dr. Morse is with the Department of Civil and Environmental Engineering. Dr.
Zak is with the Department of Biological Sciences.
11. The authors would like to express their appreciation to Mr. Christopher R. Jack-
son, Class of 2011, Texas Tech University School of Law, and Ms. Elizabeth Miller,
Class of 2011, Texas Wesleyan University School of Law, for their invaluable assistance
in the preparation of this report.
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Section III describes current legal mechanisms by which fresh water
resources are protected, both directly and indirectly. The requirements
of the Clean Water Act and the Safe Drinking Water Act are reviewed.
The management of hazardous substances and wastes, as mandated by
the Resource Conservation and Recovery Act, is reviewed as is the regula-
tion of toxic substances under the Toxic Substances Control Act. Of
particular relevance to the aquatic environment is the Endangered Spe-
cies Act, which is also reviewed.
Potential alternative strategies leading to the minimization or elimina-
tion of PPCPs in fresh water resources are discussed in Section IV. This
discussion, which addresses the reduction or elimination of anthropo-
genic sources of PPCPs, as well as the regulation and management of
such sources, sets the stage for the aforementioned case study contained
in Section V. As noted above, this case study is based on Project 2 re-
sults.
Strengths and weaknesses of the statutory, regulatory, and alternative
strategies are discussed in Section VI. Conclusions are presented in Sec-
tion VII. Section VIII contains the Project 3 bibliography.
II. SUMMARY OF THE SCIENTIFIC RESEARCH
Concern over the presence of PPCPs in fresh water resources has in-
creased significantly since 1965 when researchers at Harvard University
first determined that effluent from wastewater treatment plants contained
both natural and synthetic estrogens." By the 1970s, the subject was be-
ing studied in both the United States" and Europe."
However, as noted by Stanford et al., after these initial studies "only
sparse attention was paid to hormones and pharmaceuticals in the envi-
ronment until reproductive effects in fish were shown to be directly influ-
enced by estrogens in wastewater outfalls."" By the early 1990s, re-
searchers in Germany and Switzerland had identified multiple PPCPs in
both wastewater and surface waters into which wastewater had been dis-
charged. In large measure, the growing concern over the presence of
12. Benjamin D. Stanford et al., Estrogenic Activity of US Drinking Waters: A Rela-
tive Exposure Comparison, 102J. AM. WATER WORKS ASS'N, no. 12, at 1 (2010).
13. Id.
14. LisaJ. Schulman et al., A Human Health Risk Assessment of Pharmaceuticals in
the Aquatic Environment, 8 HUMAN & ECOLOGICAL RISK ASSESSMENT 657, 658 (2002).
15. Stanford et al., supra note 12, at 1-2.
16. Hans-Rudolf Buser et al., Occurrence and Environmental Behavior of the Chiral
Pharmaceutical Drug Ibuprolen In Surface Waters and in Wastewater, 33 ENVTL. Sc. &
TECH. 2529 (1999); Hans-Rudolf Buser et al., Occurrence of the Pharmaceutical Drug
Clol7bric Acid and the Herbicide Mecoprop in Various Swiss Lakes and in the North
Sea, 32 ENVTL. Sci. & TECH. 188 (1998); Hans-Rudolf Buser et al., Occurrence and
Fate of the Pharmaceutical Drug Diclofenac in Surface Waters: Rapid Photodegradation
in a Lake, 32 ENVTL. Sci. & TECH. 3449 (1998); C. Hartig, Detection and Identification
of Sulphonamide Drugs in Municipal Waste Water by Liquid Chromatography Coupled
with Electrospray lonisation Tandem Mass Spectrometry, 854 JOURNAL OF
CHROMATOGRAPHY A 163 (1999); Andreas Hartmann et al., Identification of Fluoro-
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PPCPs in fresh water resources resulted from an increasing number of
occurrence studies that have identified specific PPCPs in drinking water."
While it is beyond the scope of the present study to review each of these
studies, certain studies should be noted.
In 1999-2000, the USGS sampled surface and groundwater through-
out the United States.'" The study focused on the presence in U.S. water
supplies of 95 organic wastewater contaminants including "antibiotics,
other prescription drugs, nonprescription drugs, steroids, reproductive
hormones, personal care products, products of oil use and combustion,
and other extensively used chemicals."" The study found at least one of
quinolone Antibiotics as the Main Source of umuC Genotoxicity in Native Hospital
Wastewater, 17 ENVTL. ToxIcOLOGY & CHEMISTRY 377 (1998); Roman Hirsch, Occur-
rence of Antibiotics in the Aquatic Environment, 225 THE SCI. OF THE TOTAL ENv'T
109 (1999); R. Hirsch et al., Determination of Betablockers and /-Synpathominetrics
in the Aquatic Environment, 87 VOM WASSER 263 (1996); David L. Sedlak, & Karen E.
Pinkston, Factors Affecting the Concentrations of Pharinaceuticals Released to the
Aquatic Environment, 120 WATER RESOURCES UPDATE 56 (2001) (citing Hj. Stan et al.,
Occurrence of Clofibric Acid in the Aquatic Systen-is the Use in Hunan Medical Care
the Source of the Contamination of Surface, Ground, and Drinking Water? 83 Vom
WASSER 57 (1994); H. Stan & T. Heberer, Occurrence of Polar Organic Contaminants
in Berlin Drinking Water, 86 VoM WASSER 19 (1996); Marcus Stumpf et al., Polar Drug
Residues in Sewage and Natural Waters in the State ofRio dejaneiro, Brazil, 225 THE
SCI. OF THE TOTAL ENV'T 135 (1999); Thomas A. Ternes, Occurrence of Drugs in
German Sewage Treatment Plants and Rivers, 32 WATER RESEARCH 3245 (1998); Tho-
mas A. Ternes & Roman Hirsch, Occurrence and Behavior of X-ray Contrast Media in
Sewage Facilities and the Aquatic Environment, 34 ENVTL. Scd. & TECH. 2741 (2000)).
Schulman, et al., have noted that these studies "identified and measured a variety of
human pharmaceuticals including hormones, lipid regulators, pain killers, antibiotics,
anti-cancer drugs, anti-epileptic drugs, and blood pressure drugs at a range of concentra-
tions, most below 1 pg/I." Schulman et al., supra note 14, at 658.
17. However, as noted by the American Water Works Association Research Founda-
tion (AwwaRF), "[ilf water utilities choose to (or are compelled to) implement additional
treatment measures for these compounds based solely on occurrence data, without re-
gard to toxicological significance, there is a risk of spending tremendous amounts of
public funds for very little public health benefit." Djanette Khiari, Endocrine Disrup-
tors, Pharmaccuticals, and Personal Care Products in Drinking Water: An Overview of
AwwaRF Research to Date, 17 DRINKING WATER RESEARCH 1, 6 (2007) (emphasis
added). The AwwaRF has also noted:
If presence/absence becomes our litmus test for risk and subsequent actions,
treatment technology will be increasingly, and perhaps unnecessarily, costly and
energy intensive. This is an especially important consideration due to the en-
ergy cost and greenhouse gas emissions of advanced treatment.
AM. WATER WORKS Ass'N RESEARCH FOUND., ToxiCOLOGICAL RELEVANCE OF EDCs &
PHARMACEUTICALS IN DRINKING WATER, at xix (2008).
18. Dana W. Kolpin et al., Pharmaceuticals, Hormones, and Other Organic Waste-
water Containnants in U.S. Streams, 1999-2000: A National Reconnaissance, 35 ENVTL.
Sci. & TECH. 1202, (2002). The results of this study are summarized in Kimberlee K.
Barnes et al., Water-Quahtv Data for Pharmaceuticals, Horniones, and Other Organic
Wastewater Contaminants in US. Streams, 1999-2000, U.S. Geological Survey, U.S.
Dep't of the Interior, No. Open-File Report 02-94 (2002), available at
http://toxics.usgs.gov/pubs/OFR-02-94/.
19. Kolpin et al., supra note 18, at 1203.
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the ninety-five organic wastewater contaminants in eighty percent of
stream samples and in ninety-three percent of groundwater samples. As
noted in the study, the environmental presence of these compounds
raises concerns regarding potential consequences, including "abnormal
physiological processes and reproductive impairment, increased inci-
dences of cancer, the development of antibiotic-resistant bacteria, and the
potential increased toxicity of chemical mixtures."" The results of the
study are summarized below, and depicted in Figure 1.
The most frequently detected chemicals (found in more than half of
the streams) were coprostanol (fecal steroid), cholesterol (plant and ani-
mal steroid), N-N-diethyltoluamide (insect repellent), caffeine (stimulant),
triclosan (antimicrobial disinfectant), tri (2-chloroethyl) phosphate (fire
retardant), and 4-nonylphenol (nonionic detergent metabolite). Steroids,
nonprescription drugs, and insect repellent were the chemical groups
most frequently detected. Detergent metabolites, steroids, and plasticiz-
ers generally were measured at the highest concentrations."
20. Id. at 1202 (citations omitted).
21. HERBERT T. BUXTON & DANA W. KOLPIN, PHARMACEUTICALS, HORMONES, &
OTHER ORGANIC WASTEWATER CONTAMINANTS IN U.S. STREAMS, UNITED STATES
GEOLOGICAL SURVEY, DEP'T OF THE INTERIOR, FS-027-02, at 2 (2002), available at
http://toxics.usgs.gov/pubs/FS-027-02/.
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DETECTION FREQUENCY, IN PERCENT
LE
O
LU
0
0
0
O
z
0
z
0
EXPLANATION
Maximum value *Maximum values not shown:
75th percentile Steroids- 18.3Nonprescription drugs: 17.4
Median Detergent metabolites: 55.6
25 h percentile Plasticizers: 17.4Antibiotics: 3.6Minimum value Fragrances: 4.3
Figure 1: Pharnaceuticals, Hormones, and Other Organic Wastewater
Contaminants in U.S. Streams."
In 2001, Sedlak and Pinkston identified multiple prescription drugs
in wastewater.' They estimated concentrations of such drugs, concluding
22. Id.
23. Sedlak & Pinkston, supra note 16.
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that wastewater concentrations ranged from "less than 1 ng/L to approxi-
mately 133,000 ng/L."" They went on to note:
The estimated concentrations are distributed over a wide range with the
majority of compounds estimated to be present at concentrations be-
tween 100 and 1,000 ng/L. In general, the compounds expected to be
present at the highest concentrations consisted of analgesics (e.g., ace-
tominophen, ibuprofen) and antibiotics (e.g., amoxicillin, cephalexin).
Because some of the analgesics ... also are available as over-the-counter
products, their concentrations in wastewater could be considerably
higher. Compounds estimated to be present at the lowest concentra-
tions tended to be potent drugs such as hormones (e.g., medroxypro-
gresterone, equilin).
Of particular concern is the presence of antibiotics in fresh water re-
sources "because antibiotic contaminants could perturb microbial ecol-
ogy, increase the proliferation of antibiotic-resistant pathogens, and could
pose threats to human health."" Masters summarized this concern:
One of the dominating concerns is the creation of "Superbugs." New
strains of bacteria which are resistant to antibiotics are common near
major cities and in rural areas and have been found in all 15 rivers from
one study, including the Mississippi, the Ohio, and the Colorado. As
bacteria is Isic.] exposed to antibiotics they begin to adapt in order to
survive, not unlike some of the drug resistant staph infections which
have developed in hospitals. This is a concern, but like so many of to-
day's environmental issues, more research is needed."
24. Id. at 57.
25. Id. The identified pharmaceuticals suggest that a "larger suite of pharmaceuti-
cals" may be present in water supplies. Id.
26. Ching-Hua Huang et al., Assessment of Potential Antibiotic Contaminants in
Water and Preliminary Occurrence Analysis, 120 WATER RESOURCES UPDATE 30, 31
(2001) (citing Christian G. Daughton & Thomas A. Ternes, Pharnaceuticals and Per-
sonal Care Products in the Environment: Agents of Suble Change? 107 ENVTL.
HEALTH PERSP. 1 (1999)). Accord Elizabeth A. Frick et al., Presence of Pharmaceuti-
cals in Wastewater EfIluent and Drinking Water, Metropolitan Atlanta, Georgia, July-
September 1999, in PROCEEDINGS OF THE 2001 GEORGIA WATER RESOURCES
CONFERENCE (Kathryn J. Hatcher ed.) (2001); Kelly A. Reynolds, Pharnaceuticals in
Drinking Water Supplies, 45 WATER CONDITIONING & PURIFICATION (2003), available
at http://www.wcponline.com/column.cfm?T-T&ID-2199 Ihereinafter Reynolds, Phar-
maceuticals in Drinking Water Supplies].
27. Masters, supra note 4, at 1. Furthermore, "higher levels of antibiotic resistant
bacterial strains [have been detected] downstream from a swine-feed facility, compared
with upstream levels." RAPID PUB. HEALTH POL'Y RESPONSE PROJECT, SCH. OF PUB.
HEALTH & HEALTH SERVS., THE GEORGE WASHINGTON UNIV., PHARMACEUTICALS ARE
IN THE DRINKING WATER: WHAT DOES IT MEAN? 4 (2008) [hereinafter RAPID PUB.
HEALTH POL'Y RESPONSE PROJECTI (citing Amy R. Sapkota et al., Antibiotic-Resistant
Enterococci and Fecal Indicators in Surface Water and Groundwater Impacted by a
Concentrated Swine Feeding Operation, 115 ENVTL. HEALTH PERSP. 1040 (2007)).
"Evidence suggests that exposure to subtherapeutic doses of antibiotics has resulted in a
detectable increase in antibiotic resistance in some bacteria." Chad A. Kinney et al.,
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Also, in 2001, Huang et al., noted the presence in fresh water re-
sources of antibiotics used in both human therapy' and also in animal
husbandry, specifically beef, swine, and poultry production.'
By 2002, it had been determined that "the amount of pharmaceuti-
cals and personal care products (PPCPs) released into the environment
each year is tantamount to the amount of pesticides used each year.""
The principal emerging PPCPs and their uses were summarized by Ellis:
Presence and Distribution of Wasteiwater-Derived Pharmaccuticals in Soil Irrigated with
Reclaimed Water, 25 ENVTL. TOXICOLOGY & CHEMISTRY 317, 323 (2006) (citing
Rosamund J. Williams, & David L. Heymann, Containment of Antibiotic Resistance,
279 Sci. 1153 (1998); Wolfgang Witte, Medical Consequences of Antibiotic Use in
Agriculture, 279 Sci. 996 (1998)). Accord Ken Carlson et al., Antibiotics in the Cache
la Poudre River, AGRONOMY NEWs, Dec. 2004, at 4.
28. "Antibiotics that are likely to be present in discharged municipal wastewater are
primarily antibiotics used in human therapy." Huang et al., supra note 26, at 32.
29. As discussed in greater detail in Section VI, one of the challenges facing the use
of statutory and regulatory mechanisms to address PPCPs in water supplies is the fact
that both the presence of PPCPs and their concentrations vary substantially. With re-
gard to the use of antibiotics in animal husbandry, this variability was noted by Huang et
al.:
[Clonsiderable differences in antibiotic usage exist among different food animal
species (beef vs. swine vs. poultry). Therefore, the types of antibiotic coin-
pounds that are likely to be found in surface water will strongly depend upon
the types of livestock operations within the watershed.
Id. at 33.
30. Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 26.
31. Ellis, supra note 5, at 185.
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Compound group/class Compound
Pharmaceuticals
Veterinary & human
antibiotics
Analgesics & anti-
inflammatory
drugs
Psychiatric drugs
Lipid regulators
-Blockers
X-ray contrasts
Steroids & hormones
Personal care products
Fragrances
Sun-screen agents
Insect repellents
Antiseptics
Trimethoprim, erytromycine, lincomycin,
sulfamethaxole, chloramphenicol, amoxycillin
Ibuprofen, diclofenac, fenoprofen,
acetaminophen, naproxen, acetylsalicylic acid,
fluoxetine, ketoprofen, indometacine,
paracetamol
Diazepam, carbamazepine, primidone,
salbutamol
Clofibric acid, bezafibrate, fenofibric acid,
etofibrate, gemfibrozil
Metoprolol, propranolol, timolol, sotalol,
atenolol
Iopromide, iopamidol, diatrizoate
Estradiol, estrone, estriol, diethylstilbestrol
(DES)
Nitro, polycyclic and macrocyclic musks;
phthalates
Benzophenone, methylbenzylidene camphor
N,N-diethyltoluamide
Triclosan, chlorophene
Table 1: Pnncipal Emeiyng PPCP Compounds and Their Uses
It is quite probable that the specific PPCPs identified in these occur-
rence studies have been in drinking water supplies for years.' PPCPs
have chemical and physical properties that make it likely for them to end
up in hydrologic systems." Furthermore, certain PPCPs (e.g., antibiotics
and estrogens) may "persist in the environment either due to their inabil-
ity to biodegrade naturally or to their constant use keeping them ever-
present."3'
32. "As long as humans use prescription medicines and over-the-counter drugs, we
will find trace amounts in wastewater, surface water, groundwater and drinking water."
GLOBAL WATER RESEARCH COALITION, GWRC SCIENCE BRIEF: OCCURRENCE &
POTENTIAL FOR HUMAN HEALTH IMPACTS OF PHARMACEUTICALS IN THE WATER
SYSTEM 1 (2009). Accord Reynolds, Pharmaceuticals in Drinking Water Supplies, supra
note 26 ("[Ilt's reasonable to assume that as long as pharmaceuticals have been in use,
they, and their metabolites, have contributed to the overall environmental contamination
load.").
33. Frick et al., supra note 26, at 282.
34. Kelly A. Reynolds, Concern of Pharmaceuticals in Drinking Water, .50 WATER
CONDITIONING & PURIFICATION (2008), available at
http://www.wcponline.com/pdf/08040nTap.pdf [hereinafter Reynolds, Concern of
Pharmaceuticals in Drinking Wated. In fact, the presence of PPCPs in water supplies
has been suggested as a possible indicator of human fecal contamination of those water
supplies. Susan T. Glassmeyer et al., Transport of Chemical and Microbial Compounds
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The increased detection of PPCPs may result from dramatically im-
proved testing equipment and procedures, rather than any recent intro-
duction of PPCPs into drinking water supplies.4  Such new testing
equipment and procedures now allow for the detection of PPCPs at the
nanogram,' or even picogram," level. Until fairly recently, detection lev-
els were at the microgram level.' Furthermore, as noted by Schulman et
al., "detection limits are likely to decrease in the future, as more sensitive
analytical detection techniques become available." ' In essence, while the
detection of PPCPs has increased in frequency as testing equipment and
procedures have improved, the actual presence of PPCPs may not have
changed significantly."
Most of the occurrence studies that have detected PPCPs found them
to occur at very low levels, frequently at parts per trillion (picogram) or
parts per billion (nanogram) levels.
fiom Known Wastewater Dischages-Potential for Use as Indicators of Human Fecal
Contamination, 39 ENVTL. Sci. & TECH. 5157, 5166 (2005). Accord Y. Carrie Guo &
Stuart Krasner, Occurrence of Primnidone, Carbamazepine, Caffeine, and Precursors for
N-Nitrosodimethvlanine in Drinking Water Sources Impacted by Wastewate, 45 J. AM.
WATER RESOURCES ASS'N 58, 58 (2009).
35. "[Als analytical techniques grew more sensitive over the years, many more phar-
maceuticals have been detected in ambient water, wastewater, and drinking water."
ToxSERVICEs L.L.C., APPROACHES TO SCREENING FOR RISK FROM PHARMACEUTICALS
IN DRINKING WATER AND PRIORITIZATION FOR FURTHER EVALUATION 1 (2008). Ac-
cord AM. WATER WORKS Ass'N RES. FOUND., TOXICOLOGICAL RELEVANCE OF EDCs
AND PHARMACEUTICALS IN DRINKING WATER 1, 5 (2008) ("The reality is that nearly any
chemical known to man could be detected in water using the most modern and sensitive
of analytical instrumentation"). See generally Helen C. Poynton & Chris D. Vulpe,
Ecotoxicogenomics: Emerging Technologies for Emerging Contaminants, 45 J. AM.
WATER RES. Ass'N 83, 83 (2009) (describing advances in analytical techniques).
36. A nanogram (ng) is one billionth of a gram ( x 10). The detection level of such
tests is expressed as parts per billion (ppb). One ppb is roughly equivalent to "one drop
of water in an Olympic-sized swimming pool, or a single blade of grass in a football
field[.]" RAPID PUB. HEALTH POL'Y RESPONSE PROJECT, supra note 27, at 1.
37. A picogram (pg) is one trillionth of a gram (l x 10-). The detection level of such
tests is expressed as parts per trillion (ppt). One ppt is roughly equivalent to one "drop
of water in one thousand pools" or one "blade of grass in one thousand football fields."
Id.
38. A microgram (pg) is one millionth of a gram (1 x 10'). The detection level of
such tests is expressed as parts per million (ppm).
39. Schulman et al., supra note 14, at 669. Accord AM. WATER WORKS Ass'N RES.
FOUND., supra note 35, at 1 ("considering the continued advancements in analytical
technologies, today's non-detectable contaminants will be tomorrow's emerging con-
taminants").
40. As noted by the GLOBAL WATER RESEARCH COALITION:
We hear more reports about the presence of pharmaceuticals in water mainly
because of improvements of the analytical methods of detection. What was not
detectable in the past has become detectable today, even at very low concentra-
tions.
GLOBAL WATER RESEARCH COALITION, supra note 32, at 1.
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A. PATHWAYS
There are any number of pathways by which humans can be exposed
to PPCPs contained in fresh water resources. The most obvious means is
the consumption of water containing PPCPs. Other types of water expo-
sures (e.g., swimming, bathing, showering) may also provide exposure
pathways.
Other exposure pathways are more indirect. Schulman et al., note
that certain PPCPs bioaccumulate in fish." The exposure pathway, there-
fore, would be the human consumption of fish or shellfish containing
PPCPs."
In reality, there is seldom a single exposure pathway. The National
Research Council recognized this, noting the existence of both "major
and minor exposure pathways" and concluding that future risk assess-
ments for PPCPs aggregate exposure assessments across multiple path-
ways." Ellis graphically depicted this recognition:"
41. Schulman et al., supra note 14, at 659.
42. Virginia L. Cunningham, Stephen P. Binks, & Michael J. Olson, Human Health
Risk Assessment from the Presence of Human Pharmaceuticals in the Aquatic Environ-
ment, 53 REGULATORY ToxICOLOGY & PHARMACOLOGY 39, 43 (2009); Ellis, supra note
5, at 185 (citing Betty Bridges, Fragrance: Emerging Health and Environmental Con-
cerns, 17 FLAvoUR & FRAGRANCE JOURNAL 361 (2002)); Ake Wennmalm & Bo Gun-
narsson, Public Health Care Management of Water Pollution with Pharmaceuticals:
Environmental Classification and Analysis of Pharmaceutical Residues in Sewage Water,
39 DRUG INFO.J. 291, 296 (2005).
43. COMM. ON TOXICANTS AND PATHOGENS IN BIOSOLIDS APPLIED TO LAND,
NAT'L RES. COUNCIL, BIOSOLIDS APPLIED TO LAND: ADVANCING STANDARDS AND
PRACTICES 13 (2002). Accord Kolpin et al., supra note 18, at 1202 ("there are a wide
variety of transport pathways for many different chemicals to enter and persist in envi-
ronmental waters").
44. Ellis, supra note 5, at 186. It should not be assumed that these are the only
pathways by which exposure to PPCPs occurs. With regard to estrogenicity, for exam-
ple, the AwwaRF has noted:
[Viegetable juice had observed EEq [estradiol equivalent values from 1.9 to
3.3 ng/L, while coffee ranged from 11 to 17 ng/L. Various brands of beer ex-
hibited a broad range of results with EEq values ranging from 0.8 to 140 ng/L.
The highest estrogenicity was observed in soy-based food and beverage items
such as soy sauce (28 - 510 ng/L), soy baby formula (1,500 - 1,900 ng/L) and
soy milk (1,900 - 4,200 ng/L).
Considering that food items are not labeled, or often even tested, for emerging
contaminants, it is difficult to argue that the choice of exposure from food is
any less involuntary than would be exposure from tap water. . . . [Flor the
pharmaceuticals and potential EDCs detected in water, exposure to people
through water is expected to be small compared to exposures to potentially
hazardous compounds through prescription and nonprescription medications,
food and beverages, occupational exposures, and residential activities (e.g.,
cleaning products, personal care products, hobby chemicals, pesticides).
Moreover, the concentrations of some potential EDCs (e.g., plasticizers) are
orders of magnitude greater in food products than in drinking waters[.I
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Figure 2: Sources and Path ways of PPCPs in the Urban Water Cycle
B. EFFECTS OF PPCPS IN WATER
Though research is ongoing, it does not appear that short-term expo-
sure to specific PPCPs at the low levels noted above results in adverse
human health impacts.' Unfortunately, the question of adverse human or
environmental health impacts resulting from PPCPs in water is not as
simple as the foregoing conclusion might suggest.
AM. WATER WORKS Ass'N RES. FOUND., supra note 35, at 4-5. As Stanford et al. have
concluded, "the exposure to natural estrogens and other suspected EDCs from drinking
water pales in comparison to exposure through other dietary routes. . . . lFurthermorej
compared with air exposure, water consumption by humans may represent only a small
fraction of pharmaceutical, personal care products, and EDC exposure." Stanford et al.,
supra note 12, at 61, 63.
45. See, e.g., Schulman et al., supra note 14, at 669:
The main finding of this study was that detected levels of the compounds of in-
terest (parent compounds, acetylsalicylic acid, clofibrate, cyclophosphamide,
and indomethacin, as well as the metabolites, salicylic acid and clofibric acid)
in surface waters and drinking water, do not pose a risk to human health. The
concentrations of each of these pharmaceuticals found in various environ-
mental media to date, fall well below the provisional safe water quality limits
derived, according to the [U.S. Environmental Protection Agency's Methodol-
ogy for Deriving Ambient Water Quality Criteria for the Protection of Human
Health (2000)]. Thus, no adverse health effects for humans are anticipated
from the levels measured.
Accord GLOBAL WATER RESEARCH COALITION, supra note 32, at 2 ("to date, no defini-
tive link has been reported or established between pharmaceutical exposure in drinking
water and human health risk"); RAPID PUB. HEALTH POL'Y RESPONSE PROJECT, supra
note 27, at I ("At current levels, pharmaceutical residues are unlikely to pose an imme-
diate risk to human health, but the long-term consequences of individual chemicals, and
combinations of chemicals, are unknown, especially as concentrations rise.").
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1. Long-Term Low-Dose Exposures
As noted above, short-term exposure to low levels of specific PPCPs
does not appear to result in adverse human health impacts. However, as
Kolpin, et al., have noted:
For many OWCs lorganic wastewater contaminants], acute effects to
aquatic biota appear limited because of the low concentrations generally
occurring in the environment. More subtle, chronic effects from low-
level environmental exposure to select [organic wastewater contami-
nants] appear to be of much greater concern. Such chronic effects have
been documented in the literature. In addition, because antibiotics are
specifically designed to reduce bacterial populations in animals, even
low-level concentrations in the environment could increase the rate at
which pathogenic bacteria develop resistance to these compounds.'
Furthermore, Reynolds has observed that "Itirends of increased tes-
ticular cancer, reproductive abnormalities, breast cancer, early puberty
and decreased sperm count have all been suggested as problems possibly
related to low-level exposure to chemicals (pharmaceuticals and EDCs) in
the environment."" Additional research is needed regarding the effects of
long-term, low-dose exposure to PPCPs."
2. Cumulative or Syriergistic Effects
Human and environmental exposures to PPCPs are never isolated to
one specific PPCP. Such exposures are always to combinations of
PPCPs, the impacts of which are relatively unknown." Combinations of
PPCPs may have cumulative or synergistic effects that go beyond the ef-
fects of any single PPCP.'" This led Kolpin et al., to conclude:
46. Kolpin et al., supra note 18, at 1208 (citations omitted).
47. Reynolds, Concern of Pharmaceuticals in Drinking Water, supra note 34, at 2.
48. "Although a wealth of toxicological information may be available for pharmaceu-
ticals, the effects of unintended chronic exposure to subtherapeutic doses that could
occur via consumption of drinking water are often not known." Erin M. Snyder et al.,
Pharmaceuticals and EDCS in the US Water Industry-An Update, 97 J. AM. WATER
WORKS Ass'N 32, 33 (2005).
49. "In field situations, organisms are exposed to not just one compound but a m6-
lange of contaminants, which can interact within the environment and individual organ-
isms." Poynton & Vulpe, supra note 35, at 91. "Ilt is not clear what toxicological im-
plications chronic exposure to suites of trace contaminants may pose." Mark J. Benotti
et al., Pharmaceuticals and Endocrine Disrupting Compounds in U.S. Drinking Water,
43 ENVTL. Sci. & TECH. 597, 597 (2009) (emphasis added) (citing Oliver A. Jones et al.,
Pharmaceuticals: a Threat to Drinking Water, 23 TRENDS IN BIOTECHNOLOGY 163
(2005); Shane A. Snyder et al., Pharmaceuticals, Personal Care Products, and Endocrine
Disruptors in Water: Implications for the Water Industry, 20 ENVTL. ENGINEERING SCI.
449 (2003)). "A limited body of research ... suggests an additive effect when a mixture of
pharmaceuticals is present." RAPID PUB. HEALTH POL'Y RESPONSE PROJECT, supra note
27, at 4 (citing Francesco Pomati et al., Effects and Interactions in an Environmental/v
Relevant Mixture of Pharmaceuticals, 102 ToxICOLOGICAL SCI. 129 (2008)).
50. Koplin et al., supra note 18, at 1210.
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[Aldditional research on the toxicity of the target compounds should
include not only the individual [organic wastewater contaminants) but
also mixtures of these compounds. The prevalence of multiple com-
pounds in water resources has been previously documented for other
contaminants. In addition, research has shown that select chemical
combinations can exhibit additive or synergistic toxic effects, with even
compounds of different modes of action having interactive toxicological
effects.'
For example, in a study of the role of steroidal estrogens in determin-
ing sex, the researchers noted that "strong natural estrogens at low doses
may synergize with low doses of weak natural and man-made estrogens.""
This combination of low doses of estrogen "may act synergistically to
produce a strong estrogenic response."
Other research suggests that cumulative or synergistic effects may not
be a threat to human health:
The issue of mixtures, that is the simultaneous presence of multiple
pharmaceuticals, is an ever present question for trace residual com-
pounds of all types in drinking water supplies. The guidelines for "pro-
visionally safe" or "acceptable intake" levels are calculated separately
for individual compounds. However, the "worst case scenario" ap-
proach used in screening risk assessment includes large uncertainty fac-
tors and safety factors and is considered by regulatory and health au-
thorities (e.g., the World Health Organization in their Drinking Water
Quality Guidelines) to be sufficient to account for possible interactions
among compounds a person might be exposed to simultaneously."
Nevertheless, in addition to cumulative or synergistic effects, recent
research suggests that PPCPs may become more persistent if they are
combined. As Monteiro and Boxall have observed:
51. Id. (citations omitted). In a study of the effect of aquatic and terrestrial species
exposure to tricolsan and tricolcarban, Chalew and Halden concluded that "it appears
prudent to consider the possibility of additive, antagonistic or synergistic effects from
exposure to mixtures of the two." Talia E. A. Chalew & Rolf U. Halden, Environnental
Exposure of Aquatic and Terrestrial Biota to Triclosan and Triclocarban, 45 J. AM.
WATER RESOURCES Ass'N 4, 11 (Feb. 2009). It has also been noted that "[mlixtures of
pharmaceuticals, which commonly occur in surface waters where discharges from mu-
nicipal wastewater treatment plants flow, may have cumulative effects on organisms."
TDC ENVIRONMENTAL, HOUSEHOLD PHARMACEUTICAL WASTE: REGULATORY AND
MANAGEMENT ISSUES 2 (2004) (citing Sean M. Richards et al., Effects of Pharmaceutical
Mixtures in Aquatic Microcosms, 23 ENvTL. TOXICOLOGY & CHEMISTRY 1035 (2004)).
See alsoJessica G. Davis, Antibiotics in the Environment, AGRONOMY NEws 1, 2 (Dec.
2004) ("Degradation products and interactions among compounds have not been ade-
quately evaluated and could result in synergistic toxic effects").
52. Judith M. Bergeron et al., Developmental Synergism of Steroidal Estrogens in
Sex Determination, 107 ENVTL. HEALTH PERSP. 93, 96 (1999).
53. Id. at 93.
54. GLOBAL WATER RESEARCH COALITION, supra note 32, at 2.
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As pharmaceuticals will never be in the environment as single com-
pounds, a consideration of the impacts of mixtures of different pharma-
ceuticals and pharmaceuticals and other compounds needs to be as-
sessed. Our preliminary data demonstrate that degradation may be sig-
nificantly slower in mixtures[.]
For example, while the degradation of individual PPCPs identified in
Project 2 was relatively fast (half-lives of less than thirty days), the pres-
ence of two PPCPs in a simple mixture increased the persistence of both
PPCPs.";
3. Susceptible Groups
Specific population segments or groups may be unusually susceptible
to adverse effects from exposure to PPCPs. Children, for example, are
thought to be particularly susceptible, as are pregnant women." As Col-
lier has noted:
[Liong-term exposure to such chemicals, for example in children, could
potentially cause long-term changes affecting organ systems and/or
structural function. In addition, exposure to pharmaceuticals during
the fetal period when many of the growth and development patterns for
later life are laid down, may induce subtle changes that take years to
manifest, but eventually have measurable physiological, morphological,
or cognitive effects.
Other groups such as the elderly, the infirm, or the immunocom-
promised may also be unusually susceptible." Research regarding the
impacts of exposure to PPCPs on these and other population segments or
groups is ongoing.
4. Environmental Health Impacts
Human beings are not exposed continuously to fresh water resources
containing PPCPs. The same cannot be said for aquatic species, which
by their very nature are continuously exposed to water supplies contain-
ing PPCPs." Such species "are exposed continually, over many genera-
55. Sarah C. Monteiro, & Alistair B.A. Boxall, Pharmaceuticals and Personal Care
Products in the Environment: Factors Affecting the Degradation of Pharmaceuticals in
Agricultural Soils, 28 ENvTL. TOXICOLOGY & CHEMISTRY 2546, 2553 (2009).
56. Discussed infra Part V.
57. Abby C. Collier, Pharmaceutical Contaminants rn Potable Water: Potential Con-
cerns for Pregnant Women and Children, 4 EcoHEALTH 164, 170 (2007) (referencing
"the special populations of pregnant and pediatric individuals, where there is elevated
risk from exposure to several drugs that are contraindicated and to which exposure
should, ideally, be nil"). See also Cunningham, Binks, & Olson, supra note 42; Rey-
nolds, Pharmaceuticals in Drinking Water Supplies, supra note 26.
58. Collier, supra note 57, at 170.
59. Cunningham, Binks, & Olson, supra note 42, at 40, 44.
60. RAPID PUB. HEALTH POL'Y RESPONSE PROJECT, supra note 27, at 4.
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tions, to the higher concentrations of pharmaceuticals that linger in sur-
face water."" This exposure may result in "endocrine disruptions, repro-
ductive effects and renal deterioration in fish, among other damage.""
For example, with regard to both fish and other aquatic vertebrates,
the low-level presence of pharmaceutical estrogens' leads to "a suite of
adverse effects" including: feminization of males;' impaired reproductive
capacity;' and abnormal sexual development."
61. Id. at 4 (citing Environmental Protection Agency, PHARMACEUTICALS AND
PERSONAL CARE PRODUCTS, http://www.epa.gov/ppcp/faq.html#whatarethemajorissues).
62. Id. at 4.
63. Specifically, estrone (E.), 17p-estradiol (&), estriol (E) and the synthetic estro-
gen, 17a-ethinylestradiol.
64. Marlo K. Sellin et al., Estrogenic Compounds Downstream from Three Small
Cities in Eastern Nebraska: Occurrence and Biological Effect, 45 J. OF THE AM. WATER
RESOURCES ASS'N 14 (2009) (citing Gordon C. Balch et al., Feminization of Female
Leukophore-Free Strain offapanese Medaka (Oryzias laties) Exposed to 17/8-EsIradiol,
23 ENvTL. TOXICOLOGY AND CHEMISTRY 2763 (2004); F. Brion et al., Impacts of 17/3-
Estradiol, Including Environmentally Relevant Concentrations, on Reproduction After
Exposure During Embryo-Larval-, Juvenile- and Adult-Life Stages in Zebrallsh (Danio
rerio), 68 AQUATIC TOXICOLOGY 193 (2004); G.H. Panter et al., Adverse Reproductive
Effects in Male Fathead Minnows (Pimephales promelas) Exposed to Environmentally
Relevant Concentrations of the Natural Destrogens, Oestradiol and Oestrone, 42
AQUATIC TOXICOLOGY 243 (1998)).
65. Id. at 14-15 (citing Shoko Imai et al. Elfects of 17-Estradiol on the Reproduc-
tion of java-Medaka (Oryzias javanicus), a New Test Fish Species, 51 MARINE
POLLUTION BULL. 708 (2005); F. Brion et al., Impacts of 17/-Estradiol, Including Envi-
ronmentally Relevant Concentrations, on Reproduction After Exposure During Embryo-
Larval-, juvenile- and Adult-Life Stages in Zehrafish (Danio rerio), 68 AQUATIC
TOXICOLOGY 193 (2004); Tsutomu Shioda & Meiko Wakabayashi, Effect of Certain
Chemicals on the Reproduction of Medaka (Olyzias latipes), 40 CHEMOSPHERE 239
(2000); VJ. Kramer et al., Reproductive Impairment and Induction of Alkaline-Labile
Phosphate, a Biomnarker of Estrogen Exposure, in fathead Minnows (Piiephales Pro-
mnelas) Exposed to Waterborne 17-Estradiol, 40 AQUATIC TOXICOLOGY 335 (1998)).
See also Poynton & Vulpe, supra note 35, at 84 (citing Karen A. Kidd et al., Collapse of
a Fish Population After Exposure to a Synthetic Estrogen, 104 PROC. OF THE NAT'L
ACAD. OF SCI. OF THE UNITED STATES OF AMERICA. 8897 (2007) (17a ethynylestradiol
has been shown "to cause sublethal effects in fathead minnow leading to population
decline at very low concentrations")); Heiko L. Schoenfuss et al., Effects ofExposure to
Low Levels of Water-Borne 17-Estradiol on Nest Holding Ability and Sperm Quality
in Fathead Minnows, 120 WATER RESOURCES UPDATE 49 (2001). While exposure to
17p-estradiol did not result in long-term changes in sperm quality, the authors noted that
17p-estradiol "is but one of many estrogenic compounds that have been found in Isew-
age treatment planti effluent, and the overall estrogenic potency of the effluent could be
much greater than simulated in this experiment." Id. at 52. See also Schulman et al.,
supra note 14, at 676.
66. Sellin et al., supra note 64, at 15 (citing Narisato Hirai et al., Feminization of
Japanese Medaka (Oryzias laties) Exposed to 17beta-Estradiol: Formation of Testis-
Ova and Sex-Transformation During Early-Ontogeny, 77 AQUATIC TOXICOLOGY 78
(2006); Henrik Holbech et al., Detection of Endocrine Disrupters: Evaluation of a Fish
Sexual Development Test (FSDT), 144C COMP. BIOCHEMISTRY AND PHYSIOLOGY 57
(2006); W.R. Hartley et al., Gonadal Development in japanese Medaka (Oryzias latupes)
Exposed to 17/-Estradiol, 46 MARINE ENVIRONMENTAL RESEARCH 145 (1998)).
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These observations led Sellin et al. to conclude that "the presence of
estrogens in the aquatic environment, even at low concentrations, is likely
to pose a significant threat to the health of aquatic organisms.""
Such threats are not limited to the presence of low-levels of pharma-
ceutical estrogens. Antidepressants, for example, may "trigger premature
spawning in shellfish while drugs designed to treat heart ailments block
the ability of fish to repair damaged fins.""
The presence of PPCPs in water resources affect organisms through-
out the food web. Chalew and Halden note that "[mlany of the investi-
gated organisms are at the bottom of the food chain; therefore, impacts to
their populations, due to either die-off from acute toxic exposures or fail-
ure to reproduce successfully as a result of chronic exposures, may lead
to adverse consequences throughout the ecosystem and food chain.""
However, they also note that "such a scenario at present is entirely specu-
lative, since studies appropriate to probe for this outcome have not yet
been conducted.""0
The presence of antibiotics in fresh water resources may also reduce
the growth of aquatic plants." In essence, "since pharmaceuticals is one
of the few chemical classes intended to be bioactive, they are potentially
harmful to the aquatic flora and fauna.""
67. Id.
68. Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 26.
69. Chalew & Halden, supra note 51, at 10.
70. Id. The need for "appropriate" studies has been noted frequently. For example,
Poynton & Vulpe have observed:
For many emerging contaminants, their toxicity to aquatic organisms is largely
unknown. Even pharmaceuticals, which undergo extensive testing in mammal-
ian models, may exhibit different toxicity on aquatic species. In addition, many
pharmaceuticals and EDCs are not responsive to traditional toxicity assays that
measure lethality or reproduction over a single generation and are requiring
regulatory agencies to rethink testing requirements. This could also be true for
other emerging chemicals including PBDEs [polybrominated diphenyl ethers]
and nanomaterials whose mechanism of action is not known.
Poynton & Vulpe, supra note 35, at 84 (citing Mark C. Crane et al., Chronic Aquatic
Environmental Risks From Exposure to Human Pharmaceuticals, 367 SCI. OF THE
TOTAL ENV'T 23 (2006); Leon E. Gray, Jr., Tiered Screening and Testing Strategy for
Xenoestrogens and Antiandrogens, 102-103 TOXICOLOGY LETTERS 677 (1998); John P.
Sumpter, & Andrew C. Johnson, Lessons From Endocrine Disruption and Their Appli-
cation to Other Issues Concerning Trace Organics in the Aquatic Environment, 39
ENVTL. Sci. & TECH. 4321 (2005)).
71. TDC ENVIRONMENTAL, supra note 51, at 2 (citing Richard A. Brain et al., Ef-
fects of 2.5 Pharmaceutical Compounds to Lemna Gibba Using a Seven-Day Static-
Renewal Test, 23 ENvTL. TOXICOLOGY AND CHEMISTRY 371 (2004)).
72. Wennmalm & Gunnarsson, supra note 42, at 291. Accord Ellis, supra note 5, at
188 ("The persistent, long-term chronic exposure of aquatic organisms to low-dose
PPCP concentrations although individually at or below the fProbable No-Effects Con-
centration] level, may well lead to cumulative stress and toxicity which could be a catalyst
for subtle endpoint ecological changes.").
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C. SOURCES OF PPCPS IN WATER
An understanding of the sources of PPCPs in water is essential for
two reasons. First, as discussed in greater detail in the following section,
different statutory and regulatory requirements apply to different sources
of PPCPs. Second, as discussed in greater detail in Section IV, potential
alternative strategies leading to the minimization or elimination of PPCPs
in water may be source-specific.
There are, of course, some naturally occurring sources of PPCPs.
These sources appear as background amounts, not as major PPCP
sources. The major sources of PPCPs are anthropogenic." Assuming the
use of pharmaceuticals, personal care products, dietary supplements, and
other consumer products, PPCPs are contained in human and animal
feces and urine. They are also commonly contained in hospital or medi-
cal wastes and in the wastes from industrial and agricultural processes.
Another common source of PPCPs is unwanted pharmaceuticals and
personal care products that are disposed of inappropriately (i.e., by being
flushed down toilets)." Pharmaceuticals used in the fruit production in-
dustry are yet another source of PPCPs," as are leachate from landfills"
73. See Ed Means, Amlan Ghosh, & Zaid Chowdhury, Endocrine Disruptois and
Pharmaceuticals Strategic Initiative Expert Workshop Report, AM. WATER WORKS
Ass'N RES. FOUND. 5 (2007) available at
http://www.waterrf.org/Research/ResearchPrograms/StrategicResearchInitiatives/Docume
nts/EDCWorkshopReport.pdf (regarding EDCs, "[wlhile some estrogenic compounds
occur naturally, most of the detected estrogenic compounds are introduced from man-
made sources"). See also Dore Hollander, Environmental Effects on Reproductive
Health: The Endocrine Disruption Hypothesis, 29 FAMILY PLANNING PERSP. 82, 83
(1997):
Endocrine disrupters, some of which occur naturally (phytoestrogens) and
some of which are man-made, are ubiquitous: They can be found in soil, water,
air and food, as well as in commonly used industrial and household products.
Phytoestrogens are present in grains, legumes, grasses, herbs, nuts and a variety
of fruits and vegetables; some fungi also produce compounds that may interfere
with hormonal function. Phytoestrogens are weaker than endogenous estrogen
(i.e., they do not bind as well to hormone receptors) and are quickly excreted
or broken down into other compounds; they do not accumulate in body tissue.
Id.
74. Paul D. Anderson et al., Screening Analysis of Human Pharmaccutical Com-
pounds in U.S. Surface Waters, 38 ENvTL. Sci. & TECH. 838, 838 (2004). Accord Ellis,
supra note 5, at 185.
75. Thomas Heberer et al., Occurrence and Fate of Pharmaceuticals During Bank
Filtration - Preliminary Results From Investigations in Gernany and the United States,
120 WATER RES. UPDATE 4, 5 (2001) [hereinafter Heberer et al., Pharmaceuticals Dur-
ing Bank Filtration) .
76. Benotti et al., supra note 49, at 597. Accord Reynolds, Pharmaceuticals in
Drinking Water Supplies, supra note 26.
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and urban runoff.' PPCPs may also be rinsed from a person's body dur-
ing bathing."
D. PROCESSES OR MECHANISMS BY WHICH PPCPS ARE INTRODUCED
INTO FRESH WATER RESOURCES
There are numerous processes or mechanisms that can introduce
PPCPs into fresh water resources." With regard to the sources of PPCPs
noted above, wastewater treatment plants treat a substantial portion of
human wastes. Following wastewater treatment plant processing, treated
water may be discharged into a receiving stream or lake.
Typically, wastewater treatment plants remove and dispose of the re-
sidual sludge contained in the processing tanks pursuant to the regula-
tions discussed in Section III. Both the treated water discharged into a
receiving stream or lake" and the residual sludge" will contain varying
77. Juliane B. Brown, William A. Battaglin, & Robert E. Zuellig, Lagrangian Sam-
pling for Emerging Contaminants Through an Urban Stream Corridor in Colorado, 45J.
AM. WATER RES. Ass'N 68, 70 (2009); Benotti et al., supra note 49, at 597.
78. Snyder et al., supra note 48, at 32.
79. "Pharmaceutical compounds are introduced into the environment through a
number of different pathways, including excretion of the parent compound, active ingre-
dients, water soluble conjugates, or metabolites via urine and feces after therapeutic
home and hospital use, and through disposal of unused pharmaceuticals by patients or
providers via landfills and sewers." Schulman et al., supra note 14, at 658 (citing NJ.
Ayscough et al., The Environment Agency Research and Development Dissemination
Centre, REVIEW OF HUMAN PHARMACEUTICALS IN THE ENVIRONMENT 106 (2000)).
Accord Janice M. Skadsen et al., THE OCCURRENCE AND FATE OF PHARMACEUTICALS,
PERSONAL CARE PRODUCTS AND ENDOCRINE DISRUPTING COMPOUNDS IN A MUNICIPAL
WATER USE CYCLE: A CASE STUDY IN THE CITY OF ANN ARBOR 2 (2004), available at
http://wwv.a2gov.org/government/publicservices/watertreatment/Documents/Endocrine
Disruptors.pdf ("the potential exists for PPCPs to enter the environment from multiple
routes, such as, wastewater treatment discharge, industrial discharge, runoff from con-
fined animal feeding operations, and treated sludge applied to agricultural land . . .
PPCPs may enter the treatment process in a reduced form (after passing through body)
or by direct discharge of discarded PPCPs") (citing Christian G. Daughton & Thomas A.
Ternes, Pharmaceuticals and Personal Care Products in the Environment. Agents of
Subtle Change? 107 ENvTL. HEALTH PERSP. 1 (1999)).
80. Treated wastewater frequently contains "antioxidants, detergents and detergent
metabolites, disinfectants, fire retardants, fragrances, insect repellants, pharmaceuticals
(prescription and nonprescription drugs), pesticides, plasticizers, polycyclic aromatic
hydrocarbons, and steroidal compounds[.1" Brown, Battaglin, & Zuellig, supra note 77,
at 69-70. Such wastewater "has been shown to contain low, yet biologically active, con-
centrations of estrogenic compounds." Sellin et al., supra note 64, at 15 (citing Marta
Carballa et al., Behavior of Pharmaceuticals, Cosmetics and Hormones in a Sewage
Treatment Plant, 38 WATER REs. 2918 (2004); Andrew C. Johnson & John P. Sumpter,
Removal of Endocrine-Disrupting Chemicals in Activated Sludge Treatment Works, 35
ENVTL. SCI. & TECH. 4697 (2001); Chiara Baronti et al., Monitoring Natural and Syn-
thetic Estrogens at Activated Sludge Sewage Treatment Plants and in a Receiving River
Water, 34 ENVTL. SC. & TECH. 5059 (2000)). See also Chalew & Halden, supra note
51, at 7; Kinney et al., supra note 27, at 317 (citing Christian G. Daughton, & Thomas
A. Ternes, Pharmaceuticals and Personal Care Products in the Environment: Agents of
Subtle Change? 107 ENvTL. HEALTH PERSP. 907 (1999)).
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levels of PPCPs. Consequently, it is not surprising that a number of stud-
ies have noted the increased presence of PPCPs in receiving waters
downstream of wastewater treatment plants." As discussed in greater de-
tail in Section V, treated wastewater used for agricultural and landscape
irrigation may also contain PPCPs."
In fact, only a portion of the wastes which sanitary sewers collect may
actually be treated at wastewater treatment plants. Depending on the
condition of the sewer system, a significant portion of collected wastes
may be lost through cracks or breaks in sewer lines. In areas where
storm drains and sanitary sewers are combined, significant rainfall events
may produce quantities of wastes that exceed the capacity of the wastewa-
ter treatment plant." These "combined sewer overflows" (CSOs) are fre-
quently discharged into surface waters with little or no treatment, result-
ing in "elevated concentrations of bacteria, nutrients, and OWCs [organic
wastewater compounds] in receiving waters."" As a result, untreated sew-
age "derived from leaky sewers and CSOs . . . may have a disproportion-
81. "In biosolids destined for land application, a number of pharmaceuticals and
personal care products have been detected." Monteiro & Boxall, supra note 55, at 2546
(citing Chad A. Kinney et al., Survey of Organic Wastewater Contaminants in Biosolids
Destined for Land Application, 40 ENVTL. Sci. & TECH. 7207 (2006); Chris D. Metcalfe,
Distribution of Acidic and Neutral Drugs in Surface Waters Near Sewage Treatment
Plants in the Lower Great Lakes, Canada, 22 ENVTL. TOXICOLOGY AND CHEMISTRY
2881 (2003)).
82. Sellin et al., supra note 64, at 19 (greatest quantities of estrogens found in surface
water downstream of wastewater treatment plants). "[Pharmaceutical and PPCP resi-
dues have been detected in fish tissues downstream of wastewater treatment facilities
leading to bioaccumulation in muscles and critical organs." Poynton & Vulpe, supra
note 35, at 84 (citing Bryan W. Brooks et al., Determination of Select Antidepressants
in Fish From an Effluent-Dominated Stream, 24 ENvTL. TOXICOLOGY AND CHEMISTRY
464 (2005); J. Schwaiger et al., Toxic Effects of the Non-steroidal Anti-inflamnmatory
Drug Diclofenac. Part 1: Histopathological Alterations and Bioaccunulation in Rainbow
Trout, 68 AQUATIC TOXICOLOGY 141 (2004)). Accord Brown, Battaglin, & Zuellig,
supra note 77, at 68.
83. Kinney et al., supra note 27, at 317. Accord Benotti et al., supra note 49, at 597.
84. With regard to such weather events, the release of bacteria (and presumably
PPCPs) trapped in sediments may result from "sediment resuspension caused by storms,
flood, tides, or strong winds[.j" Jianyong Wu et al., Fate and Transport Modeling of
Potential Pathogens: The Contribution from Sediments, 45 J. AM. WATER RESOURCES
AsS'N 35, 36 (2009) (citing R.W. Muirhead et al., Faccal Bacteria Yields in Artificial
Flood Events: Quantifying In-Stiream Stores, 38 WATER RES. 1215 (2004); R.C.
Jamieson et al., Resuspension of Sediment-Associated Escherichia Coli in a Natural
Stiream, 34 J. EN1TL. QUALITY 581 (2005)). On a related point, there is a relationship
between climatic variability and the variable presence of PPCPs in water resources. Guo
& Krasner, supra note 34, at 64 (reduced instream flow during dry years resulting in less
dilution of wastewater treatment plant outflows).
85. P. Phillips, & A. Chalmers, Wastewater Elfluent, Combined Sewer Overflows,
and Other Sources of Organic Compounds to Lake Champlain, 45 J. AM. WATER
RESOURCES ASS'N 45, 46 (2009). Accord Brown, Battaglin, & Zuellig, supra note 77, at
70 (storm drains as a source of PPCPs).
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ately large effect on concentrations of compounds that are well removed
by wastewater treatment processes (such as caffeine and ibuprofen)."
If the surface water is diverted subsequently for use as water supply, a
portion of the PPCPs contained in the raw water supply will end up in the
drinking water supply. If surface water is used to recharge groundwater,
or if the surface stream is a "losing" stream that recharges groundwater,
PPCPs in the surface stream may end up in the groundwater." If water
treatment plants apply the sludge from the processing tanks to land, a
common disposal method in the United States for wastewater treatment
plant sludge,' then rain or melting snow will allow the PPCPs to be ab-
sorbed into soils' and to infiltrate groundwater.'
86. Phillips & Chalmers, supra note 85, at 46 (citing Lorien J. Fono, & David L.
Sedlak, Use of the Chiral Pharmaceutical Propranol to Identify Sewage Discharges Into
Surface Waters, 39 ENVTL. Sci. & TECH. 9244 (2005)).
87. Thomas Heberer et al., Removal of Pharmaceutical Residues and Other Persis-
tent Organics From Municipal Sewage and Surtce Waters Applying Membrane Filtra-
tion, 120 1VATER RES. UPDATE 18, 19 (2001) [hereinafter Heberer et al., Removal of
Pharmaceutical Residuesl (citations omitted).
88. See COMM. ON TOXICANTS AND PATHOGENS IN BIOSOLIDs APPLIED TO LAND,
supra note 43, at 1 ("Approximately 5.6 million dry tons of sewage sludge are used or
disposed of annually in the United States; approximately 60% of that is used for land
application."). See also Xia et al., supra note 4, at 47 ("Biosolids land application is
becoming the most common means of biosolids disposal as other disposal options be-
come cost prohibitive or heavily regulated.").
89. Triclosan ("TCS") is "an antimicrobial compound that is added to a wide variety
of household and personal care products" that "may be accumulated by earthworms
after land application of biosolids." Nuria Lozano et al., Fate of Triclosan in Agricultural
Soils After Biosohd Applications, 78 CHEMOSPHERE 760, 760 (2010) (citing Chad A.
Kinney et al. Bioaccumulation of Pharmaceuticals and Other Anthropogenic Waste
Indicators in Earthworms from Agilcultural Soil Amended with Biosohd or Swine Ma-
nure, 42 ENvTL. Sci. & TECH. 1863 (2008)). The potential consequences of such bioac-
cumulation are of note:
Since TCS is a bacteriostat, there is a real potential that concentrations in soils
resulting from biosolid applications might affect bacterial ecology of these sys-
tems. Especially since the ecological balance and competitive advantages of the
multiple species inhabiting any soil environment are very complex and any
small advantage one microbe might achieve due to exposure to these known
bacteriostat could be amplified under these conditions.
Id., at 764. The sorption and degradation.of PPCPs in soil is discussed in greater detail
in Section V.
90. Concluding that several pharmaceutically active compounds "can be transported
through the subsoil without any substantial attenuationi,]" Heberer et al. focused on
clofibric acid, "the pharmacologically active metabolite of the drugs clofibrate, etofyllin
clofibrate, and etofibrate, used as blood-lipid regulators in human health care." Heberer
et al., Pharmaceuticals During Bank Filtration, supra note 75, at 6-7.
[Bletween 1992 and 1995, clofibric acid . . . was detected at concentrations at
the pg/L-level in ground water samples collected from former sewage irrigation
fields near Berlin and in Berlin tap-water samples. It became evident that these
residues were caused by the infiltration of sewage effluents into the soil and
that clofibric acid is a very mobile compound that is not substantially adsorbed
in the subsoil and is leached easily into the aquifer. . . . In Germany, the first
detections of clofibric acid in ground water put focus on the presence of drug
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The presence of PPCPs in groundwater has also been detected in ar-
eas where human wastes are treated using septic tank systems." Human
wastes containing PPCPs that-flow into septic tanks will eventually flow
into groundwater.
Because of the widespread use of antibiotics in animal husbandry,'
PPCPS are also present in the feces and urine of a wide variety of domes-
ticated animals. Manure produced by such animals will contain PPCPs.
As with the sludge from wastewater treatment plants, manure is fre-
quently applied to land as a waste disposal mechanism. As with wastewa-
ter treatment plant sludge, rain or melting snow will cause PPCPs con-
tained in manure to flow into groundwater."
Much like septic tank systems, but on a larger scale, liquid wastes
from domesticated animals may be collected in lagoons or ponds." These
impoundments are quite effective in providing a means by which PPCPs
contained in liquid wastes can find their way into groundwater.' Of par-
ticular concern are both the land application of manure and the collec-
tion of liquid wastes in lagoons or ponds associated with Confined Ani-
mal Feeding Operations."
residues in the aquatic system as a new emerging issue and researchers began to
investigate the occurrence and fate of pharmaceutical residues in the aquatic
environment, during drinking-water purification, and in drinking water sam-
ples.
Id. at 6. See also Huang et al., supra note 26, at 33 ("Land application of animal waste
provides routes for agricultural antibiotics to enter the aquatic environments, which may
eventually reach drinking water supplies").
91. RAPID PUB. HEALTH POL'Y RESPONSE PROJECT, supra note 27, at 1; Kinney et
al., supra note 27.
92. "About ninety percent of the approximately 2.5 million kg of antibiotics sold in
the United States are given as growth-promoting and prophylactic agents in sub-
therapeutic doses instead of being used to treat active infections, thereby lowering the
cost of animal care." Heberer et al., Pharmaceuticals During Bank Filtration, supra note
75, at 10. Accord Reynolds, Concern of Pharnaceuticals in Driking Water, supra note
34, at 1 ("forty percent of antibiotics manufactured are fed to livestock as growth enhan-
cers").
93. Heberer et al., Pharmaceuticals During Bank Filtration, supra note 75, at 6.
Accord Davis, supra note 51, at 1-3.
94. "Researchers have shown that several classes of antibiotics (e.g., tetracyclines,
sulfonamides, macrolides and ionophores) are present in hog waste lagoons at concen-
trations as high as 0.7 mg/L." Carlson et al., supra note 27, at 4.
95. Heberer et al., Pharnaceuticals During Bank Filtration, supra note 75, at 10.
96. Benotti et al., supra note 49 at 597. See also, Carlson et al., supra note 27, at 7
("a wide range of antibiotics is present in most animal waste streams, either runoff
ponds, waste lagoons or manure stockpiles"); Heberer et al., Pharnaceuticals During
Bank Filtration, supra note 75, at 10; Masters, supra note 4, at 1.
394 Volume 15
PHARMACEUTICALS AND PERSON4L CARE PRODUCTS
III. CURRENT MEANS OF PROTECTING FRESH WATER
RESOURCES
A. COMMON LAW REMEDIES SOUNDING IN TORT
The word "tort" is derived from the Latin tortus, meaning bent or
crooked. Torts are private acts or civil wrongs in which an injured plain-
tiff seeks compensation from an allegedly responsible defendant. There
are four tort theories, each of which is potentially applicable to injuries
allegedly relating to exposure to PPCPs. It should be noted, however,
that application of any of the four theories, either individually or in com-
bination with one another, will be dependent on the facts of a specific
case.
1. Trespass
There are three elements for establishing a claim under the theory of
trespass. First, the plaintiff must have been harmed." Second, the de-
fendant's conduct must have caused the plaintiffs harm." Third, the de-
fendant must have intentionally (a) entered land in the possession of the
plaintiff (or caused something or someone else to do so); (b) remained on
the plaintiffs land; or (c) failed to remove from the plaintiff's land "a
thing which he is under a duty to remove."" In the case of personal
property (trespass to chattels), an alternative third element is applicable
when the defendant intentionally interfered with the plaintiffs personal
property by (a) damaging the personal property; (b) depriving the plaintiff
of the use of the property for a substantial period of time; or (c) "dispos-
sessing" the property from the plaintiff." With regard to the requirement
of intentionality, individuals are generally presumed to know the "natural
and probable consequences" of their actions."'
2. Nuisance
As with the theory of trespass, a nuisance claim contains three ele-
ments. First, the plaintiff's interest must be harmed."' Second, the defen-
dant's conduct must have caused the plaintiffs harm." Third, the defen-
97. RESTATEMENT (SECOND) OF TORTS SS 158, 162 (1965). The plaintiff does not
have to show harm for the defendant to be liable for trespass. However, the plaintiff
would have to show harm to receive compensatory damages, though there are other
remedies, such as nominal damages, that do not require a showing of harm.
RESTATEMENT (SECOND) OF TORTS SS 901, 907 (1979).
98. RESTATEMENT (SECOND) OF TORTS §158 (1965).
99. Id. As noted in the Restatement, the protected property interest of the plaintiff
is the right of "exclusive possession and its physical condition of land." Id. S 157.
100. Id. §§ 217-18.
101. Francis v. Franklin, 471 U.S. 307, 311 (1985) ("A person of sound mind and
discretion is presumed to intend the natural and probable consequences of his act .
102. RESTATEMENT. (SECOND) OF TORTS § 821D cmt. d (1979).
103. RESTATEMENT (SECOND) OF TORTS § 822 (1979).
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dant's intentional actions must be either a public or a private nuisance.
Public nuisances result where a defendant unreasonably interferes "with a
right common to the general public" including a significant interference
with public health, safety, peace, comfort, or convenience; additionally, a
defendant's actions may be a public nuisance when the conduct is pro-
scribed by statute or ordinance." Private nuisances result where the de-
fendant (a) substantially interfered with the plaintiffs use and enjoyment
of property or (b) caused the plaintiff harm."
3. Negligence
There are five elements to the theory of negligence, all of which must
be established to raise a claim against a defendant. First, the plaintiff
must have been harmed." Second, the evidence must show that the de-
fendant's conduct caused the plaintiff's harm." Third, the defendant
must have owed a duty of reasonable care to the plaintiff."' Fourth, the
plaintiff must evidence that the defendant breached the duty of reason-
able care." Fifth, the harm to the plaintiff resulting from the breach must
have been foreseeable."
The duty of reasonable care is particularly relevant. The standard of
care is frequently expressed as the question: What would a reasonably
prudent person have done? Professionals are usually held to a higher
standard of care than non-professionals because of both education and
licensing requirements."' Corporations, because of superior knowledge
regarding specific products, may also be held to a higher standard of care
than the general citizenry."'
104. State v. H. Samuels Co., 211 N.W.2d 417, 421 (Wis. 1973) (holding that a viola-
tion of a noise ordinance may constitute nuisance); RESTATEMENT (SECOND) OF TORTS
§ 821B (1979).
105. RESTATEMENT (SECOND) OFTORTS 6 821D (1979); Id. § 821D cmt. d.
105. RESTATEMENT (SECOND) OF TORTS § 281 (1965).
106. Id.
107. Palsgraf v. Long Island R.R. Co., 162 N.E. 99, 102 (N.Y. 1928). Reasonableness
may be defined by permit conditions, by industry custom/practice, or by statute.
RESTATEMENT (SECOND) OF TORTS § 286 (1965). Violation of permit conditions or
other statutory or regulatory requirements is almost always negligence per se. Sammons
v. Ridgeway, 293 A.2d 547, 549 (Del. 1972) (holding that the violation of a statute is
negligence per se).
108. Palsgraf, 162 N.E. at 102.
109. Id. at 100.
110. E.g., Blair v. Eblen, 461 S.W.2d 370, 373 (Ky. 1970) (holding that a doctor is
under a duty to use that degree of care and skill which is expected of a reasonably com-
petent doctor in the same class to which he belongs).
111. See, e.g., Binder v. Jones & Laughlin Steel Corp., 520 A.2d 863, 866-67 (Pa.
Super. Ct. 1987) (holding that manufacturer had an affirmative duty to warn of risk due
to its knowledge of the product's properties).
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4. Strict Liability
There are three elements to the theory of strict liability. The first two
are the same as for negligence, namely that the evidence must show that
the product harmed the plaintiff, and the defendant's conduct caused the
plaintiffs harm."' The third element requires a showing that the defen-
dant either engaged in an "abnormally dangerous activity" or manufac-
tured an inherently dangerous product."'
A number of factors must be considered in determining whether the
defendant's activities are abnormally dangerous. These include (a) a high
degree of risk or harm, (b) the gravity of the harm, (c) the possibility of
eliminating the risk with reasonable care, (d) whether the activity is in
common usage, (e) the appropriateness of the activity for the location
where it occurred, and (f) the value of the activity to the community.'" If
the defendant is engaged in an abnormally dangerous activity, the defen-
dant may be held strictly liable for injuries resulting to the plaintiff irre-
spective of the degree of care exercised by the defendant."'
As suggested above, the defendant may also be strictly liable for inju-
ries to the plaintiff resulting from manufacturing an inherently dangerous
product. Products may be inherently dangerous due to design defects,
manufacturing defects, or marketing defects."'
B. PROTECTION OF SURFACE WATER QUALITY: THE CLEAN WATER
ACT
The Clean Water Act ("CWA") was intended to restore and maintain
the chemical, physical and biological integrity of the nation's water re-
sources."' As Congress enacted it, the CWA imposes a number of re-
quirements intended to achieve these objectives. Initially, states are au-
thorized to designate water quality standards or allowable uses of rivers
112. See RESTATEMENT (SECOND) OF TORTS S 430 (1965); RESTATEMENT (SECOND)
OF TORTS § 519 (1977).
113. See Caporale v. C.W. Blakeslee & Sons, Inc., 175 A.2d 561, 564 (Conn. 1961)
(holding that construction under the circumstances was "intrinsically dangerous");
RESTATEMENT (SECOND) OF TORTS § 402A (1965); RESTATEMENT (SECOND) OF TORTS
§ 519 (1977).
114. See RESTATEMENT (SECOND) OF TORTS § 520 (1977).
115. See Rylands v. Fletcher 118681 UKHL 1, [1861-18731 Eng. Rep. 1 (appeal taken
from Eng.) (mill owner who constructed a reservoir was liable without fault when the
reservoir failed and flooded an adjoining mine; mill owner was liability without fault for
collecting "anything likely to do mischief if it escapes"). See also Caporale, 175 A.2d at
564.
116. See Saupitty v. Yazoo Mfg. Co., 726 F.2d 657 (10th Cir. 1984) (holding that a
lawnmower as designed was inherently dangerous); Dunham v. Vaughn & Bushnell Mfg.
Co., 247 N.E.2d 401 (Ill. 1969) (holding that a hammer was inherently dangerous when
used as advertised); MacPherson v. Buick Motor Co., 111 N.E. 1050 (N.Y. 1916) (find-
ing that defects in the manufacture of a motor vehicle rendered it inherently dangerous).
117. Clean Water Act, Pub. L. No. 92-500, 86 Stat. 816 (1972) (codified as amended
at 33 U.S.C. § 1251 et seq. (2006)).
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located within the state."' This designation may be in terms of maintain-
Ing river water quality standards, in terms of allowable uses, or both."'
But these standards or designated uses, which are subject to EPA ap-
proval,'" must be based on the National Recommended Water Quality
Criteria."'
If a state chooses to utilize water quality standards, the standards must
include total maximum daily loads ("TMDLs") for those pollutants that
are amenable to maximum daily load measurement." As discussed be-
low, TMDLs are an element of state water quality standards applicable to
the issuance of discharge permits.
Once water quality standards or designated uses have been approved,
implementation is carried out through the National Pollutant Discharge
Elimination System (NPDES) permit system.'' This system allows com-
panies, governmental units, and other entities to obtain an NPDES per-
mit for the discharge of effluent from a point source into "waters of the
United States.""' Absent an NPDES permit, such discharges are strictly
prohibited.'
NPDES permits contain specific provisions regarding the type of
waste treatment technology required and the type and concentration of
materials to be discharged.'" For existing facilities, the general require-
ment is Best Conventional Pollutant Control Technology ("BCT")." For
new facilities, the requirement is Best Available Technology.'"
C. PROTECTION OF GROUNDWATER AND SURFACE WATER QUALITY:
THE SAFE DRINKING WATER ACT
The primary objective of the Safe Drinking Water Act ("SDWA") is
to identify, monitor, and control contaminants in drinking water." Con-
gress also intended the SDWA to provide an enforcement mechanism,
118. See 40 C.F.R. S 130.0 (2012).
119. Jefferson Cnty v. Wash. Dep't of Ecology, 511 U.S. 700 (1994).
120. See WESTVACO v. EPA, 899 F.2d 1383 (4th Cir. 1990). Such standards or
designated uses may also be subject to EPA disapproval. Id.
121. 33 U.S.C.A. SS 1313-14 (West 2012).
122. 40 C.F.R. § 130.4 (2012).
123. 33 U.S.C.A S 1342.
124. 40 C.F.R. §§ 230.3(s), 230.12.
125. Id. § 230.12.
126. 33 U.S.C. § 1342(p)(3).
127. 40 C.F.R. S 125.3.
128. Id. The Environmental Protection Agency has issued New Source Performance
Standards mandating the use of "best available demonstrated control technology" for a
number of industrial categories. Id.
129. Safe Drinking Water Act (SDWA), Pub. L. No. 93-523, 88 Stat. 1660 (codified
as amended at 42 U.S.C. § 300f (2006)); Daniel J. Kucera, Safe Drinking Water Act, in
ENVIRONMENTAL LAw HANDBOOK 437, 439 (Thomas F.P. Sullivan ed., Government
Institutes 19th ed., 2007).
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the collection and dissemination of water-related information, and fund-
ing mechanisms to upgrade water supply systems.'"
As with many environmental statutes, implementation of the SDWA
is an example of cooperative federalism. States have primary enforce-
ment authority once the EPA approves their state SDWA program."'
SDWA requirements focus primarily on public water systems. The Na-
tional Primary Drinking Water Regulations, one of the primary enforce-
ment mechanisms of the SDWA, apply to community water systems.'"
Noncommunity or transient water systems are smaller systems that usu-
ally rely on groundwater.
1. National Primary Drinking Water Regulations
The National Primary Drinking Water Regulations are health-based
standards for drinking water supplied by public water systems." These
regulations are without exceptions. They apply to contaminants that have
been determined to pose public health risks and are expressed in terms
of Maximum Contaminant Levels ("MCLs").' In general, "Best Avail-
able Technology" is required, though cost is taken into consideration "
The technology should result in a discharge as close as possible to the
Maximum Contaminant Level Goal ("MCLG").'"
Both MCLs and MCLGs must be based on human health effects, as
determined through risk assessments. In conducting such assessments,
the EPA is to utilize "the best available, peer-reviewed science and sup-
porting studies conducted in accordance with sound and objective scien-
tific practices"' and "data collected by accepted methods or best avail-
able methods (if the reliability of the method and the nature of the deci-
sion justifies use of the data)."'"
The process for establishing MCLGs is relevant vis-4-vis the PPCP
control options discussed in Section VI.'" With regard to MCLGs for
non-carcinogens, using the methodology noted above, a substance-
130. Kucera, supra note 129, at 439-40.
131. Id. at 440.
132. Community water systems are systems having at least 15 taps or providing service
to at least 25 individuals. 42 U.S.C.A. § 300f(15).
133. 40 C.F.R. § 141.1 (2012). The National Primary Drinking Water Standards
include 85 standards divided into six categories: disinfectants, disinfection byproducts,
inorganic chemicals, microorganisms, organic chemical, and radionuclides. Id. §§
141.50-.55.
134. 42 U.S.C.A § 300g-1(b)(1). MCLs may also be expressed in terms of treatment
techniques if it is impossible to establish an MCL (i.e., difficulty in measuring or uncer-
tainty regarding appropriate exposure limits). Id. § 300g-1(b)(7).
135. See id. § 300g-1(b)(4)(D).
136. Id. § 300g-1(b)(4)(B). MCLGs are health-based goals that do not take cost into
consideration. See id. §§ 300g-1(b)(1) to (4).
137. See id. § 300g-1(b)(3)(A)(i).
138. Id. § 300g-l(b)(3)(A)(ii).
139. See RAPID PUB. HEALTH POL'Y RESPONSE PROJECT, supra note 27 (See also
infra, note 243 with accompanying text.)
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specific Reference Dose ("RfD") is determined." In general, depending
on the availability of information about a specific substance, the RfD is
calculated by dividing Lowest-Observed-Adverse-Effect Level
("LOAEL")' or No-Observed-Adverse-Effect Level ("NOAEL")"? by an
Uncertainty Factor ("UF")." The MCLG is then determined by (a) mul-
tiplying the RfD by an assumed body weight of 70 kg, (b) dividing by an
assumed daily water consumption of 2 liters to determine Drinking Wa-
ter Equivalent Level (DWEL) and (c) multiplying DWEL by an assumed
daily exposure attributed to the consumption of water."'
The SDWA also authorizes National Secondary Drinking Water
Regulations, which relate to the aesthetics of water (i.e., color, taste,
odor), rather than its safety."' The National Secondary Drinking Water
Regulations are not enforceable."
140. Reference Dose is defined as "[ain estimate of a daily oral exposure for a given
duration to the human population (including susceptible subgroups) that is likely to be
without an appreciable risk of adverse health effects over a lifetime. It is derived from a
BMDL [Benchmark Dose Levell, a NOAEL [No-Observed-Adverse-Effect Level], a
LOAEL [Lowest-Observed-Adverse-Effect Levell, or another suitable point of depar-
ture, with uncertainty/variability factors applied to reflect limitations of the data used."
Integrated Risk Information System (IRIS) Glossary, ENvTL. PROT. AGENCY,
http://www.epa.gov/iris/gloss8_arch.htm (last visited Feb. 9, 2011).
141. Id. Lowest-Observed-Adverse-Effect Level is defined as "Itlhe lowest exposure
level at which there are statistically or biologically significant increases in frequency or
severity of adverse effects between the exposed population and its appropriate control
group." Id.
142. Id. No-Observed-Adverse-Effect Level is defined as the "highest exposure level
at which there are no statistically or biologically significant increases in the frequency or
severity of adverse effect between the exposed population and its appropriate control;
some effects may be produced at this level, but they are not considered adverse, nor
precursors to adverse effects." Id.
143. Id. "Uncertainty Factor" is defined as:
loine of several, generally 10-fold factors, used in operationally deriving the
RfD [Reference Dosel and RfC [Reference Concentration] from experimental
data. UFs are intended to account for (1) the variation in sensitivity among the
members of the human population, i.e., interhuman or intraspecies variability;
(2) the uncertainty in extrapolating animal data to humans, i.e., interspecies
variability; (3) the uncertainty in extrapolating from data obtained in a study
with less-than-lifetime exposure to lifetime exposure, i.e., extrapolating from
subchronic to chronic exposure; (4) the uncertainty in extrapolating from a
LOAEL rather than from a NOAEL; and (5) the uncertainty associated with
extrapolation from animal data when the database is incomplete.
Id.
144. Regulating Public Water Systems and Contaminants Under the Safe Drinking
Water Act, ENVTL. PROT. AGENCY,
http://water.epa.gov/lawsregs/rulesregs/regulatingcontaminants/basicinformation.cfm
(last visited Feb. 9, 2011).
145. Kucera, supra note 129, at 445.
146. 40 C.F.R. § 143.1 (2012).
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2. The Unregulated Contaminant Monitoring Rule
The SDWA requires the EPA to both: (a) establish criteria for a
monitoring program for unregulated contaminants; and (b) publish a list
of contaminants to be monitored." Based on information developed
through the monitoring program, the EPA is to evaluate and prioritize
unregulated contaminants for potential inclusion on the Contaminant
Candidate List discussed below." The Unregulated Contaminant Moni-
toring Rule lists conthminants that public water systems must monitor,
describes analytical methods of assessing these contaminants, and re-
quires submission of monitoring and analysis results to the EPA for in-
clusion in the National Drinking Water Contaminant Occurrence Data-
base." The rule also requires public water systems to notify their con-
sumers of the results of the monitoring and analysis." The goal of the
Unregulated Contaminant Monitoring Rule is to ensure that sound sci-
ence, not political influence, forms the basis for decisions regarding the
regulation of specific contaminants."
3. The Contaminant Candidate List
The SDWA also requires the EPA to publish a Contaminant Candi-
date List every five years."' This list must include contaminants that are
not currently subject to National Primary Drinking Water Regulations but
are known or anticipated to occur in public water systems." The SDWA
specifies three criteria for determining whether a contaminant may be a
candidate for regulation:
(i) The contaminant may have an adverse effect on the health of per-
sons;
(ii) The contaminant is known to occur, or there is a substantial likeli-
hood that the contaminant will occur in public water systems with a
frequency and at levels of public health concern; and
(iii) In the sole judgment of the Administrator, regulation of such con-
taminant presents a meaningful opportunity for health risk reduc-
tion for persons served by public water systems."'
4. The Surface Water Treatment Rule
The SDWA also contains a Surface Water Treatment Rule, which
requires systems using surface water or groundwater under the direct in-
147. Kucera, supra note 129, at 477.
148. Id.
149. Unregulated Contaminant Monitoring Rule, 64 Fed. Reg. 50,556 (Sept. 17, 1999)
(codified at 40 C.F.R. pt. 9, 141-42).
150. Kucera, supra note 129, at 457.
151. See Safe Drinking Water Act, 42 U.S.C. S 300g-l(b) (2006).
152. Id. § 300g-1(b)(1)(B)(i).
153. Id.
154. Id. § 300g-l(b)(1)(A); see Kucera, supra note 129, at 447.
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fluence of surface water to disinfect and filter their water so that the fol-
lowing contaminants are.controlled at these levels: Cryptosporidium (99%
removal), Giardia lamblia (99.9% removal or inactivation), and viruses
(99.99% removal or inactivation).'
5. The Wellhead Protection Program
Amendments to the SDWA in 1986 enhanced the protection of un-
derground sources of drinking water by authorizing the wellhead protec-
tion program.'" Under the SDWA as amended, states were required to
develop wellhead protection programs within three years and submit
them to the Administrator of the EPA for approval.'" The goal of the
wellhead protection program was to "protect wellhead areas . . . from
contaminants which may have any adverse effect on the health of persons
To encourage the states to develop wellhead protection programs,
Congress provided both an incentive and a disincentive. As an incentive,
the SDWA provided that the activities of federal agencies having an effect
on the wellhead protection area must comply with all requirements of the
states' wellhead protection programs." As a disincentive, the SDWA
provided that failure to develop an acceptable wellhead protection pro-
gram would result in state ineligibility for certain federal funding to im-
plement the wellhead protection program.H"
6. The Underground Injection Control Program
Protection of underground sources of drinking water also occurs
through the SDWA's Underground Injection Control Program
("UICP")."' Ongoing reliance on groundwater as a source of drinking
water supplies necessitated the creation of the UICP." Over eighty per-
cent of community water systems rely on groundwater for all, or part of
their water supply."
With regard to well construction, the UICP both required permits
and established standards based on different classes of wells:
* Class I wells are used for injection of industrial non-
hazardous liquids, municipal wastewaters, or hazardous
155. Surface Water Treatment Rule, 40 C.F.R. § 141.70 (2011); see also Safe Drink-
ing Water Act § 300g-1(b)(2)(C).
156. Safe Drinking Water Act § 300h-7.
157. Id. § 300h-7(a).
158. "Wellhead protection areas" were defined as "the surface and subsurface area
surrounding a water well or wellfield, supplying a public water system, through which
contaminants are reasonably likely to move toward and reach such water well or wellfield
." Id. S 300h-7(e).
159. Id. § 300h-7(h).
160. Id. § 300h-7(d).
161. Id. S 300h.
162. Kucera, supra note 129, at 474.
163. See id.
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wastes beneath the lowermost underground source of drink-
ing water.
* Class II wells are used for injection of fluids in connection
with conventional oil or natural gas production, enhanced oil
and gas production, and the storage of hydrocarbons which
are liquid at standard temperature and pressure.
* Class III wells are used for injection of fluids associated with
the extraction of minerals or energy, including the mining of
sulfur and solution mining of minerals.
* Class IV wells are used for injection of hazardous or radioac-
tive wastes into or above underground source of drinking wa-
ters.
* Class V wells include all injection wells that are not included
in Classes I-IV.
* Class VI wells are used for injection of carbon dioxide."
7. The Biosolids Rule
The Clean Water Act Amendments of 1987 required the EPA to
promulgate regulations to protect public health and the environment
from adverse impacts associated with the disposal of biosolids (i.e., the
sludge from wastewater treatment plants). In 1993, the EPA published
these regulations, which became Title 40, Part 503 of the Code of Fed-
eral Regulations. As a result, the regulatory community commonly refers
to these as the "Part 503 Biosolids Rule.""
Of particular relevance to the issue of PPCPs in fresh water resources
is a portion of the Biosolids Rule relating to the application of biosolids
to land." Four general requirements are established under the Biosolids
Rule: (1) ceiling concentration limits for heavy metals;" (2) pollutant
164. 40 C.F.R. § 146.5 (2011). With regard to Class VI wells, see Federal Require-
ments Under the Underground Injection Control (UIC) Program for Carbon Dioxide
(CO,) Geologic Sequestration (GS) Wells, 75 Fed. Reg. 77, 230 (Dec. 10, 2010) (to be
codified at 40 C.F.R. pt. 124, 144-47).
165. 58 Fed. Reg. 9248 (Feb. 19, 1993) (as codified at CFR pt. 257, 403, 503).
166. Other portions of Part 503 apply to a variety of different uses and disposal tech-
niques for biosolids. See generally OFFICE OF WASTEWATER MANAGEMENT, ENVTL.
PROT. AGENCY, A PLAIN ENGLISH GUIDE TO THE EPA PART 503 BIOSOLIDs RULE
(1994) [hereinafter EPA GUIDE TO PART 503 BIOSOLIDS RULE].
167. Ceiling concentration limits were established for arsenic, cadmium, chromium,
copper, lead, mercury, molybdenum, nickel, selenium and zinc. See EPA GUIDE TO
PART 503 BIOSOLIDs RULE, supra note 166, ch. 2 at 29-30. To establish these limits:
EPA conducted extensive risk assessments that involved identifying the chemi-
cal constituents in biosolids judged likely to pose the greatest hazard, character-
izing the most likely exposure scenarios, and using scientific information and
assumptions to calculate concentration limits and loading rates (amount of
chemical that can be applied to a unit area of land). IHowever, there] have
been substantial advances in risk assessment since then, and there are new con-
cerns about some adverse health outcomes and chemicals not originally con-
sidered. Because of the diversity of exposed populations, environmental con-
Issue 2 403
WATER LAW REVIEW
loading rate limits; (3) pathogen control requirements;" and (4) vector-
attraction reduction requirements.
For land disposal to be permitted, all biosolids must comply with the
ceiling concentration limits for heavy metals. There are a number of op-
tions available to fulfill the other three requirements. These options are
based on the characteristics of both the biosolids and the land to which
the biosolids are to be applied.' Once biosolids have been applied to
land, an ongoing monitoring program is required."'
D. PROTECTION OF GROUNDWATER AND SURFACE WATER QUALITY
BY REGULATiNG HAZARDOUS SUBSTANCES AND WASTES: THE
RESOURCE CONSERVATION AND RECOVERY ACT
One of the primary statutes dealing with hazardous substances and
wastes is the Resource Conservation and Recovery Act ("RCRA"), which
established a program for the "cradle-to-grave" management of hazardous
ditions, and agricultural practices in the United States, it is important that na-
tionwide chemical regulations be based on the full range of exposure condi-
tions that might occur. Furthermore, there is a need to investigate whether the
biosolids produced today are similar in composition to those used in the origi-
nal assessments.
COMM. ON ToxICANTS AND PATHOGENS IN BIOSOLIDS APPLIED TO LAND, supra note
43, at 2, 12. This led the National Research Council to recommend:
[A] new national survey of chemicals in biosolids should be conducted. EPA
should review available databases from state programs in designing a new sur-
vey. Other elements that should be included in the survey are an evaluation of
the adequacy of detection methods and limits to support risk assessment; con-
sideration of chemical categories, such as odorants and pharmaceuticals, that
were not previously evaluated ....
Id. at 12 (emphasis added).
168. "In contrast to the chemical standards, the pathogen standards are not risk-based
concentration limits for individual pathogens but are technologically based requirements
aimed at reducing the presence of pathogens and potential exposures to them by treat-
ment or a combination of treatment and use restrictions." COMM. ON ToxICANTS AND
PATHOGENS IN BIOSOLIDs APPLIED TO LAND, supra note 43, at 2. In fact, with regard
to pathogens, the National Research Council has recommended use of improved risk
assessment method: "Risk-assessment methods for chemicals and pathogens have ad-
vanced over the past decade to the extent that (1) new risk assessments should be con-
ducted to update the scientific basis of the chemical limits, and (2) risk assessments
should be used to supplement technological approaches to establishing regulatory crite-
ria for pathogens in biosolids." Id. at 4.
169. Vectors are typically flies and rodents. Id. at 2.
170. The options include the Exceptional Quality option, the Pollutant Concentration
option, the Cumulative Pollutant Loading Rule option and the Annual Pollutant Loading
Rate option. These requirements were based on a comprehensive risk assessment. EPA
GUIDE TO PART 503 BIOSOLIDs RULE, supra note 166, at 30-40.
171. Monitoring must include pollutants, pathogen densities (fecal coliform, salmo-
nella, viable helminth ova and enteric virus) and vector attraction reduction. See EPA
GUIDE TO PART 503 BiosOLIDS RULE, supra note 166, at 47-49.
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substances and waste."' One of RCRA's goals, as expressed in Subtitle A,
is to protect human health and the environment from the hazards posed
by waste disposal."' Other goals include the reduction or elimination of
the amount of waste generated (including hazardous waste), and the
proper management of such waste to protect human health and the envi-
ronment."'
Subtitle C of RCRA created a hazardous waste management pro-
gram.' A waste is considered "hazardous" if it is a solid waste, defined
as:
[Any garbage, refuse, sludge from a waste treatment plant, water supply
treatment plant or air pollution control facility and other discarded ma-
terial, including solid, liquid, semisolid, or contained gaseous materials
resulting from industrial, commercial, mining and agriculture activities
and from community activities but does not include solid or dissolved
material in domestic sewage, or solid or dissolved materials in irrigation
return flows or industrial discharges which are point sources subject to
permits under section 402 of the Federal Water Pollution Control Act,
as amended, or source, special nuclear, or byproduct material as de-
fined by the Atomic Energy Act of 1954, as amended (68 Stat. 923)."'
Certain wastes are specifically excluded from the definition of solid
waste, including "(a) any mixture of domestic sewage and other wastes
that passes through a sewer system to a publicly owned treatment works
and (b) industrial wastewater discharges that are point source discharges
under the Clean Water Act."'
Waste is considered hazardous if it is:
any solid waste, or combination of solid wastes, which because of its
quantity, concentration, or physical, chemical, or infectious characteris-
tics may (A) cause, or significantly contribute to an increase in mortality
or an increase in serious irreversible, or incapacitating reversible illness;
or (B) pose a substantial present or potential hazard to human health or
the environment when improperly treated, stored, transported, or dis-
posed of, or otherwise managed."
172. Resource Conservation and Recovery Act of 1976 (RCRA; Solid Waste Disposal
Act), Pub. L. No. 94-580, 90 Stat. 2795 (codified as amended at 42 U.S.C. §§ 6901-
6992k (2006)); David R. Case, Resource Conservation and Recovery Act, in ENVTL.
LAw HANDBOOK 133, 134 (Thomas F.P. Sullivan ed., Government Institutes 19th ed.
2007).
173. 42 U.S.C. § 6902(a).
174. Id.
175. Id. §§ 6921-6931.
176. Id. § 6903(27).
177. Case, supra note 172, at 138.
178. 42 U.S.C. § 6903(5).
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This statutory language gives the EPA broad authority to define hazard-
ous wastes through regulation. Applicable regulations establish several
lists of hazardous wastes: '"
* The "F" list - hazardous wastes from nonspecific sources
(e.g., spent nonhalogenated solvents, such as toluene or
methyl ethyl ketone).
* The "K" list - hazardous wastes from specific sources (e.g.,
petroleum refining wastes or bottom sediment sludge from
the treatment of wastewaters by the wood preserving indus-
try).
* The "P" list - chemicals considered "acutely" hazardous irre-
spective of concentration (e.g., nitric oxide).
* The "U" list - chemicals considered hazardous at higher con-
centrations (e.g., acetone)
Christenson notes that, "Islince most hazardous pharmaceuticals are
on the P-list or U-list, health-care facilities focus primarily on these
lists.
1. The Mixture Rule
In addition, the "mixture rule" provides that a mixture of a listed
hazardous waste and a solid waste must also be considered a hazardous
waste."' This rule may not apply if (a) the mixture does not exhibit the
characteristics for which the waste was considered hazardous (ignitability,
corrosivity, reactivity or toxicity); (b) the mixture is regulated under the
Clean Water Act; or (c) the mixture contains only de minimis quantities
of hazardous wastes.'
2. Categories of Generators
Hazardous waste generators are regulated depending on the amount
of waste they generate each month." There are three categories:
* Large quantity generators (LQG, generators of more the
1,000 kilograms of hazardous waste per month)
* Small quantity generators (SQG, generators of between 100
and 1,000 kilograms of hazardous waste per month)
179. 40 C.F.R. S 261.31, 261.32 (2012); id. pt. 273; Case, supra note 172, at 141-42.
180. Teirney Christenson, Comment, Fish on Morphine: Protecting Wisconsin's
Natural Resources Through a Coinprehensive Plan for Proper Disposal of Pharmaceuti-
cals, 2008 Wis. L. REV. 141, 149 (2008) (citing Christian G. Daughton, Cradle-to-Cradle
Stewardship of Drugs for Minimizing Their Environmental Disposition While Promot-
ing Human Health. II. Drug Disposal, Waste Reduction, and Future Directions, 111
ENvTL. HEALTH PERSP. 775, 782 (2003)).
181. 40 C.F.R. § 261.3(a)(2); Case, supra note 172, at 145.
182. 40 C.F.R. § 261.3.
183. Id. pt. 260 (1987); see Case, supra note 172, at 152-53.
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* Conditionally exempt small quantity generators (CESQGs,
generators of less than 100 kilograms of hazardous waste per
month)
Under RCRA, hazardous waste generators must comply with regula-
tions concerning record keeping and reporting, observe waste accumula-
tion time limits, and comply with storage requirements.'
3. The Uniform Hazardous Waste Manifest System
Generators of hazardous wastes, transporters of such wastes, and op-
erators of treatment, storage, and disposal facilities ("TSDFs") must also
comply with the Uniform Hazardous Waste Manifest System." This Sys-
tem requires the use of a manifest process to track hazardous waste from
its point of origin to its ultimate point of treatment or disposal (i.e., "cra-
dle to grave")." Transporters of hazardous waste must also meet re-
quirements established by the Department of Transportation.' For ex-
ample, regulations implementing the Hazardous Materials Transportation
Act require (a) labeling, (b) placarding, (c) proper containers for hazard-
ous materials, and (d) the development of emergency (spill) response
procedures."
4. Treatment, Storage and Disposal Facilities
Requirements for TSDFs are also established under RCRA. A per-
mit is required to construct and operate a TSDF." The permit contains
specific operating standards and requirements applicable to the TSDF.'"
The operator of a TSDF must demonstrate financial responsibility (in
case of accidents) as well as the capability to close the TSDF in accor-
dance with EPA regulations.' In terms of remediation and corrective
actions that might be required at a TSDF, the owner or operator is re-
sponsible for investigating and, when necessary, remediating releases
from their facilities.
RCRA contains a number of specific limitations and prohibitions.
Bulk (non-containerized) hazardous liquid waste is prohibited from dis-
posal in any landfill.'" There are also severe restrictions on the disposal
184. Case, supra note 172, at 150.
185. 40 C.F.R. § 262.20; Case, supra note 172, at 150.
186. Case, supra note 172, at 150.
187. Id. at 134.
188. Id.
189. 40 C.F.R. § 264.1.
190. Id.
191. See Id. SS 264.144-.145, 264.147; see also Case, supra note 172, at 161.
192. Case, supra note 172, at 170.
193. 40 C.F.R. § 264.314(a).
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of containerized hazardous liquid waste." Land disposal of specific
highly hazardous waste was phased out between 1986 and 1990.'"
RCRA also establishes minimum technological standards for new
landfills and surface impoundments. Requirements include: (a) double
liners, (b) a leachate collection and treatment system, (c) groundwater
monitoring, and (d) in general, the use of "Best Demonstrated Available
Technology."'
5. The Universal Waste Rule
In 1995, the EPA promulgated regulations to streamline the man-
agement of certain types of commonly occurring hazardous wastes.'
These wastes (known as "universal wastes") included batteries, certain
types of lamps (e.g., containing mercury), mercury-containing equipment
(e.g., thermostats), and certain types of pesticides.' Concluding that the
"current RCRA regulations have been a major impediment to national
collection and recycling campaigns for these wastes,"'" the Universal
Waste Rule ("UWR")" was promulgated to "facilitate Itheir] environmen-
tally-sound collection and increase the proper recycling or treatment" of
such wastes."
To achieve these goals, the UWR allowed for longer storage of cov-
ered wastes, reduced recordkeeping requirements, and simplified the
procedure for recycling such wastes."' Transportation was facilitated by
exempting the transport of wastes included within the UWR from the
manifest requirements discussed above."'
6. State Implementation
The EPA encouraged states to assume responsibility for RCRA's haz-
ardous waste program in part by providing financial assistance."' At the
present time, all but two of the states have been granted authority to im-
plement the RCRA program.'
194. Id. § 264.314(b)-(c).
195. Case, supra note 172, at 164-65.
196. 40 C.F.R. S 264.301; Case, supra note 172, at 164-65.
197. Universal Waste Rule (Hazardous Waste Management System; Modification of
the Hazardous Waste Recycling Regulatory Program), 60 Fed. Reg. 25492 (May 11,
1995) (codified at 40 C.F.R. §§ 9, 260-66, 268, 270, 273).
198. See 40 C.F.R. § 273.1 (2005).
199. Universal Waste Rule, 60 Fed. Reg. at 25492.
200. 40 C.F.R. § 273.
201. Universal Waste Rule, 60 Fed. Reg. at 25492.
202. Id. at 25495, 25498, 25502.
203. Id. at 25501.
204. Resource Conservation and Recovery Act (RCRA) § 6947.
205. It appears that Alaska and Iowa have not been granted authority to implement
the RCRA program. See Environmental Protection Agency, Wastes-Laws & Regula-
tions-RCRA State Authorization: State Authorization Federal Register Notices and Au-
thorization Activity, Alaska State Report (2011), http://%ww.epa.gov/osw/laws-
regs/state/stats/ak.pdf (showing rule package not submitted by Alaska as of December
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E. PROTECTION OF GROUNDWATER AND SURFACE WATER QUALITY
BY REGULATING TOXIC SUBSTANCES: THE TOXIC SUBSTANCE
CONTROL ACT
In 1971, the Council on Environmental Quality ("CEQ") recom-
mended comprehensive legislation to identify and control chemicals
whose manufacture, processing, distribution, use, and/or disposal was
potentially dangerous and not adequately regulated under other environ-
mental statutes."' The resulting legislation, the Toxic Substances Control
Act ("TSCA"), was signed into law by President Ford on October 11,
1976."'
Title I of TSCA focuses on the control of toxic substances. Manufac-
turers and processors are required to conduct tests of existing chemicals
if (a) the manufacture, distribution, processing, use or disposal of the
chemicals "may present an unreasonable risk of injury to health or the
environment"; (b) the chemicals are or will be produced in substantial
quantities and the potential for environmental release or human exposure
is substantial or significant; and (c) existing data is inadequate to predict
the effects of human exposure and environmental releases." The re-
quired testing may be based on risk triggers (chemical toxicity, etc.), ex-
posure triggers (long-term, low-level exposure), or both."' Chemicals
known or suspected to be carcinogenic, mutagenic, or teratogenic are to
be assigned a higher priority for testing.
1. The Inventory
The EPA is required to develop and maintain an inventory of all
chemicals, or categories of chemicals, manufactured or processed in the
United States." All chemicals not on the Inventory are, by definition,
"new" and are subject to the Pre-Manufacture Notification requirements,
as discussed below."
In 2008, the EPA initiated a phased, multi-year program to obtain
health and safety information from manufacturers and processors of in-
31, 2011), Iowa State Report (2011), http://w-vw.epa.gov/osw/ laws-regs/state/stats/ia.pdf
(showing rule package not submitted by Iowa as of December 31, 2011).
206. This recommendation was contained in the CEQ report Toxic Substances
(1971). Linda Schierow, Toxic Control Substances Act, in ENVIRONMENTAL LAVS:
SUMMARY OF ENVIRONMENTAL LAws ADMINISTERED BY THE EPA 87, 88 (2010),
http://www.fas.org/sgp/crs/misc/RL30798.pdf.
207. Toxic Substance Control Act (TSCA), Pub. L. No. 94-469, 90 Stat. 2003 (codi-
fied as amended at 15 U.S.C. §§ 2601-1692 (2006)); Stanley W. Landfair, Toxic Sub-
stance Control Act, in ENVIRONMENTAL LAw HANDBOOK 607, 607 (Thomas F.P. Sulli-
van ed., Government Institutes 19th ed. 2007).
208. Toxic Substance Control Act § 2603; Landfair, supra note 207, at 644.
209. Landfair, supra note 208, at 644.
210. See id. at 643.
211. Toxic Substance Control Act § 2607(b)(1).
212. See id. §2607(b).
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organic, high-production volume ("HPV") chemicals."' Such information
on 2,200 organic chemical HPV chemicals has been obtained by the
EPA."
2. Pre-Manufacture Notification
With limited exceptions, manufacturers, importers, and processors of
chemicals not listed in the inventory are required to notify the EPA at
least ninety days prior to producing a new chemical product into the
United States .2" The EPA then has forty-five days to evaluate the poten-
tial risk posed by the new chemical product.2 ' If the EPA determines that
the new chemical product presents or will present an unreasonable risk of
injury to human health or the environment, then requirements to protect
against such risks must be promulgated. If data are inadequate to make
an informed judgment, the EPA may prohibit or limit the use of the new
chemical product until sufficient information has been submitted.
3. Regulatory Controls
The TSCA requires the EPA to regulate "the manufacturing, process-
ing, distribution . . . , use, land) disposal of a chemical" if it "will present
an unreasonable risk of injury to health or the environment."' This au-
thority allows the EPA to: (a) prohibit or limit the amount of production
or distribution of a chemical; (b) prohibit or limit the production or dis-
tribution of a chemical for a particular use; (c) limit the volume or con-
centration of the chemical produced; (d) prohibit or regulate the manner
or method of commercial use; (e) require warning labels and/or instruc-
tions on containers or products; (f) require notification of the risk of in-
jury to distributors and (to the extent possible) consumers; (g) require
record-keeping by producers; (h) specify disposal methods; and (i) re-
quire replacement or repurchase of products already distributed.' How-
ever, the EPA is to exercise this authority only "to the extent necessary to
protect adequately" against a risk."' Furthermore, the EPA is to use the
"least burdensome" regulatory approach, even when unreasonable risks
are being controlled.?
213. High Production Volume (HPV) Challenge Program, ENVTL. PROT. AGENCY,
http://mw.epa.gov/hpv (last updated Jan. 26, 2012).
214. Id.
215. Toxic Substance Control Act S 2604(a)(1)(B).
216. Id. §2604(e)(1)(B).
217. Id. §2604(e)(1)(A).
218. Id.
219. Id. §2605(a).
220. Id.
221. Id.
222. Id.
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4. Imminent Hazards
The TSCA also authorizes the EPA to take emergency action through
federal courts to control a chemical substance or mixture that presents an
imminent and unreasonable risk of serious, widespread injury to human
health or the environment.'
F. PROTECTION OF SPECIES: THE ENDANGERED SPECIES ACT
Perhaps the best known of the federal species protection statutes, the
Endangered Species Act ("ESA")" essentially prohibits any federal
agency from taking any action (including destruction of "critical habitat")
that would jeopardize the continued existence of a threatened or endan-
gered plant or animal species. As more fully discussed below, the ESA
also prohibits all parties (both public and private) from undertaking ac-
tions that would result in the "taking" of a threatened or endangered spe-
cies."
The purposes of the ESA are "to provide a means whereby the eco-
systems upon which endangered species and threatened species depend
may be conserved, land] to provide a program for the conservation of
such endangered species and threatened species[."' In order to achieve
these goals, Congress established the policy that "all Federal departments
and agencies shall seek to conserve endangered species and threatened
species and shall utilize their authorities in furtherance of the purposes of
this chapter.""' In essence, the ESA was intended to protect threatened
and endangered species virtually irrespective of the cost of the protec-
tion.'
1. "Taking" Endangered Species
With limited exceptions, Congress prohibited the "taking" of an "en-
dangered"' plant or animal species.' Fish and Wildlife Service regula-
223. Id. § 2606(b)(1).
224. See generally Endangered Species Act (ESA), Pub. L. No. 93-205, 87 Stat. 884
(codified as amended at 16 U.S.C. §§ 1531-1544 (2006)).
225. Endangered Species Act § 1538(a)(1).
226. Id. § 1531(b).
227. Id. § 1531(c)(1).
228. See Tennessee Valley Auth. v. Hill, 437 U.S. 153 (1978) (holding that the pro-
tection of the endangered snail darter under the ESA could preclude completion of a
water project).
229. Endangered species are defined as "any species which is in danger of extinction
throughout all or a significant portion of its range other than a species of the Class In-
secta determined by the Secretary to constitute a pest whose protection under the provi-
sions of this chapter would present an overwhelming and overriding risk to man." En-
dangered Species Act § 1532(6).
230. In relevant part, the ESA provides that "with respect to any endangered species
of fish or wildlife listed pursuant to ... this title it is unlawful for any person subject to
the jurisdiction of the United States to ... (B) take any such species within the United
States or the territorial sea of the United States ... or (G) violate any regulation pertain-
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tions extending these provisions to "threatened""' species were sustained
when challenged as a reasonable and permissible interpretation of the
ESA."-
* The Secretary of the Interior must designate critical habitat concur-
rent with the determination that a species is endangered or threatened.'
With regard to the "taking" of an endangered or threatened species,
the definition of "take" is noteworthy. "The term 'take' means to harass,
harm, pursue, hunt, shoot, wound, kill, trap, capture, or collect, or to
attempt to engage in any such conduct." To conclude that the definition
of "take" is quite broad would be an understatement. For example, regis-
tration of a pesticide by the EPA was considered a "taking" when endan-
gered species were poisoned by the pesticide.' Forest management prac-
tices of the Forest Service, which resulted in harm to an endangered spe-
cies, constituted a "taking" in Sierra Club v. Lyng."
2. Interagency Coordination
Federal agencies are required to insure that agency actions are not
likely to jeopardize the continued existence of a threatened or endan-
gered species." Such agencies are also required to insure that agency
actions do not result in the destruction or adverse modification of critical
ing to such species or to any threatened species of fish or wildlife listed pursuant to ...
this title." Id. S 1538(a)(1). Furthermore, "with respect to any endangered species of
plants listed pursuant to ... this title, it is unlawful for any person subject to the jurisdic-
tion of the United States to ... (B) remove and reduce to possession any such species
from areas under Federal jurisdiction; maliciously damage or destroy any such species
on any such area; or remove, cut, dig up, or damage or destroy any such species on any
other area in knowing violation of any law or regulation of any State or in the course of
any violation of a State criminal trespass law ... or (E) violate any regulation pertaining to
such species or to any threatened species of plants listed pursuant to ... this Act...." Id. S
1538(a)(2).
231. Threatened species are defined as "any species which is likely to become an
endangered species within the foreseeable future throughout all or a significant portion
of its range." Id. S 1532(20).
232. Sweet Home Chapter of Comts. for a Great Oregon v. Lujan, 806 F. Supp. 279
(D.D.C. 1992), aRld sub nom Sweet Home Chapter of Comts. for a Great Oregon v.
Babbitt, 1 F.3d I (D.C. Cir. 1993), modified, 17 F.3d 1463 (D.C. Cir. 1994), rev'd, 515
U.S. 687 (1995).
233. In making a determination regarding the designation of critical habitat, the Secre-
tary shall designate critical habitat ... on the basis of the best scientific data available and
after taking into consideration the economic impact, and any other relevant impact, of
specifying any particular area as critical habitat. The Secretary may exclude any area
from critical habitat if he determines that the benefits of such exclusion outweigh the
benefits of specifying such area as part of the critical habitat, unless he determines,
based on the best scientific and commercial data available, that the failure to designate
such area as critical habitat will result in the extinction of the species concerned. Endan-
gered Species Act § 1533(b)(2).
234. Id. § 1532(19).
235. Defenders of Wildlife v. Adm'r EPA, 882 F.2d 1294, 1303 (8th Cir. 1989).
236. Sierra Club v. Lyng, 694 F. Supp. 1260, 1263 (E.D. Tex. 1988), aIId in part,
vacatedin part sub nom, Sierra Club v. Yeutter, 926 F.2d 429, 439 (5th Cir. 1991).
237. Endangered Species Act S 15 3 6(a)(2).
412 Volume 15
PHARMACEUTICALS AND PERSONAL CARE PRODUCTS
habitat.' In this context, "agency action" includes: (a) actions authorized
by a federal agency (e.g., through the issuance of permits or licenses); (b)
actions funded by federal agencies; and, (c) actions undertaken by the
agency itself."
In order to fulfill this requirement, agencies are required to "use the
best scientific and commercial data available."" Agencies are also re-
quired to act "in consultation with and with the assistance of" the Secre-
tary of the Interior."'
IV. ALTERNATIVE STRATEGIES
As an alternative to a regulatory approach, there are a number of
source control possibilities that could be utilized to address the presence
of PPCPs in fresh water resources."' These possibilities fall generally into
six categories: (1) drug design; (2) drug delivery; (3) drug marketing; (4)
drug dispensing; (5) drug disposal/recycling; and (6) drug alternatives."
While these categories focus primarily on pharmaceuticals, they apply
equally to personal care products and the full array of PPCPs previously
identified.'"
238. Id.
239. Id.
240. Id.
241. Id.
242. The need for source control has been stressed in a number of studies. See, e.g.,
the recommendations of a 2008 study by the School of Public Health and Health Ser-
vices at The George Washington University included:
An emphasis on controlling the discharge of contaminated water at the source,
rather than treatment at the point of use. This would be safer for the environ-
ment, while reducing the burden on downstream drinking water treatment
plants.
RAPID PUB. HEALTH POL'Y RESPONSE PROJECT, supra note 27, at 6 (citing U.S. ENVTL.
PROT. AGENCY, SOURCE WATER PROTECTION,
http://cfpub.epa.gov/safewater/sourcewater/index.cfm, emphasis added). See also Keith
J. Jones, Endocrine Disruptors and Risk Assessment: Potential for a Big Mistake, 17
VILL. ENVTL. L.J. 357, 386 (2006) ("It might be more feasible to ban the use of an endo-
crine disruptor or otherwise prevent it from reaching source water (e.g., source water
protection programs) rather than try to remove it from drinking water.").
243. The structure of this section and the concepts described herein are based on
Christian G. Daughton, Cradle-to-Cradle Stewardship of Drugs for Minimizing Their
Environmental Disposition While Promoting Human Health. I. Rationale for and Ave-
nue Toward a Green Pharmacy, Ill ENVIRONMENTAL HEALTH PERSPECTIVES 757
(2003) [hereinafter Daughton, Rationale for and Avenues toward a Green Pharmacy]
and Christian G. Daughton, Cradle-to-Cradle Stewardship of Drugs for Minimizing
Their Environmental Disposition While Promoting Human Health. II Drug Disposal,
Waste Reduction, and Future Directions, 111 ENVIRONMENTAL HEALTH PERSPECTIVES
775 (2003) [hereinafter Daughton, Drug Disposal, Waste Reduction, and Future Direc-
tionsj. See also the section on "source water protection" in Snyder et al., supra note 48.
244. See Masters, supra note 4.
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A. DRUG DESIGN
The environmental impacts of drug use, such as the excretion of
PPCPs in both human and animal wastes, should be considered as new
drugs are being designed or formulated. While maintaining or improving
therapeutic efficacy, the chemical structure, properties, and formulation
(combinations of active and inactive ingredients) of new drugs could focus
on "maximizing their susceptibility to biodegradation, photolysis, or other
physicochemical alterations to yield innocuous end products.""
Wennmalm and Gunnarsson described the need for such an approach:
I ]It appears urgent that future drugs not be persistent. Presently, sev-
eral frequently used drugs have half-lives in surface water exceeding one
year or more. Residues of such drugs may reach concentrations in sur-
face or ground water near urban areas of 100 nanograms/litre or more
before a kinetic balance between supply of new drug residues from sew-
age treatment plant effluents and biodegradation in the aquatic medium
has been reached. Such high concentrations are not readily eliminated
in processes aimed at purifying the water to be drinkable. Thus, signifi-
cant concentrations of bioactive drug residues may appear in drinking
water.""
In this context, it should be noted that the U.S. Food and Drug Ad-
ministration mandates environmental risk assessments for new pharma-
ceuticals having a predicted environmental concentration of more than
one micrograms per liter."'
It would be possible to design drugs to improve the physiologic sorp-
tion characteristics of the drug. This would result in a reduction in the
amount of the drug ultimately excreted. This possibility is "being pur-
sued on many fronts....
Daughton notes that the "advancing 'oinnics' revolution"' could lead
to the design of drugs that specifically target certain groups of patients.
This could have the effect of reducing the use of drugs having similar
245. Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note 243,
at 765.
246. Wennmalm & Gunnarsson, supra note 42, at 295-96 (citing Ettore Zuccato et al.,
Environmental Loads and Detection of Pharmaceuticals in Italy, PHARMACEUTICALS IN
THE ENVT. 23-24 (K. Kilmmerer ed., Springer Verlag 2001)).
247. Snyder et al., supra note 48, at 34.
248. Daughton, Rationale for and A venues Toward a Green Pharmacy, supra note
244, at 765 (citing Joe Alper, Breaching membranes, 296 SCIENCE 838 (2002)) (regard-
ing the creation of in situ synthetic transporters as well as work by XenoPort, Inc. of
Santa Clara, California regarding "better drug design to accommodate existing mem-
brane transporters ... ).
249. This would include genomics (the study of genes and their functions), proteomics
(the study of proteins and their functions), glycomics (study of the structure and function
of sugars and saccharides) and metabolornics (the study of metabolites and their func-
tions). See generally -Omes and -oznics Glossary & Taxonomy: Evolving Terminologv
for Emerging Technologies, CAMBRIDGE HEALTHTECH INST.,
http://www.genomicglossaries.com/content/omes.asp (last updated Sept. 12, 2011).
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therapeutic effects by the general population.' If use of drugs resulting
in the excretion of PPCPs by the general population were reduced, then
the quantity of PPCPs entering fresh water resources would also be re-
duced.
Other drug design possibilities could include the development of
drugs that maintain their therapeutic effectiveness despite substantially
reduced dosage levels" as well as the development of "smart" drugs that
"better emulate the nonanthropocentric, native chemistries of natural
products.""
B. DRUG DELIVERY
The first step in the drug delivery system identified by Daughton as
playing a role vis-4-vis PPCPs in fresh water resources is the prescribing
of drugs.' Both physicians and patients need to be better informed of the
consequences of using specific drugs," particularly both the "medical and
environmental consequences of overprescribing medications."'
Numerous studies have shown that "the therapeutically effective dose
for many drugs can be significantly lower than that initially recommended
by the manufacturer."' In fact, Cunningham et al. have noted, "Itihe
preferred safety profile for human pharmaceuticals is that the desired
therapeutic response is the lowest effect observed (i.e., at the lowest
dose)." " With regard to drugs whose use results in the excretion of
PPCPs, lowering the dosage to the therapeutically effective level, rather
than the level recommended by the manufacturer, could have the result
of reducing the quantity of PPCPs entering fresh water resources.'
250. Daughton, Rationale for and Avenues Toward a Green Pharmacy, supra note
243, at 765.
251. Id. at 766.
252. Id.
253. Id. at 766-67.
254. Wennmalm and Gunnarsson describe such an approach in Sweden as well as
actions taken by the Stockholm County Council to implement it:
Despite the fact that pharmaceuticals may have adverse environmental effects,
no information on such effects is easily available to prescribing doctors. We
have developed a model for easy but accurate evaluation of the environmental
effects of drugs, aimed at helping doctors to make an environmentally-
conscious selection between medically-equivalent drugs with different environ-
mental impacts. Health care professionals have expressed much interest in the
classification system and the Stockholm County Council has decided that the
environmental score of each pharmaceutical obtained in the classification shall
be one variable for consideration when its list of recommended pharmaceuti-
cals is revised.
Wennmalm, & Gunnarsson, supra note 42, at 294-95.
255. Daughton, Rationale for and Avenues Toward a Green Pharmacy, supra note
243, at 766.
256. Id. at 767.
257. Cunningham et al., supra note 42, at 43.
258. Cunningham et al. state:
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The same result could be achieved through more precise formulation
and dosing of drugs."' Related to this would be "individualization of ther-
apy," which would require drug manufacturers to "provide the medical
community with more easily implementable information (and requisite
unit doses) to tailor drug dosages for the individual . . .""
The development of alternative drug delivery mechanisms is another
suggested means of improving the efficiency of drug use. This could in-
clude "better targeted delivery routes (e.g., expanding the utility of pul-
monary and transdermal/mucosal delivery), mechanisms of release (e.g.,
rapid-dissolving formulations, controlled release), and mechanisms for
delivery of drugs to the target (e.g., antibody-linked drugs; in situ im-
plants)."2"
With regard to the delivery of drugs, the role of patient education
cannot be overstated. As noted by Daughton, it is quite common for pa-
tients to "fail to finish their courses of medication. . . ."' As a result,
unused-and perhaps outdated-drugs accumulate and eventually require
disposal. If patients completed courses of medication as prescribed, the
quantity of drugs inappropriately disposed of would be reduced. This
could reduce the quantity of PPCPs entering fresh water resources.
Of equal importance is education of the medical community regard-
ing both appropriate dosages of specific drugs and appropriate disposal
mechanisms. Daughton advocates the use of continuing education pro-
grams involving both the medicine and environmental science to teach
the importance of "cradle-to-cradle stewardship" of medications."
C. DRUG MARKETING
AA noted above, patient education is a critical factor. The importance
of the role of drug marketing in educating both the patient and the public
cannot be overstated. For example, Daughton notes that the packaging of
both over-the-counter (nonprescription) and prescription drugs in the
United States does not provide guidance for the disposal of any unused
For a given use rate by the population, only low production volumes are
needed for potent pharmaceuticals. For the same population use rate, a high
therapeutic dose requires more production. So, the total amount of an API
lactive pharmaceutical ingredient) entering the environment is generally in-
versely correlated to its potency.
Id. at 44
259. Daughton, Rationale for and A venues Toward a Green Pharmacy, supra note
243, at 767.
260. Daughton notes that "individualization of therapy" is particularly relevant with
regard to long-term maintenance drugs. Id.
261. Id. (citing Mona Mort, Multiple Modes of Drug Delivery, 3 MODERN DRUG
DISCOVERY 30 (2000)).
262. Id. at 768 (citing Daughton, Drug Disposal, Waste Reduction, and Future Direc-
Lions, supra note 243).
263. Daughton, Rationale for and Avenues Toward a Green Pharmacy, supra note
243, at 768.
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portion of the medication? Guidance may also be missing regarding the
ingestion of different drugs having the same mechanism of action or the
same drug from different sources, both of which may result in a cumula-
tive dose in excess of therapeutic requirements.' This problem may be
exacerbated by different drugs having a similar name or appearance.'
With regard to the disposal of drugs, both the size and integrity of
drug packaging may play a role. Daughton notes, for example, that a
broader selection of package sizes could result in a reduction in the quan-
tity of drugs that are ultimately discarded.' This quantity could also be
reduced if improved packaging extended the shelf-life of drugs."'
Finally, the role of drug advertising must be considered. Such adver-
tising substantially influences consumer decisions regarding the use of
both over-the-counter (nonprescription) and prescription drugs. Differ-
ent types of advertising may also influence the medical community. Be-
cause of this, Daughton argues that such advertising should "include in-
formation for the public regarding the proper disposition of unused
products and the imperative for environmental stewardship."-
D. DRUG DISPENSING
There are any number of means by which both legal and illegal drugs
are dispensed. Sale of drugs via the Internet, for example, will "un-
doubtedly [lead] to overdispensing and dispensing without a prescrip-
tion[,J" which could have the effect of contributing to the overall envi-
ronmental exposure burden caused by such drug use."
This is particularly true with regard to the distribution of black-
market and counterfeit drugs, some twenty-five percent of which are sold
via the Internet." In addition to potential health benefits, reducing the
quantity of such drugs sold online would also reduce the quantity of such
drugs entering the environment either through excretion or disposal.
264. Id.
265. "This multiple-exposure pathway scenario is especially problematic when patients
are prescribed medications by multiple physicians; for patients with multiple health care
providers, poor communication can also lead to represcribing of medication that has
already been shown for the patient to be nonefficacious." Id.
266. Id. at 768-769 (citing Comm. on Quality of Health Care in America, Inst. of
Medicine, To ERR Is HUMAN: BUILDING A SAFER HEALTH SYSTEM (Linda T. Kohn,
Janet M. Corrigan, & Molla S. Donaldson eds., National Academy Press 2000)). "Al-
though these problems can jeopardize patient safety, they also lead to unnecessary (and
inappropriate) use of drugs and their eventual discharge to the environment, as well as to
the purchase of medications that might not have been made by a better-informed con-
sumer." Id. at 769.
267. Id. at 769.
2 6 8. Id.
269. Id.
270. Id. (citing U.S. FOOD & DRUG ADMINISTRATION, BUYING MEDICINES AND
MEDICAL PRODUCTS ONLINE (2002)).
271. Daughton, Rationale for and Avenues toward a Green Pharmacy, supra note 243,
at 769 (citing Press Release, Cyveillance Inc., Cyveillance Partners with Biocode to Serve
Pharmaceutical Indus. (June 5, 2001)).
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With regard to the disposal of drugs, a number of issues relate to ex-
piration dates, after which drugs are no longer considered effective.
Daughton notes that expiration dates should be based on actual, empiri-
cal data regarding stability duration rather than on the recommendations
of specific drug manufacturers."
The need to dispose of unwanted drugs could also be reduced by de-
veloping more disciplined dispensing and inventory control protocols.
Both pharmacies and consumers could be encouraged to minimize their
drug inventories in order to minimize the quantity of unwanted or un-
needed drugs needing disposal.' For example, the need to dispose of
specific drugs would be reduced if the quantity either purchased or pre-
scribed could be utilized completely prior to the expiration date of the
drug. The disposal need could also be reduced if "[rleasonable, minimal
quantities of medication could be purchased or prescribed until the ef-
fects of the medication and its therapeutic effectiveness are understood
by both the physician and patient.""'
Daughton makes two additional points regarding drug dispensing vis-
a-vis PPCPs in fresh water resources. First, the use of drugs for purposes
not originally intended requires both vigilance and ongoing review, par-
ticularly if such use results in the introduction of PPCPs into water sup-
plies.' Second, a nationwide database of drug sales is needed. This data-
base, which should be publically accessible, would compile and track the
sale and use of both over-the-counter (nonprescription) and prescription
drugs. Daughton concludes that such a database "would be extremely
useful for predicting the actual quantities of drugs that could be entering
the environment (by using pharmacokinetic models based on
ADME/Tox-adsorption, distribution, metabolism, excretion, and toxic-
ity)""
E. DRUG DISPOSAL/RECYCLING
The need for appropriate disposal or recycling of pharmaceuticals
has been noted repeatedly."' A number of suggestions have been offered
to encourage such disposal or recycling programs. Daughton, for exam-
ple, has suggested that an appropriate incentive for drug companies to
272. "Scientifically sound protocols need to be implemented for the public sector to
define, determine, predict, and/or monitor actual expiration periods for both factory-
sealed and unsealed drugs." Daughton, Rationale for and Avenues toward a Green
Pharmacy, supra note 243, at 770.
273. Id.
274. Id.
275. For example, "[tlhe long-running debates regarding the use of subtherapeutic
antibiotics and of anabolic steroids in animal feed have resulted in a number of actions
in certain countries to reduce or abolish their use." Id. at 771.
276. Id. at 769 (citing Christian G. Daughton, U.S. Envt'l Prot. Agency, Factors Com-
plicating Prediction of Drug Elimination from the Body (2002)).
277. See, e.g., TDC ENVIRONMENTAL, supra note 51, at 2; Christenson, supra note
180, at 164-166 (reviewing programs in Arizona, Arkansas and Wisconsin).
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implement drug disposal/recycling programs "would be to offer patent
extensions to companies that formulate vibrant, comprehensive steward-
ship programs tailored for each particular drug."" Daughton has also
suggested that the role of "reverse distributors" currently being used by
pharmacies in the United States for the return of unsold or expired drugs
be expanded "into a larger, comprehensive disposal/recycling program,
one that accommodates the consumer sector."" Such an expansion
might also include drug samples given to physicians because the "distribu-
tors of physician samples often instruct physicians to dispose of outdated
samples to the sewage system."'
Minimization of waste flows into the environment should have the ef-
fect of reducing the presence of PPCPs in fresh water resources. One
approach could be re-engineered toilets to separate liquid and solid
wastes. This could have the effect of both minimizing waste flows and
reducing water supply requirements."
Another approach could be "drug mining" (i.e., recovery of highly
toxic drugs from excreta and other hospital wastes)." However, with only
278. Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note
243, at 776.
279. Id. See also TDC ENVIRONMENTAL, supra note 51:
U.S. EPA has authorized reverse distribution of pharmaceuticals without haz-
ardous waste management permits. The U.S. EPA authorization specifically
requires the returns industry not to be used as a "waste management system"
(U.S. EPA, 1981; U.S. EPA, 1991). Any items that are inherently "waste-like"
(like a broken container or contaminated prescription) cannot be shipped as
products to a reverse distributor.
TDC ENVIRONMENTAL, supra note 51, at 4-5 (citing Letter from Alan S. Corson, Chief,
Waste Characterization Branch, Hazardous and Industrial Waste Division, U.S. EPA, to
Steven Wittmer, Merck, Sharp & Dohme (May 13, 1981), available at
http://yosemite.epa.gov/OSW/rcra.nsf/Documents/F3001B817EF426588525661100515
6D2; Letter from Sylvia K. Lowrance, Director, Office of Solid Waste, U.S. EPA, to
Mark J. Schulz, Browning-Ferris Industries (May 16, 1991) available at
http://yosemite.epa.gov/OSW/rcra.nsf/Documents/354FE6A290ED95E1852565DA006
FO4Al). Accord Christenson, supra note 181, at 165-166; However, it should be noted
that any consumer "reverse distribution" program would have to comply with the privacy
requirements of the Health Insurance Portability and Accountability Act (HIPAA), 42
U.S.C. §201, et seq.. TDC ENVIRONMENTAL, supra note 51, at 6.
280. Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note
243, at 776.
281. Id. (citing Tove A. Larsen et al., Re-engineering the Toilet for Sustainable
Wastewater Management, 35 ENVTL. Sci. & TECH. 192A (2001); Novaquatis, EAWAG
(Swiss Federal Institute for Environmental Science and Technology), INNOVATIVE
MANAGEMENT OF ANTHROPOGENIC NUTRIENTS IN URBAN WATER MANAGEMENT AND
AGRICULTURE (2002); R. Otterpohl, Options for Alternative Types of Sewerage and
Treatment Systems Directed to Improvement of the Overall Performance, 45 WATER
SC. & TECH. 149 (2002)).
282. Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note
243, at 776 (referring to a prototype of such a system developed by Pharmaceuti-
cals.org). See Pharmaceuticals.org, Pharmaceuticals from Human System to Human
System, http://www.toilets.com/pharmaceuticals.htm (last visited March 1, 2011).
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limited exceptions, any subsequent use of reclaimed or recycled drugs is
prohibited:
Once prescribed and given to patients, pharmaceuticals cannot be re-
used. State [Californial and Federal law require pharmacists and phar-
maceutical manufacturers to ensure that pharmaceuticals provided to
patients are pure and safe. Once a drug has left the control of a phar-
macy, its storage, handling, and condition are uncertain-and therefore
it cannot be assured to be pure and safe. Because there is no viable re-
use for unwanted residential pharmaceuticals, they are-by definition-
waste.'
Development of water recycling systems that allow wastewater to be
upgraded for both potable and non-potable uses provides another ap-
proach to minimization of waste flows.' As Daughton notes, "by use of
advanced water treatment technology such as reverse osmosis, nearly
complete removal of all PPCPs can be achieved."' This is an issue of
special concern in arid regions, particularly the southwestern United
States, where limited fresh water resources and growing populations vir-
tually mandate the reuse of water.'
Improvements to wastewater collection"' and treatment'" systems are
closely associated with the development of water recycling systems. Ad-
vanced wastewater treatment systems using reverse osmosis have the ca-
283. TDC ENVIRONMENTAL, supra note 51, at 8.
284. Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note
243, at 776; Lindsey A. Greene, Controversy Sivrls Around Toilet-to-Tap Project, 108
ENVTL. HEALTH PERSPECTIVEs A447 (2000).
285. Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note
243, at 776. It should be noted, however, that "all the solutes removed by reverse osmo-
sis are concentrated in the rejected 'brine' - a waste stream that must be disposed itself."
Id.
286. Snyder et al., supra note 48, at 34.
287. Collection system improvements need to address both combined sewer overflows
and urban stream-stormiflows as these are "significant contributors of OWCs [organic
water compounds] to receiving watersI.l" Phillips & Chalmers, supra note 85, at 56.
This in turn indicates that efforts to decrease the amounts of OWCs entering
large receiving waters need to identify and treat waters that bypass normal
wastewater-treatment processes. Future evaluations of the annual contributions
from these sources will require sampling of WWTP effluents, CSO effluents,
and urban streams under differing seasons and flow conditions.
Id.
288. With regard to the control of PPCPs in water supplies, development of advanced
wastewater treatment systems "could have the greatest potential benefit, as it would re-
move not only intentionally flushed drugs but also drugs that pass through the body
naturally." Christenson, supra note 180, at 159 (citing George J. Mannina, Jr., Medicines
and the Environment: Legal and Regulator Storms Ahead?, 21 LEGAL BACKGROUNDER
(2006)).
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pability to remove PPCPs through a physical separation process.' Utili-
zation of granular activated charcoal systems, as well as ozonation, has
been effective in removing antibiotics from wastewater." Research also
suggests using engineered wetlands and groundwater infiltration basins,"'
as well as phytoremediation," as mechanisms to attenuate PPCPs. At a
more basic level, Daughton recommends both that "[sitraight-piping of
sewage to surface waters . . . continue to be identified and eliminated"'
and that "[pirivies and septic systems. . . be converted to municipal sys-
tems when feasible.""'
With regard to reducing the environmental burden caused by both
the legal and illegal disposal of drugs, Daughton notes the need to revise
state laws that either restrict the donation of prescription drugs to charity
(e.g., Oklahoma)' or restrict or limit the authority of pharmacies to ac-
cept returns of unused drugs.'
Daughton's observation that funeral practices need to be environmen-
tally sound illustrates the complexity of issues relating to PPCPs in fresh
water resources. Not only can burial practices "pose problems with re-
spect to groundwater pollution if they have not been properly engineered
and sited with local hydrogeologic processes in mind,""' but the presence
of PPCPs in the bodies of the deceased "could be expected to be exten-
sive as a result of long-term medication and heroic treatment measures.""
The role of public education is also important in the context of.drug
disposal/recycling. Daughton emphasizes the importance of public out-
reach programs:
A well-designed, concerted public outreach program for communicating
the issues associated with PPCPs as environmental pollutants could ac-
complish dual aims: (a) enhance the public's appreciation and under-
standing of a wide range of principles associated with environmental
science, and (b) increase the public's sense of environmental responsi-
bility by showing how their actions as individuals collectively contribute
to the burden of PPCPs in the environment, how PPCPs can possibly
affect environmental processes (e.g., aquatic biota), and the collateral
289. Sedlak and Pinkston, supra note 16, at 56; Reynolds, Pharmaceuticals in Drink-
ing Water Supplies, supra note 26; Heberer et al., Removal of Pharmaceutical Residues,
supra note 87, at 28.
290. Huang et al., supra note 26, at 37; Reynolds, Pharmaceuticals in Drinking Water
Supplies, supra note 26, (citing Marc M. Huber et al., Oxidation of Pharmaceuticals
during Ozonation and Advanced Oxidation Processes, 36 ENVTL. Sci. & TECH. 1202
(2003)).
291. Sedlak & Pinkston, supra note 16, at 62.
292. Ninad Gujarathi & James Linden, Potential for Phytoremediation of Antibiotic-
Contaminated Water, 24 AGRONOMY NEws 9 (2004).
293. Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note
243, at 776.
294. Id.
295. Id. at 776-77.
296. Id. at 777.
297. Id.
298. Id.
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advantages (human health and economic) accrued by conscien-
tious/responsible disposal and use of PPCPs.'
IV. DRUG ALTERNATIVES
A condition precedent to the release of PPCPs into fresh water re-
sources is the use of PPCPs. Experts frequently overlook the obvious
fact that a reduction in the use of PPCPs would also reduce the quantity
of PPCPs released into water supplies. Daughton notes, for example,
that nutrition and health maintenance programs, by reducing the inci-
dence of diseases requiring treatment, also reduce the release of PPCPs
associated with such treatment."
When treatment is required, use of alternative drugs (i.e., drugs not
containing PPCPs) should be considered. As an example, Daughton
notes that there is a "wide range of medical uses of probiotics" (benefi-
cial, endogenous microflora)." Such "bacteriotherapy" may achieve the
same results as the use of drugs containing PPCPs but without the atten-
dant execration or disposal problems.'
V. CASE STUDY BASED ON PROJECT 2 RESULTS
The Project 2 research focused on the presence of PPCPs in soil and
groundwater in West Texas." As more thoroughly discussed below, this
research focused on four inter-related research topics: (a) the sorption of
PPCPs in different types of soils; (b) the degradation of PPCPs in soil
under aerobic and anaerobic conditions; (c) the degradation of PPCPs in
soil with high water content; and (d) the presence of PPCPs in a wastewa-
ter treatment plant and in both soil and groundwater at sites to which
treated wastewater had been applied."
299. Id.
300. Id. In terms of reducing the use of PPCPs, Daughton suggest that "more re-
search could be directed at reducing (or eliminating) drug dosages via the use of place-
bos." Id.
301. Id. (citing Bob Beale, Probiotics: Their Tiny Worlds are Under Scrutiny, 16
SCIENTIST 20 (2002)).
302. As an example, Daughton notes that probiotics "have long been used and studied
for the protection of the gut" because of the capability of probiotics to block pathogen
adhesion. Id. (citing Indu Pal Kaur et al., Probiotics: Potential Pharmaceutical Applica-
Lions, 15 EUROPEAN JOURNAL OF PHARM. SCI. 1 (2002)).
303. All of the sites involved in this research had been subjected to disposal of treated
waste water effluent through land application by the City of Lubbock's municipal waste
water treatment facility, in some cases, for the past 70 years. These sites were. ideal for
this type of study, in part, because there are very few discharges of treated waste water
effluent "upstream" of the City of Lubbock's chief sources of municipal fresh water,
which include Lake Meredith on the Canadian River and the Ogallala Aquifer. The
effects of being located downstream of a wastewater treatment are discussed supra note
82, and accompanying text.
304. Monteiro & Boxall express concern "over the potential impacts of biosolid-
associated pharmaceuticals on terrestrial systems and associated groundwaters and sur-
face watersl,)" Monteiro & Boxall, supra note 55, at 2546, noting:
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As noted in Section II, the research is relevant to the issue of PPCPs
in fresh water resources because of disposal methods used by wastewater
treatment plants for both solid and liquid wastes.' Solid wastes (sludge
or biosolids) and liquid wastes are applied to lands that have been desig-
nated as application sites, and the waste products are then degraded by
natural processes.
An emerging concern is the sufficiency of natural processes to de-
grade PPCPs before they migrate through the soils into groundwater or
bioaccumulate in species inhabiting the soil environment.' With regard
to the effects of bioaccumulation of PPCPs, specifically triclosan
("TCS"), Lozano et al. concluded:
Since TCS is a bacteriostat, there is a real potential that concentrations
in soils resulting from biosolid applications might affect bacterial ecol-
ogy of these systems. Especially since the ecological balance and com-
petitive advantages of the multiple species inhabiting any soil environ-
ment are very complex and any small advantage one microbe might
achieve due to exposure to these known bacteriostat could be amplified
under these conditions."
"In biosolids destined for land application, a number of pharmaceuticals and
personal care products have been detected." Id. (citing Chad A. Kinney et al.,
Survey of Organic Wastewater Containiants in Biosolids Destined for Land
Apphcation, 40 ENVTL. ScL & TECH. 7207 (2006); Chris D. Metcalfe et al.,
Distribution of Acidic and Neutral Drugs in Surface Waters Near Sewage
Treatment Plants in the Lower Great Lakes, Canada, 22 ENVTL. TOXICOLOGY
& CHEMISTRY 2881 (2003)).
"Other studies have detected pharmaceuticals in biosolid-amended soils." Id.
(citing Chad A. Kinney et al., Bioaccumulation of Pharmaceuticals and Other
Anthropogenic Waste Indicators in Earthworms from Agricultural Soil
Amended with Biosolid or Swine Manure, 42 ENVTL. Sci. & TECH. 1863
(2008); Eva M. Golet et al., Determination of Fluoroquinolone Antibacterial
Agents in Sewage Sludge and Sludge-treated Soil Using Accelerated Solvent Ex-
traction Followed by Solid-phase Ertraction, 64 ANALYTICAL CHEMISTRY
(2002)).
305. As noted previously, this is an increasing concern in areas of the world where
reclaimed wastewater is being used for irrigation. Kinney et al. addressed this issue:
As the range of uses and number of demands for potable water has increased,
alternatives to using drinking water for agricultural and landscape irrigation
have been of increasing interest. Reclaimed water is gaining use for irrigation;
however, little is known about the potential for contamination of surface water
and groundwater by use of this source.
Kinney et al., supra note 27, at 317 (citing H. Bouwer et al., Integrating Water Manage-
mnent and Re-use: Causes for Concern? 1-2 WATER QUALITY INT'L. 19 (1999)).
306. Id., at 318 (organic wastewater contaminants "might accumulate in soil if intro-
duced through irrigation water").
307. Lozano et al., supra note 89, at 764.
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A. SORPTION OF ESTROGENS, TRICLOSAN, AND CAFFEINE IN A
SANDY LOAM AND A SILT LOAM SOIL"
Simply stated, sorption is the process by which one substance at-
taches to or holds another substance. Karnjanapiboonwong et al. per-
formed research that focused on the sorption of sample PPCPs in differ-
ent types of soil.
The sample PPCPs were estrogens (estrone, 17-estradiol, estriol and
17a-ethynylestradiol)," triclosan,"' and caffeine. The PPCPs were con-
tained in biosolids produced from a municipal wastewater treatment
plant. The soil types were a sandy loam collected in Terry County,
Texas and a silt loam collected in Harlan County, Nebraska. Laboratory
sand served as a control."
The results of the study indicated that sorption capacity was a func-
tion of the organic carbon content of the soils. The silt loam, having the
highest organic carbon content, also had the greatest sorption capacity.
The laboratory sand, having the lowest organic carbon content, also had
the least sorption capacity.
In terms of the sample PPCPs, estrone, 17p-estradiol, 17a-
ethynylestradiol, and triclosan had a strong tendency to sorb to the test
soils. Once sorbed, the tendency of these substances to desorb and mi-
grate into groundwater was minimal. The same could not be said for
estriol and caffeine, both of which had the potential to migrate into
groundwater if soil leaching occurred.
B. MICROBIALLY MEDIATED DEGRADATION OF COMMON
PHARMACEUTICALS AND PERSONAL CARE PRODUCTS IN SOIL UNDER
AEROBIC AND ANAEROBIC CONDITIONS'
The City of Lubbock, Texas, disposes of treated effluent from its
municipal wastewater treatment plant by applying it to lands designated as
308. Adcharee Karnjanapiboonwong et al., Sorption of Estrogens, Triclosan, and
Caffeine in a Sandy Loam and a Silt Loam Soil, 10 JOURNAL OF SOILS AND SEDIMENTS
1300 (2010).
309. Estrone, 173-estradiol and estriol are naturally-occurring estrogens while 17a-
ethynylestradiol is a synthetic estrogen commonly used in birth control pills. Research
has indicated that 17a-ethynylestradiol may disrupt the reproductive capabilities of a
number of different species. Id.
310. Triclosan is an antibacterial agent found in a number of consumer products such
as soaps and cleaning supplies. Concern has been expressed that the presence of tri-
closan in water supplies may be causing bacteria to develop immunities to antibiotics. It
has also been suggested that triclosan in combination with chlorine may form chloro-
form, a known carcinogen. See Lyndsey Layton, FDA Says Studies on Triclosan, Used
in Sanitzers and Soaps, Raise Concerns, WASH. POST, April 8, 2010, available at
http://www.washingtonpost.com/wp-
dyn/content/article/2010/04/07/AR2010040704621 .html.
311. Karnjanapiboonwong et al., supra note 308.
312. Deborah L. Carr et al., Microbially Mediated Degradation of Common Pharma-
ceuticals and Personal Care Products in Soil Under Aerobic and Anaerobic Conditions,
216 WATER, AIR & SOIL POLLUTION 633 (2011).
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a land application site. This site received an average of thirteen million
gallons per day of effluent, which was applied to the land using thirty-one
center pivot sprinklers. Soil samples were collected from areas irrigated
by the sprinklers (exposed soils), and from adjacent areas that had not
been exposed to the treated effluent (unexposed soils).
The researchers identified numerous PPCPs in the treated effluent,
including estrogens (estrone, 17j-estradiol, estriol and 17a-
ethynylestradiol), triclosan, ibuprofen," and ciprofloxacin.'" The rate of
degradation of these PPCPs was calculated under aerobic and anaerobic
conditions for PPCPs introduced into both exposed and unexposed soils.
The degradation rates for specific substances varied with soil type and
with aerobic/anaerobic condition. The most notable finding was that,
under anaerobic conditions, the degradation rate increased in exposed
soils.
C. BIOLOGICAL DEGRADATION OF COMMON PHARMACEUTICALS
AND PERSONAL CARE PRODUCTS IN SOILS WITH HIGH WATER
CONTENT'
This element of this case study addressed the movement of water
through soils. As the researchers noted, soil texture affects the move-
ment of water, with more finely textured soils holding water in pore
space. The researchers also noted that oxygen availability is limited in
submerged soils and that this slows the process of biological decay.
Soil samples were collected from the aforementioned site used by the
City of Lubbock, Texas for land disposal of treated effluent. This efflu-
ent contained multiple PPCPs, including estrogens (estrone, 17j0-
estradiol, estriol and 17a-ethynylestradiol), triclosan, and ibprofen. The
research focused on the extent to which biological decay of these PPCPs
was affected by the moisture content of the soils at the land application
site.
In general, the research demonstrated that the time needed for bio-
logical decay to occur increased in soils with high water content."' The
extent of this increase varied with both the specific substance and the
duration of the high water content. Another variable was the extent to
which the soils had been exposed to the substance previously (as was the
case at the land application site) as compared to soils that had not been
previously exposed.
313. Ibprofen is a non-steroidal anti-inflammatory drug that is marketed for pain relief
under a variety of different names (e.g., Motrin, Advil, etc.).
314. Ciprofloxacin is a common antibiotic that is sold worldwide for both human and
veterinary use.
315. Deborah L. Carr, Audra N. Morse, John C. Zak & Todd A. Anderson, Biologi-
cal Degradation of Common Pharmaceuticals and Personal Care Products in Soils with
High Water Content, 217 WATER, AIR & SOIL POLLUTION 127 (2011).
316. The only exception was ibuprofen, which appeared to demonstrate increased
degradation in soils with high water content. Id.
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D. OCCURRENCE OF PPCPS AT A WASTEWATER TREATMENT PLANT
AND IN SOIL AND GROUNDWATER AT A LAND APPLICATION SITE"'
The Lubbock, Texas wastewater treatment plant and land application
site were also involved in this component of the research. Water and
sludge samples were obtained from the wastewater treatment plant with
soil and groundwater samples being obtained from the land application
site. As noted above, the treated effluent was distributed through the use
of thirty-one center pivot irrigation sprinklers. Samples were also ob-
tained from adjacent areas that were not irrigated with this effluent.
The target PPCPs, all of which were present in the wastewater efflu-
ent,"' were estrogens (estrone, 17j3-estradiol, estriol and 17a-
ethynylestradiol), triclosan, caffeine, ibuprofen, and ciprofloxacin. The
research question was whether these PPCPs biodegraded, accumulated in
the soils, or migrated into groundwater.
The research results are illustrative of the difficulties inherent in the
management of PPCPs. The presence of PPCPs in both the sludge and
effluent from the wastewater treatment plant varied over time. PPCPs
may sorb to the wastewater treatment plant sludge, which could compli-
cate land disposal of such sludge.
With regard to the land application site, PPCPs were detected within
the areas receiving effluent from the center pivot sprinklers as well as
from adjacent areas that had not been irrigated but apparently were re-
ceiving runoff from the areas that had been irrigated. The presence of
PPCPs in both areas varied over time. This variability was most likely a
function of the variable presence of PPCPs in the effluent from the
wastewater treatment plant.
The presence of PPCPs also varied with the depth of the soil froi
which samples were taken. This led the researchers to conclude: "Any
trend in target PPCP concentrations with soil depth was difficult to dis-
cern and is likely due to the various biodegradation rates of PPCPs with
soil depth; degradation of PPCPs can be affected by environmental con-
ditions such as temperature, pH, moisture content, organic carbon, pres-
ence of specific microorganisms, and presence/absence of oxygen.'"
Of all of the PPCPs included in the study, only ibuprofen was not de-
tected in the groundwater samples. This was true irrespective of whether
317. Adcharee Karnjanapiboonwong et al., Occurrence of PPCPs at a Wasteiwater
Treatment Plant and in Soil and Groundwater at a Land Application Site, 216 Water,
Air, & Soil Pollution 257 (2010) [hereinafter Karnjanapiboonwong, Occurrence of
PPCPsI.
318. Interestingly, 17a-ethynylestraliol was not detected in the sludge from the waste-
water treatment plant. All the other target PPCPs were detected. Id.
319. Id. at 18 (citing Michael S. Colucci, Henry Bork, & Edward Topp, Persistence of
Estrogenic Hormones in Agricultural Soils: L 12l-Estradiol and Estrone, 30 .1. ENvTL.
QUALITY 2070 (2001); Alistair B.A. Boxall, Fate and Transport of Veterinary Medicines
in the Soil Enwironient, in FATE OF PHARMACEUTICALS IN THE ENVIRONMENT AND IN
WATER TREATMENT SYSTEMS 123, 127 (Diana S. Aga ed., CRC Press 2007); Monteiro &
Boxall, supra note 55, at 2546).
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the groundwater samples were drawn from the areas irrigated with the
wastewater effluent or from adjacent areas that had not been irrigated.
The researchers concluded:
PPCPs in the effluent from a wastewater treatment plant can eventually
move to groundwater via land application of the effluent. However,
PPCPs detected in groundwater at the study site were at low concentra-
tions which are not likely to represent a concern and indicate that the
land application process is reasonably effective at PPCP removal[.] ...
Our findings may be important for evaluating the potential long-term ef-
fects of PPCPs from contamination of soil and eventually groundwater
if that water is to be used for drinking-water purposes.'
E. CONCLUSIONS FROM THE CASE STUDY
The research results summarized above relate to a series of studies
involving the presence of a fairly limited number of PPCPs at a relatively
small number of sites. With one exception (soil samples from Harlan
County, Nebraska), all of the sampling was done at the Lubbock, Texas
wastewater treatment plant, the land application site for effluent from the
plant, or lands adjacent to the land application site.
Nonetheless, a significant amount of variability was noted. Degrada-
tion of PPCPs was seen to be affected by: (a) soil type and organic con-
tent; (b) soil moisture content (including variation in rainfall); (c) soil
oxygen content; and (d) prior exposure to PPCPs. As noted above with
regard to the presence of PPCPs in soils, additional variables could in-
clude temperature, acidity/alkalinity and the presence of specific micro-
organisms."'
320. Id. at 22.
321. With regard to temperature, Kinney et al., have noted seasonal variability:
Down-core migration of pharmaceuticals may occur from either the reclaimed-
water irrigation or from pharmaceutical-free precipitation. This result also
could be explained by variations in the concentration of these compounds in
the reclaimed water or a change in removal/degradation rate. The latter could
be accounted for by differences in soil microbial population dynamics. Higher
soil temperatures, consistent soil moisture, and perhaps, a steady supply of
substrate and nutrients in the reclaimed water could result in greater degrada-
tion of the compounds by soil microbes during the summer irrigation period
compared to that during the winter months.
Kinney et al. supra note 27, at 322 (emphasis added). Lozano et al., noting that soil
concentrations of triclosan (TCS) were quite variable, concluded: "Our data suggests that
the two most important parameters controlling TCS top soil concentrations are the bio-
solids application rate and the time between application and sampling." Lozano et al.,
supra note 89, at 762. This variability was also addressed in Monteiro & Boxall, supra
note 55, at 2546:
"Laboratory studies show that degradation rates of pharmaceutical compounds
in soils vary widely, with half-lives ranging from days to years." Id. (citing Alis-
tair B.A. Boxall, Fate and Transport of Veterinary Medicines in the Soil Envi-
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This variability, especially when considered over a national scale,
points to the difficulty of controlling or managing PPCPs once they have
been, introduced into the environment.' Different PPCPs degrade at
different rates and under different conditions at different locations.
Given the complexity of the problem, it is highly likely that post-release
solutions will be inadequate.
Consequently, as discussed in greater detail below, eliminating or re-
ducing PPCPs in the waste stream is much more likely to reduce both
human and environmental risks than any post-release alternatives. In
ronment, in FATE OF PHARMACEUTICALS IN THE ENVIRONMENT AND IN
WATER TREATMENT SYSTEMS 123 (Diana S. Aga ed., CRC Press 2007)).
"Within the same therapeutic class, half-lives can still be significantly differ-
ent." Id. (citing Michael P. Schlisener & Kai Bester, Persistence of Antibiotics
Such as Macrolides, Tiamulin and Sahnomycin in Soil, 143 ENvTL.
POLLUTION 565 (2006)).
"These differences are probably explained by differences in soil properties
such as moisture content, organic carbon, pH, and soil bioactivity; climate
(temperature); and physicochemical properties of the compound such as de-
gree of dissociation and lipophilicity." Id. (citing Edward Topp et al., Fate of
the Nonsteroidal Anti-inIlammatory Drug Naproxen in Agricultural Soil Re-
ceiving Liquid Municipal Biosohds, 27 ENvTL. ToxICOLOGY & CHEMISTRY
2005, 2008 (2008); Melanie Kah et al., Factors Influencing Degradation of Pes-
ticides in Soil, 55 J. AGRIC. & FOOD CHEMISTRY 4487, 4491-4492 (2007); Ed-
ward Topp et al., Biodegradation of Caffeine in Agricultural Soils, 86 CAN. J.
SOIL Sci. 533, 543 (2006); M.S. Collucci et al., Persistence of Estrogenic Hor-
mones in Agricultural Soils (I. 17-beta Estradiol and Estrone), 30 J. ENVTL.
QUALITY 2070, 2075 (2001)).
322. Such variability is not confined to the case study. A study of PPCPs in the Ann
Arbor, Michigan water use cycle identified a number of antibiotics, analgesics, antiepi-
leptics, steroids and hormones in raw wastewater influent over a number of months.
Variability in the presence of these substances can be seen by comparing the mean con-
centrations with the standard deviation (a measure of variance):
Analyte Mean concentration (pg/1) Standard deviation (pg/1)
Coprostanol 682.500 568.880(steroid/hormone).
Cholesterol 560.000 451.368(steroid/hormone)
Sitosterol (steroid/hormone) 241.500 173.077
Dihydrocholesterol 67.500 46.458(steroid/hormone)
Stigmasterol 37.125 27.497(steroid/hormone) - 3 2.9
Acetaminophen (analgesic) 53.000 37.151
Ibuprofen (analgesic) 11.000 7.685
Skadsen et al., supra note 79, at 4, Table 4.
428 Volume 15
PHARMACEUTICALS AND PERSONAL CARE PRODUCTS
essence, it is much easier to keep PPCPs out of waste stream than to
safely dispose of waste containing PPCPs.
VI. STRENGTHS AND WEAKNESSES OF THE STATUTORY,
REGULATORY AND ALTERNATIVE STRATEGIES
A. STATUTORY AND REGULATORY
Statutory and regulatory approaches to the control of PPCPs may
have both substantial benefits and significant costs. Though statute-
specific strengths and weaknesses are discussed below, many of the bene-
fits and costs of a statutory or regulatory approach are not statute specific.
Any regulatory program must be authorized by statute. Such enabling
legislation defines the scope of an agency's regulatory authority. Existing
environmental statutes have vested substantial authority in the EPA.
Similar legislation at the state, territorial, and tribal levels has vested au-
thority in entities whose functions mirror those of the EPA..
323. The Food and Drug Administration also has substantial authority under the
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. S 301 et seq. This authority, which
includes the responsibility to ensure the safety and efficacy of both human and animal
drugs (21 U.S.C. S 355), was expanded with enactment of the Food Quality Protection
Act of 1996. The 1996 amendments authorized the Environmental Protection Agency
"to screen substances that may be found in sources of drinking water for endocrine dis-
ruption potential." Keith A. Johnston & Kristine Sendek-Smith, Muddy Waters: Recent
Developments Under the Clean Water Act, 24-Winter NATURAL RES. AND ENV'T 31, 37
(2010).
Through what has been a long and contentious process, the EPA's Endocrine
Disruptor Screening Program is finally making progress in helping identify en-
docrine disruptors from the tens of thousands of chemicals currently in use,
and it will eventually study the effects of those chemicals and compounds on
humans and wildlife. EPA is near publication of the results of its sampling per-
formed in 2007 to determine the prevalence of certain chemicals in drinking
water and is also set to expand sampling this year to obtain water samples from
up to fifty drinking water treatment plants to help analyze the prevalence of
about 200 emerging contaminants in drinking water.
Id. at 37-38 (citing Alan Kovski, Drinking Water: EPA Details Emerging Contaminants
Survey, Responds to Questions about Its Usefulness, 40 ENV'T REP. 2361 (Oct. 9,
2009)). Johnston and Sendek-Smith also note that the U.S. Geological Survey is in the
process of developing a national reconnaissance program for emerging contaminants.
This program is to focus "on four groups of compounds: veterinary and human antibiot-
ics, human drugs, industrial and household products (such as insecticides, detergents,
fire retardants, and fuels), and sex and steroidal hormones." Id. at 38 (citation omitted).
Authority for such a program, they note, is provided by the Safe Drinking Water Act (42
U.S.C. § 300j-17), the Toxic Substances Control Act (15 U.S.C. § 2603), the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. §§ 346(a)(p), 408(p)) and the Federal Insecti-
cide, Fungicide and Rodenticide Act (7 U.S.C. § 136(c)(2)). Id. In addition, Nidel has
noted that the authority of the Food and Drug Administration "was expanded into the
environmental realm by enactment of the National Environmental Policy Act (NEPA),
which not only provides FDA with the authority to bring environmental considerations
into its decision-making, but also requires that it take these considerations into account."
Christopher T. Nidel, Regulating the Fate of Pharmaceutical Drugs: A New Prescription
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The result has been the development of substantial agency expertise
regarding specific issues. This is one of the major strengths of the exist-
ing statutory/regulatory approach to environmental regulation.
Agency expertise has developed as environmental law in the United
States has matured. At this point in the history of environmental law, the
requirements of the statutes are fairly well known and understood, and
the scope of the EPA's authority has been established. The result is a
fairly complete understanding of the requirements of different statutes
and regulations. As with the development of agency expertise, this is also
one of the strengths of the current statutory/regulatory system.
However, a weakness associated with this system is the limited ability
of the system to respond to site-specific issues. If PPCPs are determined
to be a threat to human health and the environment, for example, a na-
tional regulatory program could be implemented based on one of the
statutes discussed herein. Unfortunately, the problem of PPCPs may be
localized, as the number of variables identified in the Section V case
study would appear to indicate. The response could be the proverbial
use of a sledgehammer to kill a gnat.
1. Common Law Remedies Sounding in Tort
Entitlement to relief under the common law remedies is based on
success in litigation. Since the common law tort theories apply to dis-
putes between individuals (civil wrongs as opposed to criminal or societal
wrongs), application of the theories arises in the context of litigation be-
tween such individuals.
Consequently, all of the weaknesses of litigation as a means of envi-
ronmental regulation would be applicable to litigation involving potential
PPCP liability. Notably, litigation is expensive and time-consuming. Fur-
thermore, assuming that the party bringing the action has the requisite
legal standing, the scope of issues before the court is limited to the issues
raised by the parties which are almost always unique to a specific case.
Likewise, any remedy provided by the court is limited to the parties
before the court. The outcome of litigation is influenced frequently by
the resources available to the parties. Any potential outcome may change
dramatically if the parties, for whatever reason, choose to settle the litiga-
tion.
In general, litigation has not proven to be an effective means of pro-
tecting public health dind the environment. That said, litigation will cer-
tainly continue based both on common law tort theories and the statutes
discussed in Section III.
It is at least theoretically possible that a trespass action could be
brought involving PPCPs. In the Section V case study, for example,
treated effluent containing PPCPs was applied to lands using center pivot
for the Environment, 58 FOOD & DRUG LAWJOURNAL 81, 92 (2003) (citing 42 U.S.C.S.
§§ 4321 et seq.). See Mannina, supra note 289, at 1, 3; see also Christenson, supra note
180, at 156.
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irrigation systems. The researchers noted that PPCPs were also found in
soil samples taken from lands adjacent to the areas where the treated ef-
fluent had been sprayed. It was speculated that PPCPs were found on
adjacent lands because of run-off from the irrigated areas. On these facts,
a trespass action might be feasible. However, in order to recover more
than merely nominal damages, the plaintiff would have to prove that the
conduct of the defendant resulted in damage to the plaintiff. Given the
low levels of PPCPs noted in the case study, fulfilling the burden of proof
regarding damages may be difficult.
A public nuisance action might be possible if it could be shown that
the use of public "streams, parks, beaches and other facilities""' was ad-
versely affected by water supplies containing PPCPs. Again, it would be
the plaintiffs burden to show harm. As noted above, given the low levels
of PPCPs noted in the case study, fulfilling this burden of proof require-
ment could prove difficult.
Application of the theory of negligence might be appropriate when it
could be documented that a specific plaintiff was injured by PPCPs re-
leased into the environment by a specific defendant. However, this as-
sumes that the appropriate chain of causation could be established. This
is not a safe assumption given the ubiquitous nature of PPCPs. There is
no question that the manufacturers of PPCPs owe a duty of due care to
prevent adverse public and environmental health impacts. The weakness
in trying to apply the theory of negligence to such manufacturers is the
great degree of difficulty in determining the manufacturer of any specific
PPCP alleged to have caused harm.
Applying the theory of strict liability would be predicated on the aver-
ment that PPCPs are inherently dangerous products for which the manu-
facturers should be strictly liable. Given the "value of the activity to the
community". (i.e., the prevention or treatment of disease), it would be
exceptionally difficult, if not impossible, for a plaintiff to demonstrate
that PPCPs are inherently dangerous."'
However, as noted above, litigation is always fact-specific. Given an
appropriate set of circumstances, application of one of the common law
324. RESTATEMENT (SECOND) OF TORTS, supra note 96, at § 821B.
325. Id. at § 402A.
326. For example, acetylsalicylic acid is used for both human therapy and in animal
husbandry. It is "a non-steroidal anti-inflammatory" that is "also used for its analgesic,
antipyretic and anti-coagulating properties." Acetylsalicylic acid "is known to cause skin,
eye and upper respiratory tract irritation upon direct contact and gastrointestinal bleed-
ing following chronic ingestion." It is "a known systemic allergen and can produce ana-
phylaxis at doses in the lowest end of the therapeutic range (10 mg/kg)." However, there
is "strong epidemiological evidence" that acetylsalicylic acid may also afford protection
from some cancers. When used for both human therapy and in animal husbandry, sali-
cylic acid and other metabolites are excreted in urine and may end up in water supplies.
On these facts, it would be difficult to argue that acetylsalicylic acid is an. inherently
dangerous product, especially since its commonly used name is aspirin. Schulman et al.,
supra note 14, at 660 (citation omitted).
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tort theories might be an appropriate response to human and environ-
mental health injuries resulting from the release of PPCPs."
2. The Clean Water Act
As noted in Section III, states are authorized to promulgate water
quality standards based on the National Recommended Water Quality
Criteria ("Criteria"). The state standards are then subject to EPA ap-
proval. Lopez has argued that the EPA has a mandatory duty to revise
the Criteria "to establish limitations for EDCs [and other PPCPs] to pro-
tect against endocrine disruption."" Should this occur, NPDES permits
ultimately would have to include appropriate measures to eliminate or
control PPCPs. Absent such an NPDES permit, discharges of PPCPs
from point sources into "waters of the United States" would be prohib-
ited.
The wastewater treatment industry is familiar with both the Clean
Water Act and the use of NPDES permits. While this may be one of the
strengths of this approach to the control of PPCPs in fresh water re-
sources, it is also one of the weaknesses. If PPCPs are to be controlled
through the use of NPDES permits, which PPCPs should the regulation
target, and using what technology? The plethora of PPCPs would appear
to require a plethora of control technologies.
A directly related question, assuming that control of PPCPs is man-
dated at wastewater treatment plants, focuses on treatment techniques
and systems. As noted in Section IV, new water treatment systems have
327. In fact, Mannina provides an example of such circumstances:
[Ain Illinois municipal water district which owns and operates a plant providing
water to municipal residents and businesses has sued the manufacturers of cer-
tain herbicides demanding that the manufacturers clean up all residue from a
substance which has found its way into the source of the drinking water and
also pay for the costs of installing and operating additional water treatment sys-
tems to guarantee the removal of any residue from this herbicide. What makes
this case significant is that the plaintiff does not allege the herbicide is being
used unlawfully or contrary to the manufacturer's instructions. Nor are there
any allegations of a violation of the safe drinking water standards established by
EPA or the State of Illinois. Rather, the plaintiff, citing various studies allegedly
demonstrating adverse human health impacts of herbicide residue at concentra-
tions less than the existing safe drinking water standards, asserts that the federal
and state standards are not protective of human health. The plaintiff then as-
serts that the herbicide manufacturers are guilty under state law of trespass,
nuisance, negligence, and releasing "contaminants" into the environment solely
because residue from the herbicide has come to be located in water owned and
used by the plaintiff. While this case does not involve pharmaceuticals or per-
sonal care products, one can imagine creative attorneys using similar and re-
lated theories.
Mannina, supra note 288, at 3 (emphasis added).
328. Jacki Lopez, Endocrine-Disrupting Chemical Pollution: Why the EPA Should
Regulate These Chemicals Under the Clean Water Act, Spring SUSTAINABLE DEV. L. &
PoL'Y 19, 22 (2010).
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been (and are being) developed.' A number of authors have noted the
need for these technological developments to continue. Nidel, for exam-
ple, notes the need to development new wastewater treatment systems
that "more effectively break down these compounds leaving only envi-
ronmentally inert effluents."" The related question, therefore, is whether
the development and use of new wastewater treatment technology should
be a condition precedent to the issuance of NPDES permits.
Requiring pretreatment of wastes containing PPCPs has been sug-
gested." Such requirements would be applicable to a variety of entities
(i.e., manufacturing facilities, health care facilities) that discharge wastes
containing PPCPs.' The goal of such requirements would be to mandate
the pretreatment of wastes that would either interfere with the operation
of a wastewater treatment plant or that would pass through a wastewater
treatment plant untreated.'
Assuming that wastewater treatment techniques and systems can be
developed to control the plethora of PPCPs, the cost could be stagger-
ing.' Imposing such costs on the operators of publically-owned treat-
ment works may be both financially and politically impossible. As Jones
has noted: "Although the public may want pure water, people are not
prepared to pay what it would actually cost even if sufficient technology
did exist."'
Finally, perhaps the most significant limitation regarding use of the
Clean Water Act as a means of preventing the introduction of PPCPs
into fresh water resources is the fact that the statutory requirements do
not apply to nonpoint sources of wastes. Such nonpoint sources (e.g.,
runoff from farms) are "a significant sources of the pharmaceuticals
found in surface water[."
3. The Safe Drinking Water Act
Inclusion of PPCPs in the National Primary Drinking Water Regula-
tions would be one means of limiting human exposure to PPCPs. Maxi-
mum Contaminant Level Goals ("MCLGs") and Maximum Contaminant
Levels ("MCLs") could be established for PPCPs.
329. Supra, notes 278 to 300 and associated text.
330. Nidel, supra note 323, at 82. However, "this solution is under-inclusive [in that
it] does not address the large amounts of animal drugs that make their way directly into
the environment." Id. at 91.
331. Christenson, supra note 180, at 163 (citing P.G. KENT & T.A. DUDIAK,
WISCONSIN WATER LAW: A GUIDE TO WATER RIGHTS AND REGULATIONS 104 (2d ed.
2001)).
332. Id.
333. See Id.
334. "The total costs of removing every possible. endocrine disrupting compound
could quickly become astronomical." Jones, supra note 243, at 385-386.
335. Id. at 386.
336. Christenson, supra note 181, at 148 (citing P.G. Kent & T.A. Dudiak,
WISCONSIN WATER LAW: A GUIDE TO WATER RIGHTS AND REGULATIONS 99, 107 (2d
ed. 2001)).
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In fact, the EPA is considering such an approach. As indicated in
Section III, the Contaminant Candidate List ("CCL") includes contami-
nants not presently subject to the National Primary Drinking Water
Regulations, but which may have an adverse impact on human health and
are known to occur in water supply systems. If so, the EPA Administra-
tor may subject the contaminant to the National Primary Drinking Water
Regulations. The current CCL, which was published on 21 August 2008,
lists 104 contaminants." Unfortunately, virtually all of the PPCPs that
were proposed for inclusion on the CCL were not included.'
Perhaps because of this outcome, the Science Advisory Board Drink-
ing Water Committee of the EPA Office of Ground Water and Drinking
Water recommended changes to the CCL selection process:
The Committee recommends consideration of emerging issues and on-
going research when selecting chemicals. There are also some clear
categories of contaminants that need special attention in selecting the
CCL including pharmaceuticals, personal care products, endocrine dis-
ruptors, antibiotics, and algal toxins. Such contaminants may warrant
changes in the CCL selection processes. General exposure to even low
levels of antibiotics in drinking water, for example, may lead to antibi-
otic-resistant pathogens either in a person drinking the water or the
general environment. The current CCL process for chemicals would
not identify this as an adverse effect.'
337. Drinking Water Contaminant Candidate List 3, 73 Fed. Reg. 194, 51850 (2008).
338. The process that preceded the current Contaminant List was described by Tox-
Services L.L.C.:
EPA identified 287 pharmaceuticals in its initial listing of a broad range of po-
tential drinking water contaminants in the draft CCL3 [Drinking Water Con-
taminant Candidate List 31 that had data to indicate a potential to occur in
drinking water and health effects. The health data used was primarily from the
FDA's Database on Maximum Recommended Daily Doses and the occurrence
data was from the U.S. Geological Survey's Toxic Substances Hydrology Pro-
gram's National Reconnaissance of Emerging Contaminants, and TRI [Toxic
Release Inventory] and high production volume chemical data. Further screen-
ing moved approximately 10 percent of the pharmaceuticals to the preliminary
CCL. Only one of the pharmaceuticals, nitroglycerin, was included in the draft
CCL3.
ToxSERVICEs L.L.C., supra note 35, at 12.
339. EPA SCIENCE ADVISORY BOARD DRINKING WATER COMMITTEE, ENVTL. PROT.
AGENCY, SAB Advisory on EPA's Draft Third Drinking Water Contamination Candi-
date List (CCL 3) 7 (2009). The Committee also addressed PPCPs in the context of
contaminants that were not included on the draft CLL. With regard to concentrations of
contaminants in wastewater and the potential reuse of such water supplies, the Commit-
tee concluded:
The Committee concludes that it will be important to consider information re-
garding wastewater concentrations when evaluating potential exposure in the
CCL process. In some areas of the country, wastewater discharges are increas-
ingly a greater percentage of water supplies, and they are being processed into
potable water. Wastewater contains a wide variety of contaminants including
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A final decision regarding "whether to regulate five or more of the
contaminants from this list" is expected by 2013.' If PPCPs are included
within the regulatory scope of the Safe Drinking Water Act, it has been
suggested that a "No Observed Transcriptional Effect Level" ("NOTEL",
defined as "the dose of chemical which results in no significant changes
to gene expression") should be the regulatory limit."'
The weakness of this approach has been noted already: the ubiqui-
tous nature of PPCPs. As with alternatives under the Clean Water Act,
requiring public water supply systems to address all PPCPs could impose
financial burdens that are neither financially nor politically feasible.
The Surface Water Treatment Rule could be amended to require
removal of PPCPs in addition to the contaminants already subject to the
Rule. Again, the cost of such an approach may not make it financially or
politically opportune.
An alternative that may not face the twin roadblocks of financial and
political feasibility would be to amend the Wellhead Protection Program
to preclude the discharge of wastes containing PPCPs in wellhead protec-
tion areas. For example, prohibiting either (a) the installation or use of
septic tanks in wellhead protection areas, or (b) the land application of
wastewater treatment plant residues (biosolids) in such areas, could pro-
tect groundwater from wastes containing PPCPs.
A similar amendment could be implemented regarding the Under-
ground Injection Control Program. Injection of wastes containing PPCPs
could be restricted to Class I injection wells. As with the possible'
amendment to the Wellhead Protection Program, the goal would be to
prevent the migration of PPCPs into groundwater resources.
Sludge or biosolids containing PPCPs from water treatment plants
could be subject to the Part 503 Biosolids Rule. The Rule would have to
be amended to establish both ceiling and loading rate limits for PPCPs.
pharmaceuticals, personal care products, enteric pathogens, and other emerg-
ing contaminants. In the case of pharmaceuticals, perflourinated surfactants,
and other contaminants that are prevalent in wastewater effluent, EPA may
want to consider using data obtained in specialized wastewater effluent moni-
toring programs for the CCL screening process.
Id. at 14. In terms of chemical contaminants, "[tlhe absence of data on the occurrence
of pharmaceuticals in surface waters was also noted. The Committee recommends use
of the data from the USGS, or any of the numerous studies in the peer-reviewed litera-
ture, to include these chemicals." Id.
340. Johnston & Sendek-Smith, supra note 323, at 38 (citing Alan Kovski, Drinking
Water: EPA Completes List of Water Contaminants to Consider as Candidates for
Regulation, 40 ENv'T REPORTER 2246 (Sept. 25, 2009)). EPA has also considered inclu-
sion of PPCPs within the Unregulated Contaminant Monitoring Rule.
341. Poynton & Vulpe, supra note 35, at 91 (citing EK. Lobenhofer et al., Explora-
tion of Low-Dose Estrogen Effects: Identiication of No Observed TranscnptionaI
MAQC Effect Level (NOTEL), 32 TOxICOLOGIC PATHOLOGY 482 (2004)). As Poyn-
ton and Vulpe concluded, "lainy significant cellular perturbation should cause some
change in gene expression; therefore, the NOTEL represents a true No Observed Effect
Concentration." Id. See also Gerald T. Ankley et al., Toxicogenonics in Regulatory
Ecotoxicology, 40 ENVTL. Sci. & TECH. 4055, 4060 (2006).
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As noted in the case study, liquid wastes containing PPCPs were used to
irrigate a waste disposal site. It may be necessary to expand the Biosolids
Rule to apply to such situations.
4. The Resource Conservation and Recovery Act
The definition of a "hazardous" waste contained in the Resource
Conservation and Recovery Act ("RCRA") could be expanded to include
additional wastes containing PPCPs. At the present time, for example,
wastes discharged pursuant to a National Pollutant Discharge Elimination
System Permit are not subject to the requirements of RCRA.
Inclusion of wastes containing PPCPs within the definition of a "haz-
ardous" waste would subject the waste stream to RCRA requirements.'
Generators and transporters of wastes containing PPCPs, as well as op-
erators of treatment, storage, and disposal facilities ("TSDF") for such
wastes, would have to comply with the requirements of RCRA, including
use of the Uniform Hazardous Waste Manifest System and permit re-
quirements to construct and operate a TSDF.
However, because of the limited number of TSDFs and the difficulty
of establishing new TSDFs, imposing such requirements could be both
costly and burdensome to the waste management community. The vol-
ume of waste subject to RCRA requirements would increase dramatically.
342. Christenson addressed this approach in the context of health-care facilities, con-
cluding:
[Tihe list of hazardous drugs "has not been substantially updated since the
rules went into effect in 1976." For example, only eight out of 100 different
chemotherapy drugs are currently on the list of hazardous wastes. In fact,
health-care facilities have an extremely difficult time dealing with the RCRA
because the regulations were not designed for the health-care industry. Thus,
when there are regulations, they are complicated and expensive to follow, and
when there are not regulations, hospitals are left in the unenviable position of
developing their own disposal programs or flushing drugs down the toilet.
Christenson, supra note 180, at 150 (citing R. Seely, Flushed Drugs Polluting Watei
Complicated Rules for Disposal Result in Most Hospitals Taking Easy Way Out, Wis.
STATEJOURNAL, Dec. 10, 2006, at Al.). See also Mannina, supra note 288, at 4 ("Pro-
visions in RCRA and in Drug Enforcement Administration regulations which are de-
signed to protect the public from the improper discharge or disposal of medical waste
and controlled substances may, in reality, be encouraging medical professionals and the
public to flush unused pharmaceuticals in toilets or drains.").
343. As noted by Mannina, "EPA has listed several common medications and nine
chemotherapy agents as hazardous waste if discarded. But there are more than 100 toxic
chemotherapy agents which are not yet RCRA regulated." Mannina, supra note 288, at
2. Regulation of these wastes could have unintended consequences:
If regulated substances are released into the environment, as those terms are
understood under Superfund [the Comprehensive Environmental Response,
Compensation and Liability Act, 42 U.S.C. § 9601 et seq.] and the Clean Wa-
ter Act, can we look forward to cleanup orders and claims for natural resource
damages under those laws? The answer is probably yes.
Id.
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The cost of disposing such waste could increase in proportion to the
quantity of wastes generated.
One result seen repeatedly when disposal costs are excessive is an in-
crease in illegal dumping of hazardous wastes. If costs increase because
of an imposition of RCRA requirements on wastes containing PPCPs, the
resultant illegal dumping would most likely include a wide variety of haz-
ardous wastes that previously would have gone to an approved TSDF.
An alternative could be to revise the Universal Waste Rule to include
PPCPs. In fact, on December 2, 2008, the EPA proposed adding PPCPs
to the Universal Waste list.'" The proposed revisions would add hazard-
ous pharmaceuticals to the list. The rule, as amended, would apply to
pharmacies, hospitals, physicians' offices, dentists' offices, outpatient care
centers, ambulatory health care services, residential care facilities and
veterinary clinics as well as other facilities that produce hazardous phar-
maceutical wastes." EPA has estimated that the proposed revision would
affect up to 634,552 entities, of which approximately 181 are large quan-
tity generators of hazardous waste.' The amendments would allow pro-
ducers of hazardous pharmaceutical wastes to choose whether to (a) con-
tinue to have their wastes regulated under the current RCRA regulations
or (b) manage their hazardous wastes under the Universal Waste Rule."'
The proposed revision is also intended to facilitate the collection of
pharmaceutical wastes from households, including non-hazardous phar-
maceutical wastes. " Of relevance to the source control options dis-
cussed below, the EPA believes that the amendments will simplify phar-
maceutical take-back programs by "streamlining the requirements for
handling hazardous pharmaceutical wastes received as part of a take-back
program.""
However, concerns have been expressed regarding the inclusion of
PPCPs on the Universal Waste list. These concerns focus on the conten-
tion that the regulation of PPCPs under the Universal Waste Rule "may
be less stringent than the rules for hazardous wastes under RCRA.""
344. Amendment to the Universal Waste Rule: Addition of Pharmaceuticals, 73 Fed.
Reg. 232, 73520 (Dec. 2, 2008) (to be codified at 40 C.F.R. pt. 260, 261, 264, 265, 268,
270 and 273).
345. ENVTL. PROT. AGENCY, EPA PROPOSEs STREAMLINED DISPOSAL OF HAZARDOUS
PHARMACEUTICAL WASTE (Nov. 2008), available at
http://www.epa.gov/osw/hazard/wastetypes/universal/pharm-fs.pdf.
346. Amendment to the Universal Waste Rule: Addition of Pharmaceuticals, 73 Fed.
Reg. 232, 73520 (Dec. 2, 2008) (to be codified at 40 C.F.R. pt. 260, 261, 264, 265, 268,
270 and 273).
347. Id.
348. Id.
349. Id. at 73526.
350. Johnston & Sendek-Smith, supra note 324, at 38 (citing Environmental News
Stand, EPA Urged to Up RCRA Pharmaceuticals Enforcement at Hospitals, INSIDE EPA
(July 1, 2009)).
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5. The Toxic Substance Control Act
Solid and liquid wastes containing PPCPs could also be subject to the
requirements of the Toxic Substances Control Act ("TSCA"). If so, Title
I of TSCA would require manufacturers and processors of such wastes to
conduct a testing program "to predict the effects of human exposure and
environmental releases.""
Regulatory controls are available under TSCA regarding the process-
ing, distribution, use or disposal of a chemical presenting an unreason-
able risk of injury to health or the environment." If wastes containing
PPCPs fall within the purview of TSCA, then this provision, as well as all
of the regulatory controls authorized by TSCA, could be applicable. If
so, given the wide variety of PPCPs, the potential scope and cost of com-
plying with these requirements could make compliance problematic.
6. The Endangered Species Act
The financial and political burdens confronting use of the aforemen-
tioned statutes would cease to be a threshold issue if wastes containing
PPCPs led to the "taking" of a threatened or endangered species. As
discussed in Section II, the impacts of PPCPs in fresh water resources
have been observed in a wide variety of aquatic species. At some point, a
cause of action will arise when PPCPs in water supplies result in the "tak-
ing" of a species protected by the ESA or similar legislation enacted by
state, local or tribal governments.'
In fact, these causes of action may already have ripened. Lopez notes
that "[tihere is evidence that EDCs are significantly degrading habitat,
including federally designated critical habitat, and are likely injuring fish
and wildlife by disrupting behavior patterns such as breeding ability."M
This could give rise to a "taking" cause of action regarding a number of
threatened or endangered species including the Razorback Sucker
(Xyrauchen texanus), the Desert Pupfish (Cyprinodon macularius), and
the Santa Ana Sucker (Catostomus santaanae)..
351. Toxic Substance Control Act (TSCA), 15 U.S.C. § 2603 (2006).
352. Id. at S 2605(a).
353. The Endangered Species Act is not the only federal species protection statute
that might provide a cause of action should protected species be affected adversely by
PPCPs. See, e.g., the Bald and Golden Eagle Protection Act, 16 U.S.C. §§ 668-668d
(2006); the Marine Mammal Protection Act, 16 U.S.C. SS 1361-1421h (2006); the Mi-
gratory Bird Treaty Act, 16 U.S.C. §§703-712 (2006). Similar species protection legisla-
tion enacted by state, local and Tribal governments might provide additional causes of
action.
354. Lopez, supra note 328, at 20 (citing Susan Jobling et al., Wild Intersexr Roach
(Rutilus rutilus) Have Reduced Fertility, 67 BIOLOGY OF REPRODUCTION 515 (2002)
(finding that EDC-caused altering of sex characteristics leads to reduced reproductive
ability)).
355. Id. at 21; see also Mannina, supra note 288, at 2 ("ESA issues may already be
present in Nevada where a USGS toxicologist detected elevated levels of pharmaceuti-
cals and hormones in waterways downstream from Las Vegas and a very large decrease
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Mannina notes an alternative cause of action, based on the ESA re-
quirement that "federal agencies (including agencies approving the use of
pharmaceuticals and hormones) 'insure' that any action they take or au-
thorize is not likely to adversely affect species protected by the ESA."'
Based on this requirement, Mannina concluded:
Experienced ESA attorneys are all too well aware of how little proof of
impact is required before the ESA's "insure" no harm standard triggers
regulatory controls. In one ESA case, a federal judge upheld a finding
that fishing was adversely affecting an ESA-protected species even
though there was no evidence that fishing was causing any impact. The
logic, using the ESA's insure no harm standard, was that fishermen
catch fish, the listed species eat fish, and, therefore, there must be an
adverse impact from fishing. Apply that reasoning to pharmaceuticals
in the environment and it is not a very long leap before the ESA can be
brought to bear on protected species such as the razorback sucker and
other listed species of lish, including virtually all the sahnon and steel-
head species in the Pacific northwest."
Implementing a recovery plan under the ESA can be both socially
disruptive and expensive. The preferred alternative is to take the neces-
sary steps to preclude the need to list a species as threatened or endan-
gered. This could include regulating or prohibiting the discharge of
wastes containing PPCPs, especially if the discharge of such wastes is the
cause of the "taking." While such an approach may not be politically
popular, the alternatives (listing a species and implementing a recovery
plan) are substantially less popular.
B. ALTERNATIVE STRATEGIES
The source control alternative strategies discussed in Section IV may
be more effective in reducing or eliminating PPCPs in fresh water re-
sources than the imposition of a statutory or regulatory approach. The
approaches advocated by Daughton and others focus on minimizing or
eliminating sources of PPCPs.'"
1. Drug Design
Designing drugs to minimize the human and animal excretion of
vastes containing PPCPs would have the effect of reducing the volume of
PPCPs entering fresh water resources. Commentators argue that the
Food and Drug Administration ("FDA") needs to assess the PPCP dis-
in sperm production in three species of fish, including the endangered razorback
sucker.").
356. Mannina, supra note 289, at 2.
357. Id. (emphasis added).
358. As in Section IV, the discussion in this Section focuses primarily on pharmaceu-
ticals. Nevertheless, the analysis is equally applicable to personal care products and the
full array of PPCPs previously identified. See supra note 4.
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charge potential as a component of the FDA's drug approval process."
The Environmental Assessment process mandated by the National Envi-
ronmental Policy Act could undertake such an assessment." "The
hope," observed Nidel, "is that with an adequately informed FDA sitting
as gatekeeper to this highly profitable market, drug design will evolve.
This will lead drug companies to internalize the external impacts of their
products and, where feasible, design drugs of the future that are noted for
their minimal impact on the environment as well as for their therapeutic
effectiveness.""
As noted below, Daughton has suggested that extending patents
would encourage drug companies to implement alternative source control
strategies. " Others have suggested the need for financial incentives or
other types of financial support, particularly with regard to drug design."'
Despite the provision of such financial support, a restraint on the fea-
sibility of this alternative could be the need for drug manufacturers to
pass the cost of drug development to the general public. Absent a defini-
tive showing of adverse human or environmental health impacts resulting
from exposure to PPCPs, the political feasibility of increasing the cost of
drugs in order to limit PPCPs in fresh water resources is an open ques-
tion.
2. Drug Delivery
The drug delivery alternatives suggested by Daughton are predicated
in part on voluntary participation by physicians, patients, pharmacies, and
drug manufacturers. Despite Daughton's faith in public education pro-
grams, such appeals to conscience have not been an effective means of
addressing environmental health problems.'
3. Drug Marketing
The cost of informing consumers of appropriate means of discarding
unused drugs should be minimal vis-A-vis the benefit of reducing PPCPs
in fresh water resources. However, the cost of producing a variety of
package sizes in order to minimize the quantity of unused drugs needing
disposal could be substantial. Given the sensitivity of consumers to drug
359. As Nidel has noted, "Irlequiring a more rigorous assessment when applying for
new drug approval would shift the focus of the root-cause of the problem." Nidel, supra
note 323, at 82.
360. Id. at 92-93.
361. Id. at 100.
362. Infra note 365 and associated text.
363. Christenson, supra note 180, at 169, 169 n.276 (citing Nidel, supra note 323, at
94 for the proposition that the Food and Drug Administration "already has the necessary
authority" to "increase environmental review of the design of new drugs or offer intellec-
tual-property or tax-based incentives to those manufacturers who voluntarily test for
environmental effects.").
364. See, e.g., Garrett Hardin, The Tragedy of the Commons, 162 SCIENCE 1243,
1246-1247 (appeals to conscience cannot remedy the "tragedy of the commons").
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prices, those alternatives with the least costs are more than likely the most
feasible.
4. Drug Dispensing
McGrath notes that the State of Maine has limited the quantity of
drugs that physicians may "prescribe for first-time users of certain medi-
cations."' The political feasibility of such an approach raises issues re-
garding both the social responsibility of physicians and the role of the
state in the doctor-patient relationship.
Dispensing the correct quantity of a drug with an appropriate expira-
tion date (i.e., the drugs will not expire before the course of treatment has
been completed) could be a win-win situation, at least for the patient and
the environment. Whether such an approach would be considered a
"win" for drug manufacturers is an open question.
5. Drug Disposal/Recycling
Existing institutional barriers to drug disposal and recycling need to
be revised. While there may be good reasons for some of these barriers
to continue (e.g., prevention of theft of discarded pharmaceuticals), blan-
ket prohibitions encourage the inappropriate disposal of unused or un-
wanted drugs.
One approach to a drug disposal and recycling program would be a
"take-back" program, such as the one described by Christenson:
Take-back events, typically organized by hospitals, pharmacies, or envi-
ronmental groups, create a place for consumers to bring their unused
pharmaceuticals. With proper personnel available to sort pharmaceuti-
cals and law enforcement available to handle controlled substances,
these events are often extremely successful, resulting in hundreds of gal-
lons of pharmaceuticals collected in single-day events.'
The successful implementation of drug take-back programs has been
challenging. As noted above, having "law enforcement available to han-
dle controlled substances" may be a condition precedent to a successful
program. This statement masks a serious impediment to take-back pro-
grams, that "the same pharmacist who is authorized to distribute medica-
tions . .. is not authorized to take the medication back without prior ap-
proval by a DEA [Drug Enforcement Administration] agent."'
365. Neal McGrath, Water Pollution: Pharma's Next Big Headache?, GREENBIZ.cOM
BLOGS (August 31, 2009), http://www.greenbiz.com/blog/2009/08/28/water-pollution-
pharmas-next-big-headache.
366. Christenson, supra note 180, at 157 (citing R. Seely, Flushed Drugs Polluting
Water; Complicated Rules for Disposal Result in Most Hospitals Taking Easy Way Out,
Wis. STATE JOURNAL, Dec. 10, 2006, at Al; R. Dickrell, Pharmaceutical Take-Back A
Community's Success Story, 167 THE CLARIFIER 48 (2006)).
367. Id. at 152 (citing Juliet Eilperin, Pharmaceuticals in Waterways Raise Concern:
Effect on Wildhfe, Humans Questioned, WASHINGTON POST, June 23, 2005, at A3).
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Despite such impediments, a number of states have sought to develop
drug take-back programs. For example, legislation enacted in Maine au-
thorized a drug mail-back program." Christenson summarized the pro-
gram:
Consumers mail unused or expired drugs in these packages to a single
collection location run by the Maine Drug Enforcement Agency
(MDEA). The MDEA then disposes of all returned drugs in an envi-
ronmentally sound manner. A fund established and maintained by the
MDEA and funded by private contributions pays the costs of the pro-
gram.
Implementation of the Maine program encountered two problems.
"First, although manufacturers regularly package and ship prescription
drugs for consumption, it is much more difficult to have them shipped
for disposal.".... "Second, due to the potentially high costs involved, it is
unlikely that pharmaceutical companies would provide the necessary
funds to run the entire program."."
For the health-care industry and consumers, "DEA laws are one of the biggest
stumbling blocks" on the road toward proper disposal. This is largely due to
the DEA's strict control of controlled substances, under which disposal be-
comes quite complicated. When an individual is unsure how to dispose of a
controlled substance, that individual may contact an authorized DEA agent,
who will then instruct the individual to dispose of the controlled substance in
one of the following manners: (1) by transfer to a person authorized to possess
controlled substances (likely a law-enforcement officer), (2) by delivery to a
DEA agent, (3) by destruction in the presence of a DEA agent, or (4) by some
other means determined by a DEA agent. In other words, the only persons
who can possess a controlled substance that is prescribed to an individual are
that individual, a law-enforcement officer, or a DEA agent.
Id. at 151-52 (citing 21 C.F.R. S 1307.21 (Drug Enforcement Administration, Office of
Diversion Control, Procedure for disposing of controlled substances); R. Seely, Flushed
Drugs Polluting Watei; Complicated Rules for Disposal Result in Most Hospitals Taking
Easy Way Our, Wis. STATEJOURNAL, Dec. 10, 2006, at Al).
368. As opposed to a take-back event as described above, a "statewide mail-back
model offers a centralized coordination component, adds an element of confidentiality
and anonymity not found with in-person take back programs and is the least burden-
some of all models in terms of consumer access and utilization." LENARD KAYE,
.JENNIFER CRITTENDEN, & STEVAN GRESSrrr, EXECUTIVE SUMMARY: REDUCING
PRESCRIPTION DRUG MISUSE THROUGH THE USE OF A CITIZEN MAIL-BACK PROGRAM
IN MAINE (2010), available athttp://www.epa.gov/aging/RX-report-Exe-Sum/.
369. Christenson, supra note 180, at 154 (citing ME. REV. STAT. ANN. tit. 22, 55
2700(3)-(5)).
370. Id. (citing ME. REv. STAT. ANN. tit. 22, § 2700(4)).
371. Id. at 155 (citing Juliet Eilperin, Pharmaceuticals in Waterways Raise Concern:
Effect on Wildlife, Humans Questioned, WASHINGTON POsT, June 23, 2005, at A3).
Christenson notes the issue of political feasibility:
Maine's government could consider legislation that would require pharmaceu-
tical companies to significantly contribute to the fund. However, given that the
pharmaceutical industry is one of the leading lobbyists in the United States, any
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McGrath notes that seven states have considered legislation to "man-
date take-back programs" and that a mandatory system, funded by the
drug companies, has been implemented in France." Alternative pro-
grams include the Canadian Medications Return Program.'" Daughton's
suggestion to extend the patents of drug companies implementing "vi-
brant, comprehensive stewardship programs tailored for each particular
drug""' has merit, but it also could mean that consumers could pay higher
drug prices over time because the introduction of alternative generic
drugs could be delayed by the patent extensions."
6. Drug Alternatives
The benefit of drug alternatives is a reduction in the discharge of
PPCPs associated with the use of such products. The burden has been
stated already: potential cost to the patient. The use of "bacteriotherapy"
may be as effective as the use of a drug resulting in the discharge of
PPCPs, but at what cost? Perhaps more importantly, does the reduction
in PPCPs discharged into fresh water resources justify the cost?
VII. CONCLUSIONS
The words of H.L. Mencken ring true: "For every complex problem,
there is a solution that is simple, neat, and wrong." Mencken's conclu-
sion appears to be particularly appropriate regarding PPCPs in fresh wa-
ter resources.
The general conclusions are deceptively simple: the anthropogenic
sources of PPCPs identified in Section II need to be reduced or elimi-
nated. As discussed in Section III, such sources of PPCPs may be sub-
ject to regulation. As discussed in Section IV, source control alternatives
proposed legislation that would force manufacturers to significantly contribute
to the fund would likely meet significant opposition.
Id. (citing Jim Drinkard, Drugmakers Go Furthest to Sway Congress, USA TODAY, Apr.
26, 2005, at BI (explaining drug companies spent more on lobbying than any other
industry from 1998 to 2004)).
372. McGrath, supra note 365.
373. Christenson, supra note 180, at 157-158 (citing Daughton, Drug Diposal, Waste
Reduction, and Future Directions, supra note 244, at 780).
374. Daughton, Drug Disposal, Waste Reduction, and Future Directions, supra note
243, at 776. The concept of stewardship underlay the Maine mail-back program. "Prod-
uct stewardship is a concept that recognizes the responsibility of the manufacturer of a
product from the manufacturing process through final disposal in an environmentally
sound manner." State of Maine Final Report of the Maine Drug Return Implementation
Group, 122nd Legis., 1st Reg. Sess. at 7 (2005), available at
http://www.maine.gov/legis/opla/drugrpt.pdf, (quoted in Christenson, supra note 180, at
154).
375. As Christenson noted, "[ilf the scheme places the financial burden on consum-
ers, it fails to follow the product-stewardship model that underlies this solution." Chris-
tenson, supra note 180, at 155.
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exist that could have the effect of reducing or eliminating some sources of
PPCPs without the costs associated with statutory or regulatory programs.
The devil, however, is in the details. As Wennmalm and Gunnarsson
note "[tihe consumption of pharmaceuticals is increasing worldwide, due
both to continued population growth and increased consumption of
pharmaceuticals per capita."" The ever-increasing number of PPCPs, "
combined with the concentration variability discussed in Section V, pre-
cludes any single approach to their regulation or management."' New
monitoring,"' detection,' and analysis"' methods are needed. New man-
agement alternatives need to be developed. New statutory or regulatory
approaches embodying the Precautionary Principle" need to be tailored
to the goal of reducing PPCPs in fresh water resources.'
376. Wennmalm & Gunnarsson, supra note 42, at 291 (citing European Federation of
Pharmaceutical Industries and Associations. THE PHARMACEUTICAL INDUSTRY IN
FIGURES (2002)). Consumption of pharmaceuticals is increasing 3-4% by weight per year.
Ellis, supra note 5, at 185 (citing Christian G. Daughton, Non-regulated Water Con-
taminants: Emerging Research, 24 ENVTL. IMPACT ASSESSMENT REVIEw 711 (2004));
Accord Reynolds, Concern of Pharmaceuticals in Drinking Water, supra note 34, at 2.
377. As of 2004 there were 'as many as 6 million PPCP substances commercially
available worldwide." Ellis, supra note 5, at 185 (citing Christian G. Daughton, Non-
regulated Water Contaminants: Emerging Research, 24 ENVIRONMENTAL IMPACT
ASSESSMENT REVIEW 711 (2004)).
378. "The aging population and more pharmaceutical development are two driving
factors behind an expectation that increased pharmaceutical use will result in higher
levels of trace residues in water." GLOBAL WATER RESEARCH COALITION, supra note
32, at 2. Accord Reynolds, Pharmaceuticals in Drinking Water Supplies, supra note 26
("With a growing and aging population as well as increased reliance on drug treatments,
and development of new drugs, the problem with pharmaceutical contamination prom-
ises to also increase").
379. G. Tracy Mehan, III, Water Data and Monitoring as Indispensable Tools to
Manage Water Quality, DAILY ENV'T REPORT, August 4, 2010, at 4.
380. "Methods of detection are not available for all pharmaceuticals, and new phar-
maceuticals are developed every year, which may require new methodologies to enable
their detection in water." GLOBAL WATER RESEARCH COALITION, supra note 32, at 1.
381. Poynton & Vulpe, supra note 35, at 92:
New chemicals and drugs are continuously developed and released in the envi-
ronment. New approaches are needed for environmental risk assessment to
catch up with the backlog of contaminants and keep pace with the increasing
surge of new potential risks.
Accord RAPID PUB. HEALTH POL'Y RESPONSE PROJECT. supra note 27, at 3-4 (discussing
need for human health assessments of low-level, chronic exposure to PPCPs); Jones,
supra note 242, at 385 (discussing need for new risk assessment models that account for
synergistic effects).
382. "Irrespective of any risks, the precautionary principle should apply and mi-
cropollutants from wastewater should not be present in drinking water." C. Zwiener,
Occurrence and Analysis of Pharmaceuticals and their Transformation Products in
Drinking Water Treatment, 387 ANALYTICAL & BIOANALYTICAL CHEMISTRY 1159
(2007) (quoted in RAPID PUB. HEALTH POL'Y RESPONSE PROJECT, supra note 27, at 6).
Among the various definitions of the Precautionary Principle, perhaps the one most
applicable to PPCPs is the definition resulting from the Wingspread Conference on the
Precautionary Principle (26 January 1998): "When an activity raises threats of harm to
human health or the environment, precautionary measures should be taken even if some
444 Volume 15
PHARMACEUTICALS AND PERSONAL CARE PRODUCTS
It is quite possible that new drinking water treatment processes will
need to be developed. However, while such processes might protect hu-
man health, they would "provide no protection for aquatic life."" Fur-
thermore, it is unlikely that any "single water treatment process will be
capable of reducing all trace organic contaminants to below increasingly
sensitive analytical detection limits."'
As noted in the Introduction, this report is predicated on the assump-
tion that the ongoing scientific inquiry regarding the effects of PPCPs in
fresh water resources produces evidence of risks to human and environ-
mental health. If so, then all of the alternatives discussed herein, as well
as any number of additional alternatives that have yet to emerge, will be
needed to protect both human and environmental health.
cause and effect relationships are not fully established scientifically." Wingspread con-
ference on the Precautionary Principle, Sci. & ENVTL. HEALTH NETWORK,
http://www.sehn.org/wing.html (last visited Feb. 29, 2012). The conferees went on to
explain that "[tihe precautionary principle shifts the burden of proof, insisting that those
responsible for an activity must vouch for its harmlessness and be held responsible if
damage occurs." Id.
383. See, e.g., Heberer et al., Removal of Pharmaceutical Residues, supra note 87, at
19 (citing T. Heberer & H.-J. Stan, Arzneimittelriickstande im Aquatischen System, 50
WASSER UND BODEN 20 (1998); Umweltbundesamt, ANNUAL REPORT 1999 (2000)):
ILlow concentrations [of pharmaceutically active compoundsl may, from a
toxicological point of view, not be harmful to humans but their occurrence in
ground or drinking water is also not desirable from a hygienic point of view or
with regard to the precautionary principle. Thus, there is a need to develop
and study new drinking water treatment technologies to remove such organic
contaminants from drinking water.
Accord Wennmalm & Gunnarsson, supra note 42, at 296 ("[Iun line with the precau-
tionary principle, measures should be taken by public health authorities to avoid con-
tamination of drinking water with [low concentrations of bioactive chemicals such as
pharmaceuticals]").
384. Snyder et al., supra note 48, at 34.
385. Stanford et al., supra note 12, at 2 (citing Benotti et al., supra note 49; Shane A.
Snyder et al., AM. WATER WORKs Ass'N, Removal of EDCs and Pharmaceuticals in
Drinking and Reuse Treatment Processes (2007); Brett J. Vanderford & Shane A. Sny-
der, Analysis of Pharmaceuticals in Water by Isotope Dilution Liquid Chromatogra-
phy/wTandem Mass Spectrometry, 40 ENVTL. Sci. & TECH. 7312 (2006)).
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